id	sid	tid	token	lemma	pos
bjos-8641742	1	1	oral	oral	ADJ
bjos-8641742	1	2	sciences	sciences	PROPN
bjos-8641742	1	3	n3	n3	PROPN
bjos-8641742	1	4	392392392392392	392392392392392	NUM
bjos-8641742	1	5	received	receive	VERB
bjos-8641742	1	6	for	for	ADP
bjos-8641742	1	7	publication	publication	NOUN
bjos-8641742	1	8	:	:	PUNCT
bjos-8641742	1	9	december	december	PROPN
bjos-8641742	1	10	07	07	NUM
bjos-8641742	1	11	,	,	PUNCT
bjos-8641742	1	12	2009	2009	NUM
bjos-8641742	1	13	accepted	accept	VERB
bjos-8641742	1	14	:	:	PUNCT
bjos-8641742	1	15	august	august	PROPN
bjos-8641742	1	16	27	27	NUM
bjos-8641742	1	17	,	,	PUNCT
bjos-8641742	1	18	2010	2010	NUM
bjos-8641742	1	19	original	original	ADJ
bjos-8641742	1	20	article	article	NOUN
bjos-8641742	1	21	braz	braz	PROPN
bjos-8641742	1	22	j	j	PROPN
bjos-8641742	1	23	oral	oral	PROPN
bjos-8641742	1	24	sci	sci	PROPN
bjos-8641742	1	25	.	.	PUNCT
bjos-8641742	2	1	october|december	october|december	PROPN
bjos-8641742	2	2	2010	2010	NUM
bjos-8641742	2	3	volume	volume	NOUN
bjos-8641742	2	4	9	9	NUM
bjos-8641742	2	5	,	,	PUNCT
bjos-8641742	2	6	number	number	NOUN
bjos-8641742	2	7	4	4	NUM
bjos-8641742	2	8	risk	risk	NOUN
bjos-8641742	2	9	factors	factor	NOUN
bjos-8641742	2	10	for	for	ADP
bjos-8641742	2	11	oral	oral	ADJ
bjos-8641742	2	12	candidiasis	candidiasis	NOUN
bjos-8641742	2	13	in	in	ADP
bjos-8641742	2	14	brazilian	brazilian	ADJ
bjos-8641742	2	15	hiv	hiv	PROPN
bjos-8641742	2	16	-	-	PUNCT
bjos-8641742	2	17	infected	infect	VERB
bjos-8641742	2	18	adult	adult	NOUN
bjos-8641742	2	19	patients	patient	NOUN
bjos-8641742	2	20	mariela	mariela	PROPN
bjos-8641742	2	21	dutra	dutra	PROPN
bjos-8641742	2	22	gontijo	gontijo	PROPN
bjos-8641742	2	23	moura1	moura1	PROPN
bjos-8641742	2	24	,	,	PUNCT
bjos-8641742	2	25	soraya	soraya	PROPN
bjos-8641742	2	26	de	de	PROPN
bjos-8641742	2	27	mattos	mattos	PROPN
bjos-8641742	2	28	camargo	camargo	PROPN
bjos-8641742	2	29	grossman1	grossman1	PROPN
bjos-8641742	2	30	,	,	PUNCT
bjos-8641742	2	31	linaena	linaena	PROPN
bjos-8641742	2	32	méricy	méricy	PROPN
bjos-8641742	2	33	da	da	PROPN
bjos-8641742	2	34	silva	silva	PROPN
bjos-8641742	2	35	fonseca2	fonseca2	PROPN
bjos-8641742	2	36	,	,	PUNCT
bjos-8641742	2	37	maria	maria	PROPN
bjos-8641742	2	38	letícia	letícia	PROPN
bjos-8641742	2	39	ramos	ramos	PROPN
bjos-8641742	2	40	-	-	NOUN
bjos-8641742	2	41	jorge3	jorge3	PROPN
bjos-8641742	2	42	,	,	PUNCT
bjos-8641742	2	43	ricardo	ricardo	PROPN
bjos-8641742	2	44	alves	alves	PROPN
bjos-8641742	2	45	mesquita4	mesquita4	PROPN
bjos-8641742	3	1	1msc	1msc	NUM
bjos-8641742	3	2	,	,	PUNCT
bjos-8641742	3	3	graduate	graduate	ADJ
bjos-8641742	3	4	students	student	NOUN
bjos-8641742	3	5	,	,	PUNCT
bjos-8641742	3	6	department	department	NOUN
bjos-8641742	3	7	of	of	ADP
bjos-8641742	3	8	oral	oral	ADJ
bjos-8641742	3	9	pathology	pathology	NOUN
bjos-8641742	3	10	,	,	PUNCT
bjos-8641742	3	11	dental	dental	ADJ
bjos-8641742	3	12	school	school	NOUN
bjos-8641742	3	13	,	,	PUNCT
bjos-8641742	3	14	federal	federal	ADJ
bjos-8641742	3	15	university	university	PROPN
bjos-8641742	3	16	of	of	ADP
bjos-8641742	3	17	minas	minas	PROPN
bjos-8641742	3	18	gerais	gerais	PROPN
bjos-8641742	3	19	,	,	PUNCT
bjos-8641742	3	20	belo	belo	PROPN
bjos-8641742	3	21	horizonte	horizonte	PROPN
bjos-8641742	3	22	,	,	PUNCT
bjos-8641742	3	23	mg	mg	PROPN
bjos-8641742	3	24	,	,	PUNCT
bjos-8641742	3	25	brazil	brazil	PROPN
bjos-8641742	3	26	2phd	2phd	PROPN
bjos-8641742	3	27	,	,	PUNCT
bjos-8641742	3	28	assistant	assistant	NOUN
bjos-8641742	3	29	professor	professor	NOUN
bjos-8641742	3	30	,	,	PUNCT
bjos-8641742	3	31	school	school	NOUN
bjos-8641742	3	32	of	of	ADP
bjos-8641742	3	33	health	health	NOUN
bjos-8641742	3	34	,	,	PUNCT
bjos-8641742	3	35	faculdades	faculdade	VERB
bjos-8641742	3	36	pitágoras	pitágora	NOUN
bjos-8641742	3	37	,	,	PUNCT
bjos-8641742	3	38	belo	belo	PROPN
bjos-8641742	3	39	horizonte	horizonte	PROPN
bjos-8641742	3	40	,	,	PUNCT
bjos-8641742	3	41	mg	mg	PROPN
bjos-8641742	3	42	,	,	PUNCT
bjos-8641742	3	43	brazil	brazil	PROPN
bjos-8641742	3	44	3phd	3phd	NUM
bjos-8641742	3	45	,	,	PUNCT
bjos-8641742	3	46	professor	professor	NOUN
bjos-8641742	3	47	.	.	PUNCT
bjos-8641742	4	1	department	department	PROPN
bjos-8641742	4	2	of	of	ADP
bjos-8641742	4	3	dentistry	dentistry	PROPN
bjos-8641742	4	4	,	,	PUNCT
bjos-8641742	4	5	federal	federal	ADJ
bjos-8641742	4	6	university	university	NOUN
bjos-8641742	4	7	of	of	ADP
bjos-8641742	4	8	vales	vale	NOUN
bjos-8641742	4	9	jequitinhonha	jequitinhonha	NOUN
bjos-8641742	4	10	and	and	CCONJ
bjos-8641742	4	11	mucuri	mucuri	NOUN
bjos-8641742	4	12	,	,	PUNCT
bjos-8641742	4	13	diamantina	diamantina	PROPN
bjos-8641742	4	14	,	,	PUNCT
bjos-8641742	4	15	mg	mg	PROPN
bjos-8641742	4	16	,	,	PUNCT
bjos-8641742	4	17	brazil	brazil	PROPN
bjos-8641742	4	18	4phd	4phd	NOUN
bjos-8641742	4	19	,	,	PUNCT
bjos-8641742	4	20	associate	associate	NOUN
bjos-8641742	4	21	professor	professor	NOUN
bjos-8641742	4	22	,	,	PUNCT
bjos-8641742	4	23	department	department	NOUN
bjos-8641742	4	24	of	of	ADP
bjos-8641742	4	25	oral	oral	ADJ
bjos-8641742	4	26	pathology	pathology	NOUN
bjos-8641742	4	27	,	,	PUNCT
bjos-8641742	4	28	dental	dental	ADJ
bjos-8641742	4	29	school	school	NOUN
bjos-8641742	4	30	,	,	PUNCT
bjos-8641742	4	31	federal	federal	ADJ
bjos-8641742	4	32	university	university	PROPN
bjos-8641742	4	33	of	of	ADP
bjos-8641742	4	34	minas	minas	PROPN
bjos-8641742	4	35	gerais	gerais	PROPN
bjos-8641742	4	36	,	,	PUNCT
bjos-8641742	4	37	belo	belo	PROPN
bjos-8641742	4	38	horizonte	horizonte	PROPN
bjos-8641742	4	39	,	,	PUNCT
bjos-8641742	4	40	mg	mg	PROPN
bjos-8641742	4	41	,	,	PUNCT
bjos-8641742	4	42	brazil	brazil	PROPN
bjos-8641742	4	43	correspondence	correspondence	NOUN
bjos-8641742	4	44	to	to	ADP
bjos-8641742	4	45	:	:	PUNCT
bjos-8641742	4	46	ricardo	ricardo	PROPN
bjos-8641742	4	47	alves	alves	PROPN
bjos-8641742	4	48	mesquita	mesquita	PROPN
bjos-8641742	4	49	faculdade	faculdade	PROPN
bjos-8641742	4	50	de	de	PROPN
bjos-8641742	4	51	odontologia	odontologia	PROPN
bjos-8641742	4	52	da	da	PROPN
bjos-8641742	4	53	ufmg	ufmg	PROPN
bjos-8641742	4	54	disciplina	disciplina	PROPN
bjos-8641742	4	55	de	de	PROPN
bjos-8641742	4	56	patologia	patologia	PROPN
bjos-8641742	4	57	bucal	bucal	NOUN
bjos-8641742	4	58	,	,	PUNCT
bjos-8641742	4	59	sala	sala	PROPN
bjos-8641742	4	60	3202	3202	NUM
bjos-8641742	4	61	-	-	PUNCT
bjos-8641742	4	62	d	d	PROPN
bjos-8641742	4	63	av	av	PROPN
bjos-8641742	4	64	.	.	PROPN
bjos-8641742	4	65	antônio	antônio	PROPN
bjos-8641742	4	66	carlos	carlos	PROPN
bjos-8641742	4	67	,	,	PUNCT
bjos-8641742	4	68	6627	6627	NUM
bjos-8641742	4	69	pampulha	pampulha	NOUN
bjos-8641742	4	70	31270	31270	NUM
bjos-8641742	4	71	-	-	SYM
bjos-8641742	4	72	901	901	NUM
bjos-8641742	4	73	belo	belo	NOUN
bjos-8641742	4	74	horizonte	horizonte	ADV
bjos-8641742	4	75	mg	mg	PROPN
bjos-8641742	4	76	,	,	PUNCT
bjos-8641742	4	77	brasil	brasil	PROPN
bjos-8641742	4	78	phone	phone	NOUN
bjos-8641742	4	79	:	:	PUNCT
bjos-8641742	4	80	+55	+55	NUM
bjos-8641742	4	81	-	-	PUNCT
bjos-8641742	4	82	31	31	NUM
bjos-8641742	4	83	-	-	PUNCT
bjos-8641742	4	84	3409	3409	NUM
bjos-8641742	4	85	-	-	SYM
bjos-8641742	4	86	2499	2499	NUM
bjos-8641742	4	87	e	e	NOUN
bjos-8641742	4	88	-	-	NOUN
bjos-8641742	4	89	mail	mail	NOUN
bjos-8641742	4	90	:	:	PUNCT
bjos-8641742	4	91	ramesquita@ufmg.br	ramesquita@ufmg.br	VERB
bjos-8641742	4	92	abstract	abstract	ADJ
bjos-8641742	4	93	aim	aim	NOUN
bjos-8641742	4	94	:	:	PUNCT
bjos-8641742	4	95	the	the	DET
bjos-8641742	4	96	goals	goal	NOUN
bjos-8641742	4	97	of	of	ADP
bjos-8641742	4	98	this	this	DET
bjos-8641742	4	99	study	study	NOUN
bjos-8641742	4	100	were	be	AUX
bjos-8641742	4	101	:	:	PUNCT
bjos-8641742	4	102	1	1	X
bjos-8641742	4	103	)	)	PUNCT
bjos-8641742	4	104	to	to	PART
bjos-8641742	4	105	estimate	estimate	VERB
bjos-8641742	4	106	the	the	DET
bjos-8641742	4	107	prevalence	prevalence	NOUN
bjos-8641742	4	108	of	of	ADP
bjos-8641742	4	109	oral	oral	ADJ
bjos-8641742	4	110	candidiasis	candidiasis	NOUN
bjos-8641742	4	111	(	(	PUNCT
bjos-8641742	4	112	oc	oc	NOUN
bjos-8641742	4	113	)	)	PUNCT
bjos-8641742	4	114	in	in	ADP
bjos-8641742	4	115	a	a	DET
bjos-8641742	4	116	sample	sample	NOUN
bjos-8641742	4	117	of	of	ADP
bjos-8641742	4	118	brazilian	brazilian	ADJ
bjos-8641742	4	119	hiv	hiv	PROPN
bjos-8641742	4	120	-	-	PUNCT
bjos-8641742	4	121	infected	infect	VERB
bjos-8641742	4	122	adult	adult	NOUN
bjos-8641742	4	123	patients	patient	NOUN
bjos-8641742	4	124	,	,	PUNCT
bjos-8641742	4	125	and	and	CCONJ
bjos-8641742	4	126	2	2	NUM
bjos-8641742	4	127	)	)	PUNCT
bjos-8641742	4	128	to	to	PART
bjos-8641742	4	129	investigate	investigate	VERB
bjos-8641742	4	130	the	the	DET
bjos-8641742	4	131	risk	risk	NOUN
bjos-8641742	4	132	factors	factor	NOUN
bjos-8641742	4	133	for	for	ADP
bjos-8641742	4	134	hivassociated	hivassociated	ADJ
bjos-8641742	4	135	oc	oc	NOUN
bjos-8641742	4	136	in	in	ADP
bjos-8641742	4	137	this	this	DET
bjos-8641742	4	138	sample	sample	NOUN
bjos-8641742	4	139	.	.	PUNCT
bjos-8641742	5	1	methods	method	NOUN
bjos-8641742	5	2	:	:	PUNCT
bjos-8641742	5	3	this	this	DET
bjos-8641742	5	4	case	case	NOUN
bjos-8641742	5	5	-	-	PUNCT
bjos-8641742	5	6	control	control	NOUN
bjos-8641742	5	7	study	study	NOUN
bjos-8641742	5	8	included	include	VERB
bjos-8641742	5	9	112	112	NUM
bjos-8641742	5	10	hiv	hiv	PROPN
bjos-8641742	5	11	-	-	PUNCT
bjos-8641742	5	12	infected	infect	VERB
bjos-8641742	5	13	patients	patient	NOUN
bjos-8641742	5	14	treated	treat	VERB
bjos-8641742	5	15	between	between	ADP
bjos-8641742	5	16	2002	2002	NUM
bjos-8641742	5	17	and	and	CCONJ
bjos-8641742	5	18	2004	2004	NUM
bjos-8641742	5	19	at	at	ADP
bjos-8641742	5	20	a	a	DET
bjos-8641742	5	21	clinic	clinic	NOUN
bjos-8641742	5	22	for	for	ADP
bjos-8641742	5	23	sexually	sexually	ADV
bjos-8641742	5	24	transmitted	transmit	VERB
bjos-8641742	5	25	diseases	disease	NOUN
bjos-8641742	5	26	.	.	PUNCT
bjos-8641742	6	1	data	datum	NOUN
bjos-8641742	6	2	were	be	AUX
bjos-8641742	6	3	collected	collect	VERB
bjos-8641742	6	4	from	from	ADP
bjos-8641742	6	5	medical	medical	ADJ
bjos-8641742	6	6	records	record	NOUN
bjos-8641742	6	7	and	and	CCONJ
bjos-8641742	6	8	clinical	clinical	ADJ
bjos-8641742	6	9	examinations	examination	NOUN
bjos-8641742	6	10	.	.	PUNCT
bjos-8641742	7	1	diagnosis	diagnosis	NOUN
bjos-8641742	7	2	of	of	ADP
bjos-8641742	7	3	oc	oc	NOUN
bjos-8641742	7	4	was	be	AUX
bjos-8641742	7	5	performed	perform	VERB
bjos-8641742	7	6	in	in	ADP
bjos-8641742	7	7	accordance	accordance	NOUN
bjos-8641742	7	8	with	with	ADP
bjos-8641742	7	9	the	the	DET
bjos-8641742	7	10	international	international	ADJ
bjos-8641742	7	11	classification	classification	NOUN
bjos-8641742	7	12	system	system	NOUN
bjos-8641742	7	13	and	and	CCONJ
bjos-8641742	7	14	cytological	cytological	ADJ
bjos-8641742	7	15	features	feature	NOUN
bjos-8641742	7	16	.	.	PUNCT
bjos-8641742	8	1	seventeen	seventeen	NUM
bjos-8641742	8	2	clinical	clinical	ADJ
bjos-8641742	8	3	and	and	CCONJ
bjos-8641742	8	4	laboratorial	laboratorial	ADJ
bjos-8641742	8	5	variables	variable	NOUN
bjos-8641742	8	6	were	be	AUX
bjos-8641742	8	7	registered	register	VERB
bjos-8641742	8	8	.	.	PUNCT
bjos-8641742	9	1	univariate	univariate	ADJ
bjos-8641742	9	2	analyses	analysis	NOUN
bjos-8641742	9	3	were	be	AUX
bjos-8641742	9	4	performed	perform	VERB
bjos-8641742	9	5	on	on	ADP
bjos-8641742	9	6	all	all	DET
bjos-8641742	9	7	variables	variable	NOUN
bjos-8641742	9	8	.	.	PUNCT
bjos-8641742	10	1	multiple	multiple	ADJ
bjos-8641742	10	2	logistic	logistic	ADJ
bjos-8641742	10	3	regression	regression	NOUN
bjos-8641742	10	4	techniques	technique	NOUN
bjos-8641742	10	5	were	be	AUX
bjos-8641742	10	6	used	use	VERB
bjos-8641742	10	7	to	to	PART
bjos-8641742	10	8	develop	develop	VERB
bjos-8641742	10	9	a	a	DET
bjos-8641742	10	10	model	model	NOUN
bjos-8641742	10	11	and	and	CCONJ
bjos-8641742	10	12	identify	identify	VERB
bjos-8641742	10	13	the	the	DET
bjos-8641742	10	14	set	set	NOUN
bjos-8641742	10	15	of	of	ADP
bjos-8641742	10	16	variables	variable	NOUN
bjos-8641742	10	17	that	that	PRON
bjos-8641742	10	18	may	may	AUX
bjos-8641742	10	19	predict	predict	VERB
bjos-8641742	10	20	risk	risk	NOUN
bjos-8641742	10	21	factors	factor	NOUN
bjos-8641742	10	22	in	in	ADP
bjos-8641742	10	23	hiv	hiv	PROPN
bjos-8641742	10	24	-	-	PUNCT
bjos-8641742	10	25	infected	infect	VERB
bjos-8641742	10	26	adult	adult	NOUN
bjos-8641742	10	27	patients	patient	NOUN
bjos-8641742	10	28	with	with	ADP
bjos-8641742	10	29	oc	oc	PROPN
bjos-8641742	10	30	.	.	PROPN
bjos-8641742	10	31	results	result	NOUN
bjos-8641742	10	32	:	:	PUNCT
bjos-8641742	10	33	prevalence	prevalence	NOUN
bjos-8641742	10	34	of	of	ADP
bjos-8641742	10	35	oc	oc	NOUN
bjos-8641742	10	36	was	be	AUX
bjos-8641742	10	37	31.3	31.3	NUM
bjos-8641742	10	38	%	%	NOUN
bjos-8641742	10	39	.	.	PUNCT
bjos-8641742	11	1	oc	oc	PROPN
bjos-8641742	11	2	was	be	AUX
bjos-8641742	11	3	associated	associate	VERB
bjos-8641742	11	4	with	with	ADP
bjos-8641742	11	5	oral	oral	ADJ
bjos-8641742	11	6	hairy	hairy	ADJ
bjos-8641742	11	7	leukoplakia	leukoplakia	NOUN
bjos-8641742	11	8	(	(	PUNCT
bjos-8641742	11	9	ohl	ohl	NOUN
bjos-8641742	11	10	)	)	PUNCT
bjos-8641742	12	1	[	[	X
bjos-8641742	12	2	p<0.001	p<0.001	X
bjos-8641742	12	3	;	;	PUNCT
bjos-8641742	12	4	odds	odd	NOUN
bjos-8641742	12	5	ratio	ratio	NOUN
bjos-8641742	12	6	(	(	PUNCT
bjos-8641742	12	7	or	or	CCONJ
bjos-8641742	12	8	)	)	PUNCT
bjos-8641742	12	9	=	=	SYM
bjos-8641742	12	10	10.2	10.2	NUM
bjos-8641742	12	11	(	(	PUNCT
bjos-8641742	12	12	95%ci	95%ci	NUM
bjos-8641742	12	13	:	:	PUNCT
bjos-8641742	12	14	4.0	4.0	NUM
bjos-8641742	12	15	-	-	SYM
bjos-8641742	12	16	26.0	26.0	NUM
bjos-8641742	12	17	)	)	PUNCT
bjos-8641742	12	18	]	]	PUNCT
bjos-8641742	12	19	,	,	PUNCT
bjos-8641742	12	20	previous	previous	ADJ
bjos-8641742	12	21	use	use	NOUN
bjos-8641742	12	22	of	of	ADP
bjos-8641742	12	23	fluconazole	fluconazole	NOUN
bjos-8641742	12	24	[	[	X
bjos-8641742	12	25	p<0.001	p<0.001	X
bjos-8641742	12	26	;	;	PUNCT
bjos-8641742	12	27	or=27.4	or=27.4	PROPN
bjos-8641742	12	28	(	(	PUNCT
bjos-8641742	12	29	95%ci	95%ci	NUM
bjos-8641742	12	30	:	:	PUNCT
bjos-8641742	12	31	8.1	8.1	NUM
bjos-8641742	12	32	-	-	SYM
bjos-8641742	12	33	92.0	92.0	NUM
bjos-8641742	12	34	)	)	PUNCT
bjos-8641742	12	35	]	]	PUNCT
bjos-8641742	12	36	and	and	CCONJ
bjos-8641742	12	37	viral	viral	ADJ
bjos-8641742	12	38	load	load	NOUN
bjos-8641742	12	39	[	[	X
bjos-8641742	12	40	p=0.042	p=0.042	NUM
bjos-8641742	12	41	;	;	PUNCT
bjos-8641742	12	42	or=2.3	or=2.3	X
bjos-8641742	12	43	(	(	PUNCT
bjos-8641742	12	44	95%ci	95%ci	NUM
bjos-8641742	12	45	:	:	PUNCT
bjos-8641742	12	46	1.0	1.0	NUM
bjos-8641742	12	47	-	-	SYM
bjos-8641742	12	48	5.3	5.3	NUM
bjos-8641742	12	49	)	)	PUNCT
bjos-8641742	12	50	]	]	PUNCT
bjos-8641742	12	51	.	.	PUNCT
bjos-8641742	13	1	conclusions	conclusion	NOUN
bjos-8641742	13	2	:	:	PUNCT
bjos-8641742	13	3	these	these	DET
bjos-8641742	13	4	results	result	NOUN
bjos-8641742	13	5	are	be	AUX
bjos-8641742	13	6	important	important	ADJ
bjos-8641742	13	7	for	for	ADP
bjos-8641742	13	8	the	the	DET
bjos-8641742	13	9	development	development	NOUN
bjos-8641742	13	10	of	of	ADP
bjos-8641742	13	11	strategies	strategy	NOUN
bjos-8641742	13	12	to	to	PART
bjos-8641742	13	13	eliminate	eliminate	VERB
bjos-8641742	13	14	these	these	DET
bjos-8641742	13	15	risk	risk	NOUN
bjos-8641742	13	16	factors	factor	NOUN
bjos-8641742	13	17	and	and	CCONJ
bjos-8641742	13	18	significantly	significantly	ADV
bjos-8641742	13	19	reduce	reduce	VERB
bjos-8641742	13	20	oc	oc	NOUN
bjos-8641742	13	21	in	in	ADP
bjos-8641742	13	22	hiv	hiv	PROPN
bjos-8641742	13	23	-	-	PUNCT
bjos-8641742	13	24	infected	infect	VERB
bjos-8641742	13	25	patients	patient	NOUN
bjos-8641742	13	26	.	.	PUNCT
bjos-8641742	14	1	keywords	keyword	NOUN
bjos-8641742	14	2	:	:	PUNCT
bjos-8641742	14	3	aids	aid	NOUN
bjos-8641742	14	4	,	,	PUNCT
bjos-8641742	14	5	candidiasis	candidiasis	NOUN
bjos-8641742	14	6	,	,	PUNCT
bjos-8641742	14	7	haart	haart	PROPN
bjos-8641742	14	8	,	,	PUNCT
bjos-8641742	14	9	hiv	hiv	PROPN
bjos-8641742	14	10	infection	infection	NOUN
bjos-8641742	14	11	,	,	PUNCT
bjos-8641742	14	12	prevalence	prevalence	NOUN
bjos-8641742	14	13	ratio	ratio	NOUN
bjos-8641742	14	14	,	,	PUNCT
bjos-8641742	14	15	risk	risk	NOUN
bjos-8641742	14	16	factors	factor	NOUN
bjos-8641742	14	17	.	.	PUNCT
bjos-8641742	15	1	introduction	introduction	NOUN
bjos-8641742	15	2	oral	oral	ADJ
bjos-8641742	15	3	candidiasis	candidiasis	NOUN
bjos-8641742	15	4	(	(	PUNCT
bjos-8641742	15	5	oc	oc	NOUN
bjos-8641742	15	6	)	)	PUNCT
bjos-8641742	15	7	is	be	AUX
bjos-8641742	15	8	the	the	DET
bjos-8641742	15	9	most	most	ADV
bjos-8641742	15	10	frequent	frequent	ADJ
bjos-8641742	15	11	hiv	hiv	PROPN
bjos-8641742	15	12	infection	infection	NOUN
bjos-8641742	15	13	-	-	PUNCT
bjos-8641742	15	14	associated	associate	VERB
bjos-8641742	15	15	oral	oral	ADJ
bjos-8641742	15	16	disease	disease	NOUN
bjos-8641742	15	17	,	,	PUNCT
bjos-8641742	15	18	and	and	CCONJ
bjos-8641742	15	19	can	can	AUX
bjos-8641742	15	20	also	also	ADV
bjos-8641742	15	21	act	act	VERB
bjos-8641742	15	22	as	as	ADP
bjos-8641742	15	23	a	a	DET
bjos-8641742	15	24	marker	marker	NOUN
bjos-8641742	15	25	for	for	ADP
bjos-8641742	15	26	immunosuppression1	immunosuppression1	NOUN
bjos-8641742	15	27	-	-	SYM
bjos-8641742	15	28	6	6	NUM
bjos-8641742	15	29	.	.	PUNCT
bjos-8641742	16	1	the	the	DET
bjos-8641742	16	2	prevalence	prevalence	NOUN
bjos-8641742	16	3	and	and	CCONJ
bjos-8641742	16	4	incidence	incidence	NOUN
bjos-8641742	16	5	of	of	ADP
bjos-8641742	16	6	hiv	hiv	PROPN
bjos-8641742	16	7	infection	infection	NOUN
bjos-8641742	16	8	in	in	ADP
bjos-8641742	16	9	brazil	brazil	PROPN
bjos-8641742	16	10	are	be	AUX
bjos-8641742	16	11	7.5	7.5	NUM
bjos-8641742	16	12	%	%	NOUN
bjos-8641742	16	13	and	and	CCONJ
bjos-8641742	16	14	1.39	1.39	NUM
bjos-8641742	16	15	%	%	NOUN
bjos-8641742	16	16	,	,	PUNCT
bjos-8641742	16	17	respectively5	respectively5	PROPN
bjos-8641742	16	18	.	.	PUNCT
bjos-8641742	17	1	the	the	DET
bjos-8641742	17	2	literature	literature	NOUN
bjos-8641742	17	3	supports	support	VERB
bjos-8641742	17	4	the	the	DET
bjos-8641742	17	5	position	position	NOUN
bjos-8641742	17	6	that	that	PRON
bjos-8641742	17	7	systemically	systemically	ADV
bjos-8641742	17	8	applied	apply	VERB
bjos-8641742	17	9	antifungal	antifungal	ADJ
bjos-8641742	17	10	drugs	drug	NOUN
bjos-8641742	17	11	have	have	VERB
bjos-8641742	17	12	the	the	DET
bjos-8641742	17	13	greatest	great	ADJ
bjos-8641742	17	14	efficacy	efficacy	NOUN
bjos-8641742	17	15	for	for	ADP
bjos-8641742	17	16	the	the	DET
bjos-8641742	17	17	treatment	treatment	NOUN
bjos-8641742	17	18	of	of	ADP
bjos-8641742	17	19	oc	oc	PROPN
bjos-8641742	17	20	.	.	PUNCT
bjos-8641742	18	1	however	however	ADV
bjos-8641742	18	2	,	,	PUNCT
bjos-8641742	18	3	these	these	DET
bjos-8641742	18	4	therapies	therapy	NOUN
bjos-8641742	18	5	must	must	AUX
bjos-8641742	18	6	be	be	AUX
bjos-8641742	18	7	prescribed	prescribe	VERB
bjos-8641742	18	8	following	follow	VERB
bjos-8641742	18	9	a	a	DET
bjos-8641742	18	10	thorough	thorough	ADJ
bjos-8641742	18	11	assessment	assessment	NOUN
bjos-8641742	18	12	of	of	ADP
bjos-8641742	18	13	the	the	DET
bjos-8641742	18	14	risk	risk	NOUN
bjos-8641742	18	15	for	for	ADP
bjos-8641742	18	16	developing	develop	VERB
bjos-8641742	18	17	drug	drug	NOUN
bjos-8641742	18	18	-	-	PUNCT
bjos-8641742	18	19	induced	induce	VERB
bjos-8641742	18	20	toxicities6	toxicities6	NOUN
bjos-8641742	18	21	.	.	PUNCT
bjos-8641742	19	1	oc	oc	AUX
bjos-8641742	19	2	responds	respond	NOUN
bjos-8641742	19	3	to	to	ADP
bjos-8641742	19	4	antifungal	antifungal	ADJ
bjos-8641742	19	5	therapy	therapy	NOUN
bjos-8641742	19	6	,	,	PUNCT
bjos-8641742	19	7	but	but	CCONJ
bjos-8641742	19	8	eradication	eradication	NOUN
bjos-8641742	19	9	is	be	AUX
bjos-8641742	19	10	rarely	rarely	ADV
bjos-8641742	19	11	achieved	achieve	VERB
bjos-8641742	19	12	unless	unless	SCONJ
bjos-8641742	19	13	the	the	DET
bjos-8641742	19	14	underlying	underlying	ADJ
bjos-8641742	19	15	immune	immune	NOUN
bjos-8641742	19	16	-	-	PUNCT
bjos-8641742	19	17	compromised	compromise	VERB
bjos-8641742	19	18	state	state	NOUN
bjos-8641742	19	19	is	be	AUX
bjos-8641742	19	20	resolved2,7	resolved2,7	PROPN
bjos-8641742	19	21	.	.	PUNCT
bjos-8641742	20	1	data	datum	NOUN
bjos-8641742	20	2	about	about	ADP
bjos-8641742	20	3	risk	risk	NOUN
bjos-8641742	20	4	factors	factor	NOUN
bjos-8641742	20	5	for	for	ADP
bjos-8641742	20	6	hiv	hiv	PROPN
bjos-8641742	20	7	infection	infection	NOUN
bjos-8641742	20	8	-	-	PUNCT
bjos-8641742	20	9	associated	associate	VERB
bjos-8641742	20	10	oral	oral	ADJ
bjos-8641742	20	11	lesions	lesion	NOUN
bjos-8641742	20	12	in	in	ADP
bjos-8641742	20	13	the	the	DET
bjos-8641742	20	14	south	south	ADJ
bjos-8641742	20	15	american	american	ADJ
bjos-8641742	20	16	population	population	NOUN
bjos-8641742	20	17	are	be	AUX
bjos-8641742	20	18	insufficient1,3,8	insufficient1,3,8	VERB
bjos-8641742	20	19	.	.	PUNCT
bjos-8641742	21	1	some	some	DET
bjos-8641742	21	2	studies	study	NOUN
bjos-8641742	21	3	have	have	AUX
bjos-8641742	21	4	identified	identify	VERB
bjos-8641742	21	5	potential	potential	ADJ
bjos-8641742	21	6	risk	risk	NOUN
bjos-8641742	21	7	factors	factor	NOUN
bjos-8641742	21	8	for	for	ADP
bjos-8641742	21	9	development	development	NOUN
bjos-8641742	21	10	of	of	ADP
bjos-8641742	21	11	hiv	hiv	PROPN
bjos-8641742	21	12	-	-	PUNCT
bjos-8641742	21	13	associated	associate	VERB
bjos-8641742	21	14	oral	oral	ADJ
bjos-8641742	21	15	diseases3	diseases3	PROPN
bjos-8641742	21	16	-	-	PUNCT
bjos-8641742	21	17	4,7,9	4,7,9	NUM
bjos-8641742	21	18	-	-	PUNCT
bjos-8641742	21	19	11	11	NUM
bjos-8641742	21	20	.	.	PUNCT
bjos-8641742	22	1	moura	moura	NOUN
bjos-8641742	22	2	et	et	PROPN
bjos-8641742	22	3	al.4	al.4	PROPN
bjos-8641742	22	4	demonstrated	demonstrate	VERB
bjos-8641742	22	5	statistically	statistically	ADV
bjos-8641742	22	6	significant	significant	ADJ
bjos-8641742	22	7	associations	association	NOUN
bjos-8641742	22	8	between	between	ADP
bjos-8641742	22	9	oral	oral	ADJ
bjos-8641742	22	10	hairy	hairy	ADJ
bjos-8641742	22	11	leukoplakia	leukoplakia	NOUN
bjos-8641742	22	12	(	(	PUNCT
bjos-8641742	22	13	ohl	ohl	NOUN
bjos-8641742	22	14	)	)	PUNCT
bjos-8641742	22	15	and	and	CCONJ
bjos-8641742	22	16	hiv-1	hiv-1	PUNCT
bjos-8641742	22	17	viral	viral	ADJ
bjos-8641742	22	18	load	load	NOUN
bjos-8641742	22	19	,	,	PUNCT
bjos-8641742	22	20	oc	oc	ADP
bjos-8641742	22	21	,	,	PUNCT
bjos-8641742	22	22	previous	previous	ADJ
bjos-8641742	22	23	use	use	NOUN
bjos-8641742	22	24	of	of	ADP
bjos-8641742	22	25	fluconazole	fluconazole	NOUN
bjos-8641742	22	26	and	and	CCONJ
bjos-8641742	22	27	systemic	systemic	ADJ
bjos-8641742	22	28	acyclovir	acyclovir	PROPN
bjos-8641742	22	29	in	in	ADP
bjos-8641742	22	30	brazilian	brazilian	PROPN
bjos-8641742	22	31	hiv	hiv	PROPN
bjos-8641742	22	32	-	-	PUNCT
bjos-8641742	22	33	infected	infect	VERB
bjos-8641742	22	34	adult	adult	NOUN
bjos-8641742	22	35	patients	patient	NOUN
bjos-8641742	22	36	.	.	PUNCT
bjos-8641742	23	1	therefore	therefore	ADV
bjos-8641742	23	2	,	,	PUNCT
bjos-8641742	23	3	the	the	DET
bjos-8641742	23	4	goals	goal	NOUN
bjos-8641742	23	5	of	of	ADP
bjos-8641742	23	6	this	this	DET
bjos-8641742	23	7	study	study	NOUN
bjos-8641742	23	8	were	be	AUX
bjos-8641742	23	9	:	:	PUNCT
bjos-8641742	23	10	1	1	X
bjos-8641742	23	11	)	)	PUNCT
bjos-8641742	23	12	braz	braz	PROPN
bjos-8641742	23	13	j	j	PROPN
bjos-8641742	23	14	oral	oral	PROPN
bjos-8641742	23	15	sci	sci	PROPN
bjos-8641742	23	16	.	.	PROPN
bjos-8641742	24	1	9(4):470	9(4):470	NUM
bjos-8641742	24	2	-	-	PUNCT
bjos-8641742	24	3	474	474	NUM
bjos-8641742	24	4	to	to	PART
bjos-8641742	24	5	estimate	estimate	VERB
bjos-8641742	24	6	the	the	DET
bjos-8641742	24	7	prevalence	prevalence	NOUN
bjos-8641742	24	8	of	of	ADP
bjos-8641742	24	9	oc	oc	NOUN
bjos-8641742	24	10	in	in	ADP
bjos-8641742	24	11	a	a	DET
bjos-8641742	24	12	sample	sample	NOUN
bjos-8641742	24	13	of	of	ADP
bjos-8641742	24	14	brazilian	brazilian	ADJ
bjos-8641742	24	15	hiv	hiv	PROPN
bjos-8641742	24	16	-	-	PUNCT
bjos-8641742	24	17	infected	infect	VERB
bjos-8641742	24	18	adult	adult	NOUN
bjos-8641742	24	19	patients	patient	NOUN
bjos-8641742	24	20	,	,	PUNCT
bjos-8641742	24	21	and	and	CCONJ
bjos-8641742	24	22	2	2	NUM
bjos-8641742	24	23	)	)	PUNCT
bjos-8641742	24	24	to	to	PART
bjos-8641742	24	25	investigate	investigate	VERB
bjos-8641742	24	26	the	the	DET
bjos-8641742	24	27	risk	risk	NOUN
bjos-8641742	24	28	factors	factor	NOUN
bjos-8641742	24	29	for	for	ADP
bjos-8641742	24	30	hiv	hiv	PROPN
bjos-8641742	24	31	-	-	PUNCT
bjos-8641742	24	32	associated	associate	VERB
bjos-8641742	24	33	oc	oc	NOUN
bjos-8641742	24	34	in	in	ADP
bjos-8641742	24	35	this	this	DET
bjos-8641742	24	36	sample	sample	NOUN
bjos-8641742	24	37	.	.	PUNCT
bjos-8641742	25	1	material	material	NOUN
bjos-8641742	25	2	and	and	CCONJ
bjos-8641742	25	3	methods	method	NOUN
bjos-8641742	25	4	between	between	ADP
bjos-8641742	25	5	2002	2002	NUM
bjos-8641742	25	6	and	and	CCONJ
bjos-8641742	25	7	2004	2004	NUM
bjos-8641742	25	8	,	,	PUNCT
bjos-8641742	25	9	112	112	NUM
bjos-8641742	25	10	hiv	hiv	NOUN
bjos-8641742	25	11	-	-	PUNCT
bjos-8641742	25	12	infected	infect	VERB
bjos-8641742	25	13	adult	adult	NOUN
bjos-8641742	25	14	volunteers	volunteer	NOUN
bjos-8641742	25	15	were	be	AUX
bjos-8641742	25	16	recruited	recruit	VERB
bjos-8641742	25	17	from	from	ADP
bjos-8641742	25	18	the	the	DET
bjos-8641742	25	19	orestes	oreste	NOUN
bjos-8641742	25	20	diniz	diniz	PROPN
bjos-8641742	25	21	treatment	treatment	NOUN
bjos-8641742	25	22	center	center	NOUN
bjos-8641742	25	23	of	of	ADP
bjos-8641742	25	24	parasitic	parasitic	ADJ
bjos-8641742	25	25	and	and	CCONJ
bjos-8641742	25	26	infectious	infectious	ADJ
bjos-8641742	25	27	diseases	disease	NOUN
bjos-8641742	25	28	(	(	PUNCT
bjos-8641742	25	29	ctr	ctr	PROPN
bjos-8641742	25	30	-	-	PUNCT
bjos-8641742	25	31	dip	dip	NOUN
bjos-8641742	25	32	)	)	PUNCT
bjos-8641742	25	33	(	(	PUNCT
bjos-8641742	25	34	belo	belo	PROPN
bjos-8641742	25	35	horizonte	horizonte	PROPN
bjos-8641742	25	36	,	,	PUNCT
bjos-8641742	25	37	mg	mg	PROPN
bjos-8641742	25	38	,	,	PUNCT
bjos-8641742	25	39	brazil	brazil	PROPN
bjos-8641742	25	40	)	)	PUNCT
bjos-8641742	25	41	to	to	PART
bjos-8641742	25	42	participate	participate	VERB
bjos-8641742	25	43	in	in	ADP
bjos-8641742	25	44	this	this	DET
bjos-8641742	25	45	case	case	NOUN
bjos-8641742	25	46	-	-	PUNCT
bjos-8641742	25	47	control	control	NOUN
bjos-8641742	25	48	study	study	NOUN
bjos-8641742	25	49	,	,	PUNCT
bjos-8641742	25	50	approved	approve	VERB
bjos-8641742	25	51	by	by	ADP
bjos-8641742	25	52	the	the	DET
bjos-8641742	25	53	ufmg	ufmg	PROPN
bjos-8641742	25	54	’s	’s	PART
bjos-8641742	25	55	bioethics	bioethics	PROPN
bjos-8641742	25	56	research	research	PROPN
bjos-8641742	25	57	committee	committee	PROPN
bjos-8641742	25	58	(	(	PUNCT
bjos-8641742	25	59	protocol	protocol	NOUN
bjos-8641742	25	60	number	number	NOUN
bjos-8641742	25	61	339/03	339/03	NUM
bjos-8641742	25	62	)	)	PUNCT
bjos-8641742	25	63	.	.	PUNCT
bjos-8641742	26	1	all	all	DET
bjos-8641742	26	2	patients	patient	NOUN
bjos-8641742	26	3	were	be	AUX
bjos-8641742	26	4	first	first	ADV
bjos-8641742	26	5	diagnosed	diagnose	VERB
bjos-8641742	26	6	with	with	ADP
bjos-8641742	26	7	hiv	hiv	PROPN
bjos-8641742	26	8	-	-	PUNCT
bjos-8641742	26	9	infection	infection	NOUN
bjos-8641742	26	10	by	by	ADP
bjos-8641742	26	11	enzyme	enzyme	NOUN
bjos-8641742	26	12	-	-	PUNCT
bjos-8641742	26	13	linked	link	VERB
bjos-8641742	26	14	immunosorbant	immunosorbant	NOUN
bjos-8641742	26	15	assay	assay	NOUN
bjos-8641742	26	16	(	(	PUNCT
bjos-8641742	26	17	elisa	elisa	NOUN
bjos-8641742	26	18	)	)	PUNCT
bjos-8641742	26	19	as	as	ADP
bjos-8641742	26	20	the	the	DET
bjos-8641742	26	21	primary	primary	ADJ
bjos-8641742	26	22	detection	detection	NOUN
bjos-8641742	26	23	test	test	NOUN
bjos-8641742	26	24	,	,	PUNCT
bjos-8641742	26	25	and	and	CCONJ
bjos-8641742	26	26	the	the	DET
bjos-8641742	26	27	diagnoses	diagnosis	NOUN
bjos-8641742	26	28	were	be	AUX
bjos-8641742	26	29	subsequently	subsequently	ADV
bjos-8641742	26	30	confirmed	confirm	VERB
bjos-8641742	26	31	by	by	ADP
bjos-8641742	26	32	the	the	DET
bjos-8641742	26	33	western	western	ADJ
bjos-8641742	26	34	blot	blot	NOUN
bjos-8641742	26	35	test	test	NOUN
bjos-8641742	26	36	.	.	PUNCT
bjos-8641742	27	1	the	the	DET
bjos-8641742	27	2	diagnosis	diagnosis	NOUN
bjos-8641742	27	3	for	for	ADP
bjos-8641742	27	4	hiv	hiv	NOUN
bjos-8641742	27	5	-	-	PUNCT
bjos-8641742	27	6	infection	infection	NOUN
bjos-8641742	27	7	had	have	AUX
bjos-8641742	27	8	already	already	ADV
bjos-8641742	27	9	been	be	AUX
bjos-8641742	27	10	established	establish	VERB
bjos-8641742	27	11	during	during	ADP
bjos-8641742	27	12	the	the	DET
bjos-8641742	27	13	period	period	NOUN
bjos-8641742	27	14	of	of	ADP
bjos-8641742	27	15	the	the	DET
bjos-8641742	27	16	first	first	ADJ
bjos-8641742	27	17	exam	exam	NOUN
bjos-8641742	27	18	for	for	ADP
bjos-8641742	27	19	all	all	DET
bjos-8641742	27	20	patients	patient	NOUN
bjos-8641742	27	21	.	.	PUNCT
bjos-8641742	28	1	a	a	DET
bjos-8641742	28	2	single	single	ADJ
bjos-8641742	28	3	,	,	PUNCT
bjos-8641742	28	4	validated	validated	ADJ
bjos-8641742	28	5	examiner	examiner	NOUN
bjos-8641742	28	6	,	,	PUNCT
bjos-8641742	28	7	trained	train	VERB
bjos-8641742	28	8	in	in	ADP
bjos-8641742	28	9	oral	oral	ADJ
bjos-8641742	28	10	medicine	medicine	NOUN
bjos-8641742	28	11	,	,	PUNCT
bjos-8641742	28	12	conducted	conduct	VERB
bjos-8641742	28	13	the	the	DET
bjos-8641742	28	14	oral	oral	ADJ
bjos-8641742	28	15	clinical	clinical	ADJ
bjos-8641742	28	16	exam	exam	NOUN
bjos-8641742	28	17	in	in	ADP
bjos-8641742	28	18	accordance	accordance	NOUN
bjos-8641742	28	19	with	with	ADP
bjos-8641742	28	20	the	the	DET
bjos-8641742	28	21	world	world	PROPN
bjos-8641742	28	22	health	health	PROPN
bjos-8641742	28	23	organization	organization	PROPN
bjos-8641742	28	24	standards12	standards12	PROPN
bjos-8641742	28	25	.	.	PUNCT
bjos-8641742	29	1	oc	oc	ADP
bjos-8641742	29	2	diagnosis	diagnosis	NOUN
bjos-8641742	29	3	was	be	AUX
bjos-8641742	29	4	based	base	VERB
bjos-8641742	29	5	on	on	ADP
bjos-8641742	29	6	the	the	DET
bjos-8641742	29	7	published	publish	VERB
bjos-8641742	29	8	standard	standard	ADJ
bjos-8641742	29	9	presumptive	presumptive	ADJ
bjos-8641742	29	10	clinical	clinical	ADJ
bjos-8641742	29	11	criteria	criterion	NOUN
bjos-8641742	29	12	of	of	ADP
bjos-8641742	29	13	international	international	ADJ
bjos-8641742	29	14	classification	classification	NOUN
bjos-8641742	29	15	systems13	systems13	NOUN
bjos-8641742	29	16	.	.	PUNCT
bjos-8641742	30	1	also	also	ADV
bjos-8641742	30	2	,	,	PUNCT
bjos-8641742	30	3	cytological	cytological	ADJ
bjos-8641742	30	4	features	feature	NOUN
bjos-8641742	30	5	were	be	AUX
bjos-8641742	30	6	considered	consider	VERB
bjos-8641742	30	7	in	in	ADP
bjos-8641742	30	8	the	the	DET
bjos-8641742	30	9	diagnosis	diagnosis	NOUN
bjos-8641742	30	10	of	of	ADP
bjos-8641742	30	11	oc	oc	NOUN
bjos-8641742	30	12	:	:	PUNCT
bjos-8641742	30	13	morphologic	morphologic	ADJ
bjos-8641742	30	14	microscopic	microscopic	ADJ
bjos-8641742	30	15	observation	observation	NOUN
bjos-8641742	30	16	of	of	ADP
bjos-8641742	30	17	fungal	fungal	ADJ
bjos-8641742	30	18	mycelial	mycelial	NOUN
bjos-8641742	30	19	filaments	filament	NOUN
bjos-8641742	30	20	from	from	ADP
bjos-8641742	30	21	a	a	DET
bjos-8641742	30	22	non	non	ADJ
bjos-8641742	30	23	-	-	ADJ
bjos-8641742	30	24	cultured	cultured	ADJ
bjos-8641742	30	25	specimen	speciman	NOUN
bjos-8641742	30	26	scraped	scrape	VERB
bjos-8641742	30	27	from	from	ADP
bjos-8641742	30	28	the	the	DET
bjos-8641742	30	29	oral	oral	ADJ
bjos-8641742	30	30	mucosa	mucosa	NOUN
bjos-8641742	30	31	by	by	ADP
bjos-8641742	30	32	periodic	periodic	ADJ
bjos-8641742	30	33	acid	acid	NOUN
bjos-8641742	30	34	schiff	schiff	NOUN
bjos-8641742	30	35	(	(	PUNCT
bjos-8641742	30	36	pas	pas	PROPN
bjos-8641742	30	37	)	)	PUNCT
bjos-8641742	30	38	staining	stain	VERB
bjos-8641742	30	39	.	.	PUNCT
bjos-8641742	31	1	patients	patient	NOUN
bjos-8641742	31	2	with	with	ADP
bjos-8641742	31	3	a	a	DET
bjos-8641742	31	4	confirmed	confirm	VERB
bjos-8641742	31	5	diagnosis	diagnosis	NOUN
bjos-8641742	31	6	of	of	ADP
bjos-8641742	31	7	oc	oc	NOUN
bjos-8641742	31	8	were	be	AUX
bjos-8641742	31	9	included	include	VERB
bjos-8641742	31	10	in	in	ADP
bjos-8641742	31	11	the	the	DET
bjos-8641742	31	12	case	case	NOUN
bjos-8641742	31	13	group	group	NOUN
bjos-8641742	31	14	;	;	PUNCT
bjos-8641742	31	15	those	those	PRON
bjos-8641742	31	16	without	without	ADP
bjos-8641742	31	17	clinical	clinical	ADJ
bjos-8641742	31	18	features	feature	NOUN
bjos-8641742	31	19	of	of	ADP
bjos-8641742	31	20	oc	oc	NOUN
bjos-8641742	31	21	were	be	AUX
bjos-8641742	31	22	included	include	VERB
bjos-8641742	31	23	in	in	ADP
bjos-8641742	31	24	the	the	DET
bjos-8641742	31	25	control	control	NOUN
bjos-8641742	31	26	group	group	NOUN
bjos-8641742	31	27	.	.	PUNCT
bjos-8641742	32	1	the	the	DET
bjos-8641742	32	2	following	follow	VERB
bjos-8641742	32	3	variables	variable	NOUN
bjos-8641742	32	4	were	be	AUX
bjos-8641742	32	5	obtained	obtain	VERB
bjos-8641742	32	6	from	from	ADP
bjos-8641742	32	7	the	the	DET
bjos-8641742	32	8	case	case	NOUN
bjos-8641742	32	9	and	and	CCONJ
bjos-8641742	32	10	control	control	NOUN
bjos-8641742	32	11	groups	group	NOUN
bjos-8641742	32	12	:	:	PUNCT
bjos-8641742	32	13	age	age	NOUN
bjos-8641742	32	14	,	,	PUNCT
bjos-8641742	32	15	gender	gender	NOUN
bjos-8641742	32	16	,	,	PUNCT
bjos-8641742	32	17	race	race	NOUN
bjos-8641742	32	18	,	,	PUNCT
bjos-8641742	32	19	route	route	NOUN
bjos-8641742	32	20	of	of	ADP
bjos-8641742	32	21	transmission	transmission	NOUN
bjos-8641742	32	22	,	,	PUNCT
bjos-8641742	32	23	cd4	cd4	PROPN
bjos-8641742	32	24	t	t	PROPN
bjos-8641742	32	25	lymphocytes	lymphocyte	VERB
bjos-8641742	32	26	count	count	NOUN
bjos-8641742	32	27	,	,	PUNCT
bjos-8641742	32	28	viral	viral	ADJ
bjos-8641742	32	29	load	load	NOUN
bjos-8641742	32	30	,	,	PUNCT
bjos-8641742	32	31	platelets	platelet	NOUN
bjos-8641742	32	32	count	count	NOUN
bjos-8641742	32	33	,	,	PUNCT
bjos-8641742	32	34	salivary	salivary	ADJ
bjos-8641742	32	35	flow	flow	NOUN
bjos-8641742	32	36	,	,	PUNCT
bjos-8641742	32	37	xerostomia	xerostomia	PROPN
bjos-8641742	32	38	,	,	PUNCT
bjos-8641742	32	39	ohl	ohl	PROPN
bjos-8641742	32	40	,	,	PUNCT
bjos-8641742	32	41	previous	previous	ADJ
bjos-8641742	32	42	use	use	NOUN
bjos-8641742	32	43	of	of	ADP
bjos-8641742	32	44	fluconazole	fluconazole	NOUN
bjos-8641742	32	45	,	,	PUNCT
bjos-8641742	32	46	previous	previous	ADJ
bjos-8641742	32	47	use	use	NOUN
bjos-8641742	32	48	of	of	ADP
bjos-8641742	32	49	systemic	systemic	ADJ
bjos-8641742	32	50	acyclovir	acyclovir	NOUN
bjos-8641742	32	51	,	,	PUNCT
bjos-8641742	32	52	use	use	NOUN
bjos-8641742	32	53	of	of	ADP
bjos-8641742	32	54	highly	highly	ADV
bjos-8641742	32	55	active	active	ADJ
bjos-8641742	32	56	anti	anti	ADJ
bjos-8641742	32	57	-	-	ADJ
bjos-8641742	32	58	retroviral	retroviral	ADJ
bjos-8641742	32	59	therapy	therapy	NOUN
bjos-8641742	32	60	(	(	PUNCT
bjos-8641742	32	61	haart	haart	PROPN
bjos-8641742	32	62	)	)	PUNCT
bjos-8641742	32	63	,	,	PUNCT
bjos-8641742	32	64	use	use	NOUN
bjos-8641742	32	65	of	of	ADP
bjos-8641742	32	66	zidovudine	zidovudine	PROPN
bjos-8641742	32	67	(	(	PUNCT
bjos-8641742	32	68	azt	azt	PROPN
bjos-8641742	32	69	)	)	PUNCT
bjos-8641742	32	70	,	,	PUNCT
bjos-8641742	32	71	intravenous	intravenous	ADJ
bjos-8641742	32	72	drug	drug	NOUN
bjos-8641742	32	73	use	use	NOUN
bjos-8641742	32	74	,	,	PUNCT
bjos-8641742	32	75	smoking	smoking	NOUN
bjos-8641742	32	76	,	,	PUNCT
bjos-8641742	32	77	and	and	CCONJ
bjos-8641742	32	78	alcohol	alcohol	NOUN
bjos-8641742	32	79	consumption	consumption	NOUN
bjos-8641742	32	80	.	.	PUNCT
bjos-8641742	33	1	the	the	DET
bjos-8641742	33	2	cd4	cd4	PROPN
bjos-8641742	33	3	t	t	PROPN
bjos-8641742	33	4	lymphocyte	lymphocyte	ADJ
bjos-8641742	33	5	count	count	NOUN
bjos-8641742	33	6	was	be	AUX
bjos-8641742	33	7	divided	divide	VERB
bjos-8641742	33	8	into	into	ADP
bjos-8641742	33	9	<	<	NOUN
bjos-8641742	33	10	200	200	NUM
bjos-8641742	33	11	cells	cell	NOUN
bjos-8641742	33	12	/	/	SYM
bjos-8641742	33	13	mm3	mm3	NOUN
bjos-8641742	33	14	and	and	CCONJ
bjos-8641742	33	15	>	>	SYM
bjos-8641742	33	16	200	200	NUM
bjos-8641742	33	17	cells	cell	NOUN
bjos-8641742	33	18	/	/	SYM
bjos-8641742	33	19	mm3	mm3	NOUN
bjos-8641742	33	20	.	.	PUNCT
bjos-8641742	34	1	the	the	DET
bjos-8641742	34	2	viral	viral	ADJ
bjos-8641742	34	3	load	load	NOUN
bjos-8641742	34	4	was	be	AUX
bjos-8641742	34	5	divided	divide	VERB
bjos-8641742	34	6	into	into	ADP
bjos-8641742	34	7	<	<	PROPN
bjos-8641742	34	8	3,000	3,000	NUM
bjos-8641742	34	9	copies/µl	copies/µl	PROPN
bjos-8641742	34	10	and	and	CCONJ
bjos-8641742	34	11	>	>	SYM
bjos-8641742	34	12	3,000	3,000	NUM
bjos-8641742	34	13	copies/µl	copies/µl	PROPN
bjos-8641742	34	14	.	.	PUNCT
bjos-8641742	35	1	platelet	platelet	NOUN
bjos-8641742	35	2	count	count	NOUN
bjos-8641742	35	3	was	be	AUX
bjos-8641742	35	4	divided	divide	VERB
bjos-8641742	35	5	into	into	ADP
bjos-8641742	35	6	<	<	PROPN
bjos-8641742	35	7	150,000	150,000	NUM
bjos-8641742	35	8	/	/	SYM
bjos-8641742	35	9	mm3	mm3	NOUN
bjos-8641742	35	10	and	and	CCONJ
bjos-8641742	35	11	>	>	SYM
bjos-8641742	35	12	150,000	150,000	NUM
bjos-8641742	35	13	/	/	SYM
bjos-8641742	35	14	mm	mm	PROPN
bjos-8641742	35	15	3,4,14	3,4,14	NUM
bjos-8641742	35	16	-	-	SYM
bjos-8641742	35	17	16	16	NUM
bjos-8641742	35	18	.	.	PUNCT
bjos-8641742	36	1	the	the	DET
bjos-8641742	36	2	measurement	measurement	NOUN
bjos-8641742	36	3	of	of	ADP
bjos-8641742	36	4	the	the	DET
bjos-8641742	36	5	salivary	salivary	ADJ
bjos-8641742	36	6	flow	flow	NOUN
bjos-8641742	36	7	was	be	AUX
bjos-8641742	36	8	performed	perform	VERB
bjos-8641742	36	9	through	through	ADP
bjos-8641742	36	10	the	the	DET
bjos-8641742	36	11	collection	collection	NOUN
bjos-8641742	36	12	of	of	ADP
bjos-8641742	36	13	stimulated	stimulate	VERB
bjos-8641742	36	14	saliva	saliva	NOUN
bjos-8641742	36	15	,	,	PUNCT
bjos-8641742	36	16	over	over	ADP
bjos-8641742	36	17	the	the	DET
bjos-8641742	36	18	course	course	NOUN
bjos-8641742	36	19	of	of	ADP
bjos-8641742	36	20	five	five	NUM
bjos-8641742	36	21	minutes	minute	NOUN
bjos-8641742	36	22	,	,	PUNCT
bjos-8641742	36	23	in	in	ADP
bjos-8641742	36	24	accordance	accordance	NOUN
bjos-8641742	36	25	to	to	PART
bjos-8641742	36	26	tárzia17	tárzia17	VERB
bjos-8641742	36	27	.	.	PUNCT
bjos-8641742	37	1	the	the	DET
bjos-8641742	37	2	salivary	salivary	ADJ
bjos-8641742	37	3	flow	flow	NOUN
bjos-8641742	37	4	was	be	AUX
bjos-8641742	37	5	identified	identify	VERB
bjos-8641742	37	6	as	as	ADP
bjos-8641742	37	7	normal	normal	ADJ
bjos-8641742	37	8	(	(	PUNCT
bjos-8641742	37	9	>	>	X
bjos-8641742	37	10	0.70ml	0.70ml	PROPN
bjos-8641742	37	11	/	/	SYM
bjos-8641742	37	12	min	min	NOUN
bjos-8641742	37	13	)	)	PUNCT
bjos-8641742	37	14	,	,	PUNCT
bjos-8641742	37	15	moderately	moderately	ADV
bjos-8641742	37	16	low	low	ADJ
bjos-8641742	37	17	(	(	PUNCT
bjos-8641742	37	18	0.50	0.50	NUM
bjos-8641742	37	19	to	to	ADP
bjos-8641742	37	20	0.70	0.70	NUM
bjos-8641742	37	21	ml	ml	NOUN
bjos-8641742	37	22	/	/	SYM
bjos-8641742	37	23	min	min	NOUN
bjos-8641742	37	24	)	)	PUNCT
bjos-8641742	37	25	,	,	PUNCT
bjos-8641742	37	26	low	low	ADJ
bjos-8641742	37	27	(	(	PUNCT
bjos-8641742	37	28	0.30	0.30	NUM
bjos-8641742	37	29	to	to	ADP
bjos-8641742	37	30	0.49	0.49	NUM
bjos-8641742	37	31	ml	ml	NOUN
bjos-8641742	37	32	/	/	SYM
bjos-8641742	37	33	min	min	NOUN
bjos-8641742	37	34	)	)	PUNCT
bjos-8641742	37	35	,	,	PUNCT
bjos-8641742	37	36	or	or	CCONJ
bjos-8641742	37	37	severely	severely	ADV
bjos-8641742	37	38	low	low	ADJ
bjos-8641742	37	39	(	(	PUNCT
bjos-8641742	37	40	0	0	NUM
bjos-8641742	37	41	to	to	ADP
bjos-8641742	37	42	0.29	0.29	NUM
bjos-8641742	37	43	ml	ml	NOUN
bjos-8641742	37	44	/	/	SYM
bjos-8641742	37	45	min)17	min)17	NOUN
bjos-8641742	37	46	.	.	PUNCT
bjos-8641742	38	1	xerostomia	xerostomia	PROPN
bjos-8641742	38	2	was	be	AUX
bjos-8641742	38	3	identified	identify	VERB
bjos-8641742	38	4	when	when	SCONJ
bjos-8641742	38	5	the	the	DET
bjos-8641742	38	6	patient	patient	NOUN
bjos-8641742	38	7	complained	complain	VERB
bjos-8641742	38	8	of	of	ADP
bjos-8641742	38	9	dry	dry	ADJ
bjos-8641742	38	10	mouth	mouth	NOUN
bjos-8641742	38	11	.	.	PUNCT
bjos-8641742	39	1	the	the	DET
bjos-8641742	39	2	diagnosis	diagnosis	NOUN
bjos-8641742	39	3	of	of	ADP
bjos-8641742	39	4	ohl	ohl	NOUN
bjos-8641742	39	5	was	be	AUX
bjos-8641742	39	6	established	establish	VERB
bjos-8641742	39	7	according	accord	VERB
bjos-8641742	39	8	to	to	ADP
bjos-8641742	39	9	clinical	clinical	ADJ
bjos-8641742	39	10	features	feature	NOUN
bjos-8641742	39	11	and	and	CCONJ
bjos-8641742	39	12	exfoliative	exfoliative	ADJ
bjos-8641742	39	13	cytology18	cytology18	NOUN
bjos-8641742	39	14	-	-	PUNCT
bjos-8641742	39	15	19	19	NUM
bjos-8641742	39	16	.	.	PUNCT
bjos-8641742	40	1	ohl	ohl	PROPN
bjos-8641742	40	2	was	be	AUX
bjos-8641742	40	3	treated	treat	VERB
bjos-8641742	40	4	with	with	ADP
bjos-8641742	40	5	topical	topical	ADJ
bjos-8641742	40	6	applications	application	NOUN
bjos-8641742	40	7	of	of	ADP
bjos-8641742	40	8	either	either	CCONJ
bjos-8641742	40	9	podophyllin	podophyllin	ADJ
bjos-8641742	40	10	resin	resin	NOUN
bjos-8641742	40	11	(	(	PUNCT
bjos-8641742	40	12	25	25	NUM
bjos-8641742	40	13	%	%	NOUN
bjos-8641742	40	14	)	)	PUNCT
bjos-8641742	40	15	(	(	PUNCT
bjos-8641742	40	16	prepared	prepare	VERB
bjos-8641742	40	17	at	at	ADP
bjos-8641742	40	18	ufmg	ufmg	PROPN
bjos-8641742	40	19	’s	’s	PART
bjos-8641742	40	20	pharmacy	pharmacy	NOUN
bjos-8641742	40	21	)	)	PUNCT
bjos-8641742	40	22	,	,	PUNCT
bjos-8641742	40	23	or	or	CCONJ
bjos-8641742	40	24	podophyllin	podophyllin	ADJ
bjos-8641742	40	25	resin	resin	NOUN
bjos-8641742	40	26	(	(	PUNCT
bjos-8641742	40	27	25	25	NUM
bjos-8641742	40	28	%	%	NOUN
bjos-8641742	40	29	)	)	PUNCT
bjos-8641742	40	30	together	together	ADV
bjos-8641742	40	31	with	with	ADP
bjos-8641742	40	32	acyclovir	acyclovir	PROPN
bjos-8641742	40	33	cream	cream	PROPN
bjos-8641742	40	34	(	(	PUNCT
bjos-8641742	40	35	5	5	NUM
bjos-8641742	40	36	%	%	NOUN
bjos-8641742	40	37	)	)	PUNCT
bjos-8641742	40	38	(	(	PUNCT
bjos-8641742	40	39	ems	ems	PROPN
bjos-8641742	40	40	-	-	PUNCT
bjos-8641742	40	41	genéricos	genéricos	PROPN
bjos-8641742	40	42	®	®	NOUN
bjos-8641742	40	43	,	,	PUNCT
bjos-8641742	40	44	são	são	PROPN
bjos-8641742	40	45	bernardo	bernardo	PROPN
bjos-8641742	40	46	do	do	VERB
bjos-8641742	40	47	campo	campo	PROPN
bjos-8641742	40	48	,	,	PUNCT
bjos-8641742	40	49	sp	sp	NOUN
bjos-8641742	40	50	,	,	PUNCT
bjos-8641742	40	51	brazil)20	brazil)20	PROPN
bjos-8641742	40	52	.	.	PUNCT
bjos-8641742	41	1	smoking	smoking	NOUN
bjos-8641742	41	2	individuals	individual	NOUN
bjos-8641742	41	3	were	be	AUX
bjos-8641742	41	4	identified	identify	VERB
bjos-8641742	41	5	as	as	ADP
bjos-8641742	41	6	those	those	PRON
bjos-8641742	41	7	who	who	PRON
bjos-8641742	41	8	had	have	AUX
bjos-8641742	41	9	smoked	smoke	VERB
bjos-8641742	41	10	>	>	PUNCT
bjos-8641742	41	11	100	100	NUM
bjos-8641742	41	12	cigarettes	cigarette	NOUN
bjos-8641742	41	13	over	over	ADP
bjos-8641742	41	14	their	their	PRON
bjos-8641742	41	15	lifetime	lifetime	NOUN
bjos-8641742	41	16	and	and	CCONJ
bjos-8641742	41	17	smoked	smoke	VERB
bjos-8641742	41	18	at	at	ADP
bjos-8641742	41	19	the	the	DET
bjos-8641742	41	20	time	time	NOUN
bjos-8641742	41	21	of	of	ADP
bjos-8641742	41	22	the	the	DET
bjos-8641742	41	23	study	study	NOUN
bjos-8641742	41	24	.	.	PUNCT
bjos-8641742	42	1	non	non	ADJ
bjos-8641742	42	2	-	-	ADJ
bjos-8641742	42	3	smoking	smoking	ADJ
bjos-8641742	42	4	individuals	individual	NOUN
bjos-8641742	42	5	were	be	AUX
bjos-8641742	42	6	identified	identify	VERB
bjos-8641742	42	7	as	as	ADP
bjos-8641742	42	8	those	those	PRON
bjos-8641742	42	9	who	who	PRON
bjos-8641742	42	10	had	have	AUX
bjos-8641742	42	11	not	not	PART
bjos-8641742	42	12	smoked	smoke	VERB
bjos-8641742	42	13	>	>	PUNCT
bjos-8641742	42	14	100	100	NUM
bjos-8641742	42	15	cigarettes	cigarette	NOUN
bjos-8641742	42	16	in	in	ADP
bjos-8641742	42	17	their	their	PRON
bjos-8641742	42	18	lifetime16	lifetime16	NOUN
bjos-8641742	42	19	.	.	PUNCT
bjos-8641742	43	1	alcohol	alcohol	NOUN
bjos-8641742	43	2	consumption	consumption	NOUN
bjos-8641742	43	3	was	be	AUX
bjos-8641742	43	4	considered	consider	VERB
bjos-8641742	43	5	when	when	SCONJ
bjos-8641742	43	6	the	the	DET
bjos-8641742	43	7	patient	patient	NOUN
bjos-8641742	43	8	consumed	consume	VERB
bjos-8641742	43	9	alcohol	alcohol	NOUN
bjos-8641742	43	10	on	on	ADP
bjos-8641742	43	11	a	a	DET
bjos-8641742	43	12	daily	daily	ADJ
bjos-8641742	43	13	basis	basis	NOUN
bjos-8641742	43	14	.	.	PUNCT
bjos-8641742	44	1	statistical	statistical	ADJ
bjos-8641742	44	2	analysis	analysis	NOUN
bjos-8641742	44	3	of	of	ADP
bjos-8641742	44	4	data	datum	NOUN
bjos-8641742	44	5	was	be	AUX
bjos-8641742	44	6	performed	perform	VERB
bjos-8641742	44	7	using	use	VERB
bjos-8641742	44	8	the	the	DET
bjos-8641742	44	9	statistical	statistical	ADJ
bjos-8641742	44	10	package	package	NOUN
bjos-8641742	44	11	for	for	ADP
bjos-8641742	44	12	social	social	ADJ
bjos-8641742	44	13	service	service	NOUN
bjos-8641742	44	14	(	(	PUNCT
bjos-8641742	44	15	spss	spss	ADJ
bjos-8641742	44	16	)	)	PUNCT
bjos-8641742	44	17	software	software	NOUN
bjos-8641742	44	18	program	program	NOUN
bjos-8641742	44	19	(	(	PUNCT
bjos-8641742	44	20	version	version	NOUN
bjos-8641742	44	21	16.0	16.0	NUM
bjos-8641742	44	22	,	,	PUNCT
bjos-8641742	44	23	spss	spss	PROPN
bjos-8641742	44	24	inc	inc	PROPN
bjos-8641742	44	25	.	.	PROPN
bjos-8641742	44	26	,	,	PUNCT
bjos-8641742	44	27	chicago	chicago	PROPN
bjos-8641742	44	28	,	,	PUNCT
bjos-8641742	44	29	il	il	PROPN
bjos-8641742	44	30	,	,	PUNCT
bjos-8641742	44	31	usa	usa	PROPN
bjos-8641742	44	32	)	)	PUNCT
bjos-8641742	44	33	.	.	PUNCT
bjos-8641742	45	1	univariate	univariate	ADJ
bjos-8641742	45	2	analyses	analysis	NOUN
bjos-8641742	45	3	were	be	AUX
bjos-8641742	45	4	performed	perform	VERB
bjos-8641742	45	5	on	on	ADP
bjos-8641742	45	6	all	all	DET
bjos-8641742	45	7	variables	variable	NOUN
bjos-8641742	45	8	of	of	ADP
bjos-8641742	45	9	this	this	DET
bjos-8641742	45	10	study	study	NOUN
bjos-8641742	45	11	using	use	VERB
bjos-8641742	45	12	the	the	DET
bjos-8641742	45	13	fisher	fisher	NOUN
bjos-8641742	45	14	’s	’s	PART
bjos-8641742	45	15	and	and	CCONJ
bjos-8641742	45	16	chi	chi	ADJ
bjos-8641742	45	17	-	-	PUNCT
bjos-8641742	45	18	squared	square	VERB
bjos-8641742	45	19	tests	test	NOUN
bjos-8641742	45	20	(	(	PUNCT
bjos-8641742	45	21	2	2	NUM
bjos-8641742	45	22	-	-	PUNCT
bjos-8641742	45	23	sided	sided	ADJ
bjos-8641742	45	24	tests	test	NOUN
bjos-8641742	45	25	)	)	PUNCT
bjos-8641742	45	26	.	.	PUNCT
bjos-8641742	46	1	statistical	statistical	ADJ
bjos-8641742	46	2	significance	significance	NOUN
bjos-8641742	46	3	was	be	AUX
bjos-8641742	46	4	at	at	ADP
bjos-8641742	46	5	a	a	DET
bjos-8641742	46	6	level	level	NOUN
bjos-8641742	46	7	of	of	ADP
bjos-8641742	46	8	0.05	0.05	NUM
bjos-8641742	46	9	.	.	PUNCT
bjos-8641742	47	1	the	the	DET
bjos-8641742	47	2	results	result	NOUN
bjos-8641742	47	3	of	of	ADP
bjos-8641742	47	4	this	this	DET
bjos-8641742	47	5	analysis	analysis	NOUN
bjos-8641742	47	6	were	be	AUX
bjos-8641742	47	7	expressed	express	VERB
bjos-8641742	47	8	as	as	ADP
bjos-8641742	47	9	an	an	DET
bjos-8641742	47	10	odds	odd	NOUN
bjos-8641742	47	11	ratio	ratio	NOUN
bjos-8641742	47	12	(	(	PUNCT
bjos-8641742	47	13	or	or	CCONJ
bjos-8641742	47	14	)	)	PUNCT
bjos-8641742	47	15	with	with	ADP
bjos-8641742	47	16	a	a	DET
bjos-8641742	47	17	95	95	NUM
bjos-8641742	47	18	%	%	NOUN
bjos-8641742	47	19	confidence	confidence	NOUN
bjos-8641742	47	20	interval	interval	NOUN
bjos-8641742	47	21	(	(	PUNCT
bjos-8641742	47	22	ci	ci	NOUN
bjos-8641742	47	23	)	)	PUNCT
bjos-8641742	47	24	.	.	PUNCT
bjos-8641742	48	1	variables	variable	NOUN
bjos-8641742	48	2	with	with	ADP
bjos-8641742	48	3	p<0.25	p<0.25	PROPN
bjos-8641742	48	4	were	be	AUX
bjos-8641742	48	5	identified	identify	VERB
bjos-8641742	48	6	and	and	CCONJ
bjos-8641742	48	7	included	include	VERB
bjos-8641742	48	8	in	in	ADP
bjos-8641742	48	9	the	the	DET
bjos-8641742	48	10	multivariate	multivariate	NOUN
bjos-8641742	48	11	analyses	analysis	NOUN
bjos-8641742	48	12	.	.	PUNCT
bjos-8641742	49	1	multiple	multiple	ADJ
bjos-8641742	49	2	logistic	logistic	ADJ
bjos-8641742	49	3	regression	regression	NOUN
bjos-8641742	49	4	techniques	technique	NOUN
bjos-8641742	49	5	were	be	AUX
bjos-8641742	49	6	then	then	ADV
bjos-8641742	49	7	used	use	VERB
bjos-8641742	49	8	to	to	PART
bjos-8641742	49	9	develop	develop	VERB
bjos-8641742	49	10	a	a	DET
bjos-8641742	49	11	model	model	NOUN
bjos-8641742	49	12	and	and	CCONJ
bjos-8641742	49	13	identify	identify	VERB
bjos-8641742	49	14	the	the	DET
bjos-8641742	49	15	set	set	NOUN
bjos-8641742	49	16	of	of	ADP
bjos-8641742	49	17	variables	variable	NOUN
bjos-8641742	49	18	that	that	PRON
bjos-8641742	49	19	may	may	AUX
bjos-8641742	49	20	predict	predict	VERB
bjos-8641742	49	21	risk	risk	NOUN
bjos-8641742	49	22	indicators	indicator	NOUN
bjos-8641742	49	23	in	in	ADP
bjos-8641742	49	24	hiv	hiv	PROPN
bjos-8641742	49	25	-	-	PUNCT
bjos-8641742	49	26	infected	infect	VERB
bjos-8641742	49	27	adult	adult	NOUN
bjos-8641742	49	28	patients	patient	NOUN
bjos-8641742	49	29	with	with	ADP
bjos-8641742	49	30	oc	oc	PROPN
bjos-8641742	49	31	.	.	PROPN
bjos-8641742	50	1	results	result	VERB
bjos-8641742	50	2	the	the	DET
bjos-8641742	50	3	sample	sample	NOUN
bjos-8641742	50	4	included	include	VERB
bjos-8641742	50	5	35	35	NUM
bjos-8641742	50	6	(	(	PUNCT
bjos-8641742	50	7	31.3	31.3	NUM
bjos-8641742	50	8	%	%	NOUN
bjos-8641742	50	9	)	)	PUNCT
bjos-8641742	50	10	hiv	hiv	PROPN
bjos-8641742	50	11	-	-	PUNCT
bjos-8641742	50	12	infected	infect	VERB
bjos-8641742	50	13	adult	adult	NOUN
bjos-8641742	50	14	patients	patient	NOUN
bjos-8641742	50	15	with	with	ADP
bjos-8641742	50	16	oc	oc	NOUN
bjos-8641742	50	17	and	and	CCONJ
bjos-8641742	51	1	77	77	NUM
bjos-8641742	51	2	(	(	PUNCT
bjos-8641742	51	3	68.7	68.7	NUM
bjos-8641742	51	4	%	%	NOUN
bjos-8641742	51	5	)	)	PUNCT
bjos-8641742	51	6	patients	patient	NOUN
bjos-8641742	51	7	who	who	PRON
bjos-8641742	51	8	did	do	AUX
bjos-8641742	51	9	not	not	PART
bjos-8641742	51	10	have	have	VERB
bjos-8641742	51	11	oc	oc	NOUN
bjos-8641742	51	12	.	.	PUNCT
bjos-8641742	52	1	the	the	DET
bjos-8641742	52	2	majority	majority	NOUN
bjos-8641742	52	3	of	of	ADP
bjos-8641742	52	4	patients	patient	NOUN
bjos-8641742	52	5	,	,	PUNCT
bjos-8641742	52	6	82	82	NUM
bjos-8641742	52	7	(	(	PUNCT
bjos-8641742	52	8	73.2	73.2	NUM
bjos-8641742	52	9	%	%	NOUN
bjos-8641742	52	10	)	)	PUNCT
bjos-8641742	52	11	,	,	PUNCT
bjos-8641742	52	12	were	be	AUX
bjos-8641742	52	13	men	man	NOUN
bjos-8641742	52	14	.	.	PUNCT
bjos-8641742	53	1	sixtyfive	sixtyfive	ADJ
bjos-8641742	53	2	patients	patient	NOUN
bjos-8641742	53	3	(	(	PUNCT
bjos-8641742	53	4	58.0	58.0	NUM
bjos-8641742	53	5	%	%	NOUN
bjos-8641742	53	6	)	)	PUNCT
bjos-8641742	53	7	were	be	AUX
bjos-8641742	53	8	caucasian	caucasian	ADJ
bjos-8641742	53	9	and	and	CCONJ
bjos-8641742	53	10	47	47	NUM
bjos-8641742	53	11	(	(	PUNCT
bjos-8641742	53	12	42.0	42.0	NUM
bjos-8641742	53	13	%	%	NOUN
bjos-8641742	53	14	)	)	PUNCT
bjos-8641742	53	15	were	be	AUX
bjos-8641742	53	16	black	black	ADJ
bjos-8641742	53	17	.	.	PUNCT
bjos-8641742	54	1	age	age	NOUN
bjos-8641742	54	2	varied	varied	ADJ
bjos-8641742	54	3	from	from	ADP
bjos-8641742	54	4	20	20	NUM
bjos-8641742	54	5	to	to	PART
bjos-8641742	54	6	59	59	NUM
bjos-8641742	54	7	years	year	NOUN
bjos-8641742	54	8	(	(	PUNCT
bjos-8641742	54	9	mean	mean	INTJ
bjos-8641742	54	10	age	age	NOUN
bjos-8641742	54	11	of	of	ADP
bjos-8641742	54	12	39.5	39.5	NUM
bjos-8641742	54	13	years	year	NOUN
bjos-8641742	54	14	)	)	PUNCT
bjos-8641742	54	15	.	.	PUNCT
bjos-8641742	55	1	regarding	regard	VERB
bjos-8641742	55	2	the	the	DET
bjos-8641742	55	3	route	route	NOUN
bjos-8641742	55	4	of	of	ADP
bjos-8641742	55	5	transmissions	transmission	NOUN
bjos-8641742	55	6	,	,	PUNCT
bjos-8641742	55	7	the	the	DET
bjos-8641742	55	8	sample	sample	NOUN
bjos-8641742	55	9	included	include	VERB
bjos-8641742	55	10	4	4	NUM
bjos-8641742	55	11	(	(	PUNCT
bjos-8641742	55	12	3.6	3.6	NUM
bjos-8641742	55	13	%	%	NOUN
bjos-8641742	55	14	)	)	PUNCT
bjos-8641742	55	15	intravenous	intravenous	ADJ
bjos-8641742	55	16	drug	drug	NOUN
bjos-8641742	55	17	users	user	NOUN
bjos-8641742	55	18	,	,	PUNCT
bjos-8641742	55	19	13	13	NUM
bjos-8641742	55	20	(	(	PUNCT
bjos-8641742	55	21	11.6	11.6	NUM
bjos-8641742	55	22	%	%	NOUN
bjos-8641742	55	23	)	)	PUNCT
bjos-8641742	55	24	not	not	PART
bjos-8641742	55	25	informed	inform	VERB
bjos-8641742	55	26	,	,	PUNCT
bjos-8641742	55	27	51	51	NUM
bjos-8641742	55	28	(	(	PUNCT
bjos-8641742	55	29	45.5	45.5	NUM
bjos-8641742	55	30	%	%	NOUN
bjos-8641742	55	31	)	)	PUNCT
bjos-8641742	55	32	heterosexuals	heterosexual	NOUN
bjos-8641742	55	33	,	,	PUNCT
bjos-8641742	55	34	40	40	NUM
bjos-8641742	55	35	(	(	PUNCT
bjos-8641742	55	36	35.7	35.7	NUM
bjos-8641742	55	37	%	%	NOUN
bjos-8641742	55	38	)	)	PUNCT
bjos-8641742	55	39	men	man	NOUN
bjos-8641742	55	40	who	who	PRON
bjos-8641742	55	41	have	have	VERB
bjos-8641742	55	42	sex	sex	NOUN
bjos-8641742	55	43	with	with	ADP
bjos-8641742	55	44	men	man	NOUN
bjos-8641742	55	45	(	(	PUNCT
bjos-8641742	55	46	msm	msm	NOUN
bjos-8641742	55	47	)	)	PUNCT
bjos-8641742	55	48	and	and	CCONJ
bjos-8641742	55	49	4	4	NUM
bjos-8641742	55	50	(	(	PUNCT
bjos-8641742	55	51	3.6	3.6	NUM
bjos-8641742	55	52	%	%	NOUN
bjos-8641742	55	53	)	)	PUNCT
bjos-8641742	55	54	bisexuals	bisexual	NOUN
bjos-8641742	55	55	.	.	PUNCT
bjos-8641742	56	1	of	of	ADP
bjos-8641742	56	2	the	the	DET
bjos-8641742	56	3	35	35	NUM
bjos-8641742	56	4	patients	patient	NOUN
bjos-8641742	56	5	with	with	ADP
bjos-8641742	56	6	oc	oc	NOUN
bjos-8641742	56	7	,	,	PUNCT
bjos-8641742	56	8	20	20	NUM
bjos-8641742	56	9	(	(	PUNCT
bjos-8641742	56	10	57.1	57.1	NUM
bjos-8641742	56	11	%	%	NOUN
bjos-8641742	56	12	)	)	PUNCT
bjos-8641742	56	13	were	be	AUX
bjos-8641742	56	14	heterosexual	heterosexual	ADJ
bjos-8641742	56	15	,	,	PUNCT
bjos-8641742	56	16	8	8	NUM
bjos-8641742	56	17	(	(	PUNCT
bjos-8641742	56	18	22.8	22.8	NUM
bjos-8641742	56	19	%	%	NOUN
bjos-8641742	56	20	)	)	PUNCT
bjos-8641742	56	21	were	be	AUX
bjos-8641742	56	22	msm	msm	NOUN
bjos-8641742	56	23	,	,	PUNCT
bjos-8641742	56	24	2	2	NUM
bjos-8641742	56	25	(	(	PUNCT
bjos-8641742	56	26	5.7	5.7	NUM
bjos-8641742	56	27	%	%	NOUN
bjos-8641742	56	28	)	)	PUNCT
bjos-8641742	56	29	were	be	AUX
bjos-8641742	56	30	bisexual	bisexual	NOUN
bjos-8641742	56	31	,	,	PUNCT
bjos-8641742	56	32	1	1	NUM
bjos-8641742	56	33	(	(	PUNCT
bjos-8641742	56	34	2.8	2.8	NUM
bjos-8641742	56	35	%	%	NOUN
bjos-8641742	56	36	)	)	PUNCT
bjos-8641742	57	1	was	be	AUX
bjos-8641742	57	2	intravenous	intravenous	ADJ
bjos-8641742	57	3	drug	drug	NOUN
bjos-8641742	57	4	user	user	NOUN
bjos-8641742	57	5	,	,	PUNCT
bjos-8641742	57	6	and	and	CCONJ
bjos-8641742	57	7	4	4	NUM
bjos-8641742	57	8	(	(	PUNCT
bjos-8641742	57	9	11.4	11.4	NUM
bjos-8641742	57	10	%	%	NOUN
bjos-8641742	57	11	)	)	PUNCT
bjos-8641742	57	12	did	do	AUX
bjos-8641742	57	13	not	not	PART
bjos-8641742	57	14	inform	inform	VERB
bjos-8641742	57	15	.	.	PUNCT
bjos-8641742	58	1	oc	oc	PROPN
bjos-8641742	58	2	was	be	AUX
bjos-8641742	58	3	erythematous	erythematous	ADJ
bjos-8641742	58	4	in	in	ADP
bjos-8641742	58	5	19	19	NUM
bjos-8641742	58	6	cases	case	NOUN
bjos-8641742	58	7	(	(	PUNCT
bjos-8641742	58	8	54.3	54.3	NUM
bjos-8641742	58	9	%	%	NOUN
bjos-8641742	58	10	)	)	PUNCT
bjos-8641742	58	11	,	,	PUNCT
bjos-8641742	58	12	pseudomembranous	pseudomembranous	ADJ
bjos-8641742	58	13	in	in	ADP
bjos-8641742	58	14	10	10	NUM
bjos-8641742	58	15	cases	case	NOUN
bjos-8641742	58	16	(	(	PUNCT
bjos-8641742	58	17	28.6	28.6	NUM
bjos-8641742	58	18	%	%	NOUN
bjos-8641742	58	19	)	)	PUNCT
bjos-8641742	58	20	,	,	PUNCT
bjos-8641742	58	21	and	and	CCONJ
bjos-8641742	58	22	both	both	PRON
bjos-8641742	58	23	in	in	ADP
bjos-8641742	58	24	06	06	NUM
bjos-8641742	58	25	cases	case	NOUN
bjos-8641742	58	26	(	(	PUNCT
bjos-8641742	58	27	17.1	17.1	NUM
bjos-8641742	58	28	%	%	NOUN
bjos-8641742	58	29	)	)	PUNCT
bjos-8641742	58	30	.	.	PUNCT
bjos-8641742	59	1	angular	angular	ADJ
bjos-8641742	59	2	cheilitis	cheilitis	NOUN
bjos-8641742	59	3	(	(	PUNCT
bjos-8641742	59	4	9	9	NUM
bjos-8641742	59	5	cases	case	NOUN
bjos-8641742	59	6	)	)	PUNCT
bjos-8641742	59	7	was	be	AUX
bjos-8641742	59	8	also	also	ADV
bjos-8641742	59	9	identified	identify	VERB
bjos-8641742	59	10	in	in	ADP
bjos-8641742	59	11	our	our	PRON
bjos-8641742	59	12	study	study	NOUN
bjos-8641742	59	13	,	,	PUNCT
bjos-8641742	59	14	but	but	CCONJ
bjos-8641742	59	15	all	all	DET
bjos-8641742	59	16	cases	case	NOUN
bjos-8641742	59	17	were	be	AUX
bjos-8641742	59	18	in	in	ADP
bjos-8641742	59	19	association	association	NOUN
bjos-8641742	59	20	with	with	ADP
bjos-8641742	59	21	erythematous	erythematous	ADJ
bjos-8641742	59	22	oc	oc	PROPN
bjos-8641742	59	23	.	.	PROPN
bjos-8641742	59	24	table	table	NOUN
bjos-8641742	59	25	1	1	NUM
bjos-8641742	59	26	summarizes	summarize	NOUN
bjos-8641742	59	27	the	the	DET
bjos-8641742	59	28	proportional	proportional	ADJ
bjos-8641742	59	29	prevalence	prevalence	NOUN
bjos-8641742	59	30	and	and	CCONJ
bjos-8641742	59	31	univariate	univariate	ADJ
bjos-8641742	59	32	analyses	analysis	NOUN
bjos-8641742	59	33	.	.	PUNCT
bjos-8641742	60	1	statistically	statistically	ADV
bjos-8641742	60	2	significant	significant	ADJ
bjos-8641742	60	3	association	association	NOUN
bjos-8641742	60	4	was	be	AUX
bjos-8641742	60	5	identified	identify	VERB
bjos-8641742	60	6	between	between	ADP
bjos-8641742	60	7	the	the	DET
bjos-8641742	60	8	viral	viral	ADJ
bjos-8641742	60	9	load	load	NOUN
bjos-8641742	60	10	of	of	ADP
bjos-8641742	60	11	3,000	3,000	NUM
bjos-8641742	60	12	copies/µl	copies/µl	NOUN
bjos-8641742	60	13	or	or	CCONJ
bjos-8641742	60	14	greater	great	ADJ
bjos-8641742	60	15	(	(	PUNCT
bjos-8641742	60	16	p=0.042	p=0.042	X
bjos-8641742	60	17	;	;	PUNCT
bjos-8641742	60	18	or=2.3	or=2.3	NUM
bjos-8641742	60	19	)	)	PUNCT
bjos-8641742	60	20	,	,	PUNCT
bjos-8641742	60	21	the	the	DET
bjos-8641742	60	22	ohl	ohl	NOUN
bjos-8641742	60	23	(	(	PUNCT
bjos-8641742	60	24	p<0.001	p<0.001	PROPN
bjos-8641742	60	25	;	;	PUNCT
bjos-8641742	60	26	or=10.2	or=10.2	X
bjos-8641742	60	27	)	)	PUNCT
bjos-8641742	60	28	and	and	CCONJ
bjos-8641742	60	29	the	the	DET
bjos-8641742	60	30	previous	previous	ADJ
bjos-8641742	60	31	use	use	NOUN
bjos-8641742	60	32	of	of	ADP
bjos-8641742	60	33	fluconazole	fluconazole	NOUN
bjos-8641742	60	34	(	(	PUNCT
bjos-8641742	60	35	p<0.001	p<0.001	PROPN
bjos-8641742	60	36	;	;	PUNCT
bjos-8641742	60	37	or=27.4	or=27.4	PROPN
bjos-8641742	60	38	)	)	PUNCT
bjos-8641742	60	39	with	with	ADP
bjos-8641742	60	40	oc	oc	PROPN
bjos-8641742	60	41	.	.	PUNCT
bjos-8641742	61	1	platelets	platelet	NOUN
bjos-8641742	61	2	count	count	NOUN
bjos-8641742	61	3	(	(	PUNCT
bjos-8641742	61	4	<	<	NOUN
bjos-8641742	61	5	150,000	150,000	NUM
bjos-8641742	61	6	/	/	SYM
bjos-8641742	61	7	mm3	mm3	NOUN
bjos-8641742	61	8	)	)	PUNCT
bjos-8641742	61	9	,	,	PUNCT
bjos-8641742	61	10	haart	haart	PROPN
bjos-8641742	61	11	(	(	PUNCT
bjos-8641742	61	12	patients	patient	NOUN
bjos-8641742	61	13	that	that	PRON
bjos-8641742	61	14	did	do	AUX
bjos-8641742	61	15	not	not	PART
bjos-8641742	61	16	take	take	VERB
bjos-8641742	61	17	)	)	PUNCT
bjos-8641742	61	18	,	,	PUNCT
bjos-8641742	61	19	gender	gender	NOUN
bjos-8641742	61	20	(	(	PUNCT
bjos-8641742	61	21	men	man	NOUN
bjos-8641742	61	22	)	)	PUNCT
bjos-8641742	61	23	,	,	PUNCT
bjos-8641742	61	24	reduction	reduction	NOUN
bjos-8641742	61	25	of	of	ADP
bjos-8641742	61	26	salivary	salivary	ADJ
bjos-8641742	61	27	flow	flow	NOUN
bjos-8641742	61	28	,	,	PUNCT
bjos-8641742	61	29	previous	previous	ADJ
bjos-8641742	61	30	use	use	NOUN
bjos-8641742	61	31	of	of	ADP
bjos-8641742	61	32	systemic	systemic	ADJ
bjos-8641742	61	33	acyclovir	acyclovir	NOUN
bjos-8641742	61	34	,	,	PUNCT
bjos-8641742	61	35	use	use	NOUN
bjos-8641742	61	36	of	of	ADP
bjos-8641742	61	37	azt	azt	PROPN
bjos-8641742	61	38	(	(	PUNCT
bjos-8641742	61	39	patients	patient	NOUN
bjos-8641742	61	40	that	that	PRON
bjos-8641742	61	41	did	do	AUX
bjos-8641742	61	42	not	not	PART
bjos-8641742	61	43	take	take	VERB
bjos-8641742	61	44	)	)	PUNCT
bjos-8641742	61	45	and	and	CCONJ
bjos-8641742	61	46	intravenous	intravenous	ADJ
bjos-8641742	61	47	drug	drug	NOUN
bjos-8641742	61	48	use	use	NOUN
bjos-8641742	61	49	(	(	PUNCT
bjos-8641742	61	50	patients	patient	NOUN
bjos-8641742	61	51	that	that	PRON
bjos-8641742	61	52	did	do	AUX
bjos-8641742	61	53	not	not	PART
bjos-8641742	61	54	use	use	VERB
bjos-8641742	61	55	)	)	PUNCT
bjos-8641742	61	56	were	be	AUX
bjos-8641742	61	57	more	more	ADV
bjos-8641742	61	58	frequently	frequently	ADV
bjos-8641742	61	59	present	present	ADJ
bjos-8641742	61	60	in	in	ADP
bjos-8641742	61	61	association	association	NOUN
bjos-8641742	61	62	with	with	ADP
bjos-8641742	61	63	oc	oc	NOUN
bjos-8641742	61	64	,	,	PUNCT
bjos-8641742	61	65	though	though	SCONJ
bjos-8641742	61	66	without	without	ADP
bjos-8641742	61	67	a	a	DET
bjos-8641742	61	68	significant	significant	ADJ
bjos-8641742	61	69	relationship	relationship	NOUN
bjos-8641742	61	70	(	(	PUNCT
bjos-8641742	61	71	table	table	NOUN
bjos-8641742	61	72	1	1	NUM
bjos-8641742	61	73	)	)	PUNCT
bjos-8641742	61	74	.	.	PUNCT
bjos-8641742	62	1	table	table	NOUN
bjos-8641742	62	2	2	2	NUM
bjos-8641742	62	3	demonstrates	demonstrate	VERB
bjos-8641742	62	4	the	the	DET
bjos-8641742	62	5	logistic	logistic	ADJ
bjos-8641742	62	6	regression	regression	NOUN
bjos-8641742	62	7	models	model	NOUN
bjos-8641742	62	8	.	.	PUNCT
bjos-8641742	63	1	multiple	multiple	ADJ
bjos-8641742	63	2	logistic	logistic	ADJ
bjos-8641742	63	3	regression	regression	NOUN
bjos-8641742	63	4	tests	test	NOUN
bjos-8641742	63	5	confirmed	confirm	VERB
bjos-8641742	63	6	the	the	DET
bjos-8641742	63	7	statistically	statistically	ADV
bjos-8641742	63	8	significant	significant	ADJ
bjos-8641742	63	9	association	association	NOUN
bjos-8641742	63	10	between	between	ADP
bjos-8641742	63	11	the	the	DET
bjos-8641742	63	12	previous	previous	ADJ
bjos-8641742	63	13	use	use	NOUN
bjos-8641742	63	14	of	of	ADP
bjos-8641742	63	15	fluconazole	fluconazole	NOUN
bjos-8641742	63	16	and	and	CCONJ
bjos-8641742	63	17	ohl	ohl	NOUN
bjos-8641742	63	18	with	with	ADP
bjos-8641742	63	19	oc	oc	NOUN
bjos-8641742	63	20	,	,	PUNCT
bjos-8641742	63	21	regardless	regardless	ADV
bjos-8641742	63	22	of	of	ADP
bjos-8641742	63	23	the	the	DET
bjos-8641742	63	24	use	use	NOUN
bjos-8641742	63	25	of	of	ADP
bjos-8641742	63	26	haart	haart	PROPN
bjos-8641742	63	27	.	.	PUNCT
bjos-8641742	64	1	adjusted	adjust	VERB
bjos-8641742	64	2	results	result	NOUN
bjos-8641742	64	3	showed	show	VERB
bjos-8641742	64	4	that	that	SCONJ
bjos-8641742	64	5	hiv	hiv	PROPN
bjos-8641742	64	6	-	-	PUNCT
bjos-8641742	64	7	infected	infect	VERB
bjos-8641742	64	8	patients	patient	NOUN
bjos-8641742	64	9	with	with	ADP
bjos-8641742	64	10	ohl	ohl	NOUN
bjos-8641742	64	11	,	,	PUNCT
bjos-8641742	64	12	and	and	CCONJ
bjos-8641742	64	13	those	those	PRON
bjos-8641742	64	14	who	who	PRON
bjos-8641742	64	15	had	have	AUX
bjos-8641742	64	16	previously	previously	ADV
bjos-8641742	64	17	used	use	VERB
bjos-8641742	64	18	fluconazole	fluconazole	NOUN
bjos-8641742	64	19	,	,	PUNCT
bjos-8641742	64	20	were	be	AUX
bjos-8641742	64	21	3.6	3.6	NUM
bjos-8641742	64	22	times	time	NOUN
bjos-8641742	64	23	(	(	PUNCT
bjos-8641742	64	24	95	95	NUM
bjos-8641742	64	25	%	%	NOUN
bjos-8641742	64	26	ci=1.1	ci=1.1	NOUN
bjos-8641742	64	27	-	-	PUNCT
bjos-8641742	64	28	12.3	12.3	NUM
bjos-8641742	64	29	)	)	PUNCT
bjos-8641742	64	30	and	and	CCONJ
bjos-8641742	64	31	14.3	14.3	NUM
bjos-8641742	64	32	times	time	NOUN
bjos-8641742	64	33	(	(	PUNCT
bjos-8641742	64	34	95	95	NUM
bjos-8641742	64	35	%	%	NOUN
bjos-8641742	64	36	ci=3.8	ci=3.8	NOUN
bjos-8641742	64	37	-	-	PUNCT
bjos-8641742	64	38	53.6	53.6	NUM
bjos-8641742	64	39	)	)	PUNCT
bjos-8641742	64	40	more	more	ADV
bjos-8641742	64	41	likely	likely	ADJ
bjos-8641742	64	42	to	to	PART
bjos-8641742	64	43	present	present	VERB
bjos-8641742	64	44	oc	oc	ADP
bjos-8641742	64	45	,	,	PUNCT
bjos-8641742	64	46	respectively	respectively	ADV
bjos-8641742	64	47	,	,	PUNCT
bjos-8641742	64	48	regardless	regardless	ADV
bjos-8641742	64	49	of	of	ADP
bjos-8641742	64	50	the	the	DET
bjos-8641742	64	51	use	use	NOUN
bjos-8641742	64	52	of	of	ADP
bjos-8641742	64	53	haart	haart	PROPN
bjos-8641742	64	54	.	.	PUNCT
bjos-8641742	65	1	discussion	discussion	NOUN
bjos-8641742	65	2	it	it	PRON
bjos-8641742	65	3	has	have	AUX
bjos-8641742	65	4	been	be	AUX
bjos-8641742	65	5	suggested	suggest	VERB
bjos-8641742	65	6	that	that	SCONJ
bjos-8641742	65	7	oc	oc	NOUN
bjos-8641742	65	8	represents	represent	VERB
bjos-8641742	65	9	a	a	DET
bjos-8641742	65	10	relevant	relevant	ADJ
bjos-8641742	65	11	marker	marker	NOUN
bjos-8641742	65	12	of	of	ADP
bjos-8641742	65	13	immune	immune	ADJ
bjos-8641742	65	14	system	system	NOUN
bjos-8641742	65	15	status	status	NOUN
bjos-8641742	65	16	in	in	ADP
bjos-8641742	65	17	hiv	hiv	PROPN
bjos-8641742	65	18	-	-	PUNCT
bjos-8641742	65	19	infected	infect	VERB
bjos-8641742	65	20	patients	patient	NOUN
bjos-8641742	65	21	,	,	PUNCT
bjos-8641742	65	22	471471471471471	471471471471471	NUM
bjos-8641742	65	23	risk	risk	NOUN
bjos-8641742	65	24	factors	factor	NOUN
bjos-8641742	65	25	for	for	ADP
bjos-8641742	65	26	oral	oral	ADJ
bjos-8641742	65	27	candidiasis	candidiasis	NOUN
bjos-8641742	65	28	in	in	ADP
bjos-8641742	65	29	brazilian	brazilian	ADJ
bjos-8641742	65	30	hiv	hiv	PROPN
bjos-8641742	65	31	-	-	PUNCT
bjos-8641742	65	32	infected	infect	VERB
bjos-8641742	65	33	adult	adult	NOUN
bjos-8641742	65	34	patients	patient	NOUN
bjos-8641742	65	35	braz	braz	PROPN
bjos-8641742	65	36	j	j	PROPN
bjos-8641742	65	37	oral	oral	PROPN
bjos-8641742	65	38	sci	sci	PROPN
bjos-8641742	65	39	.	.	PROPN
bjos-8641742	66	1	9(4):470	9(4):470	NUM
bjos-8641742	66	2	-	-	SYM
bjos-8641742	66	3	474	474	NUM
bjos-8641742	66	4	472472472472472	472472472472472	NUM
bjos-8641742	66	5	variable	variable	ADJ
bjos-8641742	66	6	level	level	NOUN
bjos-8641742	66	7	or	or	CCONJ
bjos-8641742	66	8	unadjusted	unadjuste	VERB
bjos-8641742	66	9	(	(	PUNCT
bjos-8641742	66	10	95	95	NUM
bjos-8641742	66	11	%	%	NOUN
bjos-8641742	66	12	ci	ci	NOUN
bjos-8641742	66	13	)	)	PUNCT
bjos-8641742	66	14	p	p	NOUN
bjos-8641742	66	15	or	or	CCONJ
bjos-8641742	66	16	adjusted	adjust	VERB
bjos-8641742	66	17	(	(	PUNCT
bjos-8641742	66	18	95	95	NUM
bjos-8641742	66	19	%	%	NOUN
bjos-8641742	66	20	ci	ci	NOUN
bjos-8641742	66	21	)	)	PUNCT
bjos-8641742	66	22	p	p	NOUN
bjos-8641742	66	23	haart	haart	PROPN
bjos-8641742	67	1	yes	yes	INTJ
bjos-8641742	67	2	1	1	NUM
bjos-8641742	67	3	0.173	0.173	NUM
bjos-8641742	67	4	1	1	NUM
bjos-8641742	67	5	0.823	0.823	NUM
bjos-8641742	67	6	no	no	DET
bjos-8641742	67	7	2.2	2.2	NUM
bjos-8641742	67	8	(	(	PUNCT
bjos-8641742	67	9	0.7	0.7	NUM
bjos-8641742	67	10	-	-	SYM
bjos-8641742	67	11	6.5	6.5	NUM
bjos-8641742	67	12	)	)	PUNCT
bjos-8641742	67	13	0.84	0.84	NUM
bjos-8641742	67	14	(	(	PUNCT
bjos-8641742	67	15	0.2	0.2	NUM
bjos-8641742	67	16	-	-	PUNCT
bjos-8641742	67	17	4.0	4.0	NUM
bjos-8641742	67	18	)	)	PUNCT
bjos-8641742	67	19	oral	oral	ADJ
bjos-8641742	67	20	hairy	hairy	ADJ
bjos-8641742	67	21	leukoplakia	leukoplakia	NOUN
bjos-8641742	67	22	no	no	DET
bjos-8641742	67	23	1	1	NUM
bjos-8641742	67	24	<	<	NOUN
bjos-8641742	67	25	.001	.001	NUM
bjos-8641742	67	26	1	1	NUM
bjos-8641742	67	27	0.041	0.041	NUM
bjos-8641742	67	28	yes	yes	NOUN
bjos-8641742	67	29	10.2	10.2	NUM
bjos-8641742	67	30	(	(	PUNCT
bjos-8641742	67	31	4.0	4.0	NUM
bjos-8641742	67	32	-	-	SYM
bjos-8641742	67	33	26.0	26.0	NUM
bjos-8641742	67	34	)	)	PUNCT
bjos-8641742	67	35	3.6	3.6	NUM
bjos-8641742	67	36	(	(	PUNCT
bjos-8641742	67	37	1.1	1.1	NUM
bjos-8641742	67	38	-	-	SYM
bjos-8641742	67	39	12.3	12.3	NUM
bjos-8641742	67	40	)	)	PUNCT
bjos-8641742	67	41	previous	previous	ADJ
bjos-8641742	67	42	use	use	NOUN
bjos-8641742	67	43	of	of	ADP
bjos-8641742	67	44	fluconazole	fluconazole	NOUN
bjos-8641742	67	45	yes	yes	INTJ
bjos-8641742	67	46	1	1	NUM
bjos-8641742	67	47	<	<	X
bjos-8641742	67	48	.001	.001	NUM
bjos-8641742	67	49	1	1	NUM
bjos-8641742	67	50	<	<	NOUN
bjos-8641742	67	51	.001	.001	NUM
bjos-8641742	67	52	no	no	DET
bjos-8641742	67	53	27.4	27.4	NUM
bjos-8641742	67	54	(	(	PUNCT
bjos-8641742	67	55	8.1	8.1	NUM
bjos-8641742	67	56	-	-	SYM
bjos-8641742	67	57	92.0	92.0	NUM
bjos-8641742	67	58	)	)	PUNCT
bjos-8641742	67	59	14.3	14.3	NUM
bjos-8641742	67	60	(	(	PUNCT
bjos-8641742	67	61	3.8	3.8	NUM
bjos-8641742	67	62	-	-	SYM
bjos-8641742	67	63	53.6	53.6	NUM
bjos-8641742	67	64	)	)	PUNCT
bjos-8641742	67	65	viral	viral	ADJ
bjos-8641742	67	66	load	load	NOUN
bjos-8641742	67	67	(	(	PUNCT
bjos-8641742	67	68	copies/µl	copies/µl	PROPN
bjos-8641742	67	69	)	)	PUNCT
bjos-8641742	67	70	<	<	X
bjos-8641742	67	71	3,000	3,000	NUM
bjos-8641742	67	72	1	1	NUM
bjos-8641742	67	73	0.042	0.042	NUM
bjos-8641742	67	74	>	>	PUNCT
bjos-8641742	67	75	3,000	3,000	NUM
bjos-8641742	67	76	2.3	2.3	NUM
bjos-8641742	67	77	(	(	PUNCT
bjos-8641742	67	78	1.0	1.0	NUM
bjos-8641742	67	79	-	-	SYM
bjos-8641742	67	80	5.3	5.3	NUM
bjos-8641742	67	81	)	)	PUNCT
bjos-8641742	67	82	nam	nam	NOUN
bjos-8641742	67	83	table	table	NOUN
bjos-8641742	67	84	2	2	NUM
bjos-8641742	67	85	.	.	PUNCT
bjos-8641742	68	1	unconditional	unconditional	ADJ
bjos-8641742	68	2	simple	simple	ADJ
bjos-8641742	68	3	and	and	CCONJ
bjos-8641742	68	4	multiple	multiple	ADJ
bjos-8641742	68	5	logistic	logistic	ADJ
bjos-8641742	68	6	regression	regression	NOUN
bjos-8641742	68	7	analysis	analysis	NOUN
bjos-8641742	68	8	between	between	ADP
bjos-8641742	68	9	independent	independent	ADJ
bjos-8641742	68	10	variables	variable	NOUN
bjos-8641742	68	11	and	and	CCONJ
bjos-8641742	68	12	oral	oral	ADJ
bjos-8641742	68	13	candidiasis	candidiasis	NOUN
bjos-8641742	68	14	(	(	PUNCT
bjos-8641742	68	15	final	final	ADJ
bjos-8641742	68	16	model	model	NOUN
bjos-8641742	68	17	)	)	PUNCT
bjos-8641742	68	18	among	among	ADP
bjos-8641742	68	19	112	112	NUM
bjos-8641742	68	20	hiv	hiv	PROPN
bjos-8641742	68	21	/	/	SYM
bjos-8641742	68	22	aids	aid	NOUN
bjos-8641742	68	23	patients	patient	NOUN
bjos-8641742	68	24	attended	attend	VERB
bjos-8641742	68	25	at	at	ADP
bjos-8641742	68	26	the	the	DET
bjos-8641742	68	27	ctr	ctr	PROPN
bjos-8641742	68	28	-	-	PUNCT
bjos-8641742	68	29	dip	dip	PROPN
bjos-8641742	68	30	,	,	PUNCT
bjos-8641742	68	31	belo	belo	PROPN
bjos-8641742	68	32	horizonte	horizonte	PROPN
bjos-8641742	68	33	,	,	PUNCT
bjos-8641742	68	34	mg	mg	PROPN
bjos-8641742	68	35	,	,	PUNCT
bjos-8641742	68	36	brazil	brazil	PROPN
bjos-8641742	68	37	,	,	PUNCT
bjos-8641742	68	38	during	during	ADP
bjos-8641742	68	39	2002	2002	NUM
bjos-8641742	68	40	to	to	ADP
bjos-8641742	68	41	2004	2004	NUM
bjos-8641742	68	42	haart	haart	PROPN
bjos-8641742	68	43	:	:	PUNCT
bjos-8641742	68	44	highly	highly	ADV
bjos-8641742	68	45	active	active	ADJ
bjos-8641742	68	46	anti	anti	ADJ
bjos-8641742	68	47	-	-	ADJ
bjos-8641742	68	48	retroviral	retroviral	ADJ
bjos-8641742	68	49	therapy	therapy	NOUN
bjos-8641742	68	50	;	;	PUNCT
bjos-8641742	68	51	or	or	CCONJ
bjos-8641742	68	52	:	:	PUNCT
bjos-8641742	68	53	odds	odd	NOUN
bjos-8641742	68	54	ratio	ratio	NOUN
bjos-8641742	68	55	;	;	PUNCT
bjos-8641742	68	56	ci	ci	NOUN
bjos-8641742	68	57	:	:	PUNCT
bjos-8641742	68	58	95	95	NUM
bjos-8641742	68	59	%	%	NOUN
bjos-8641742	68	60	confidence	confidence	NOUN
bjos-8641742	68	61	interval	interval	NOUN
bjos-8641742	68	62	;	;	PUNCT
bjos-8641742	68	63	nam	nam	NOUN
bjos-8641742	68	64	:	:	PUNCT
bjos-8641742	68	65	non	non	NOUN
bjos-8641742	68	66	adjusted	adjust	VERB
bjos-8641742	68	67	to	to	ADP
bjos-8641742	68	68	the	the	DET
bjos-8641742	68	69	model	model	NOUN
bjos-8641742	68	70	and	and	CCONJ
bjos-8641742	68	71	is	be	AUX
bjos-8641742	68	72	also	also	ADV
bjos-8641742	68	73	a	a	DET
bjos-8641742	68	74	clinical	clinical	ADJ
bjos-8641742	68	75	predictor	predictor	NOUN
bjos-8641742	68	76	of	of	ADP
bjos-8641742	68	77	aids	aids	PROPN
bjos-8641742	68	78	progression3	progression3	PROPN
bjos-8641742	68	79	-	-	PROPN
bjos-8641742	68	80	4,7,11,14	4,7,11,14	PROPN
bjos-8641742	68	81	.	.	PUNCT
bjos-8641742	69	1	in	in	ADP
bjos-8641742	69	2	the	the	DET
bjos-8641742	69	3	present	present	ADJ
bjos-8641742	69	4	study	study	NOUN
bjos-8641742	69	5	,	,	PUNCT
bjos-8641742	69	6	the	the	DET
bjos-8641742	69	7	prevalence	prevalence	NOUN
bjos-8641742	69	8	of	of	ADP
bjos-8641742	69	9	oc	oc	NOUN
bjos-8641742	69	10	was	be	AUX
bjos-8641742	69	11	31.3	31.3	NUM
bjos-8641742	69	12	%	%	NOUN
bjos-8641742	69	13	.	.	PUNCT
bjos-8641742	70	1	most	most	ADJ
bjos-8641742	70	2	studies	study	NOUN
bjos-8641742	70	3	have	have	AUX
bjos-8641742	70	4	reported	report	VERB
bjos-8641742	70	5	prevalence	prevalence	NOUN
bjos-8641742	70	6	rates	rate	NOUN
bjos-8641742	70	7	of	of	ADP
bjos-8641742	70	8	oc	oc	NOUN
bjos-8641742	70	9	between	between	ADP
bjos-8641742	70	10	17.2	17.2	NUM
bjos-8641742	70	11	%	%	NOUN
bjos-8641742	70	12	and	and	CCONJ
bjos-8641742	70	13	58.6%3,7,11,21	58.6%3,7,11,21	NUM
bjos-8641742	70	14	.	.	PUNCT
bjos-8641742	71	1	it	it	PRON
bjos-8641742	71	2	is	be	AUX
bjos-8641742	71	3	intuitive	intuitive	ADJ
bjos-8641742	71	4	to	to	PART
bjos-8641742	71	5	expect	expect	VERB
bjos-8641742	71	6	an	an	DET
bjos-8641742	71	7	increase	increase	NOUN
bjos-8641742	71	8	of	of	ADP
bjos-8641742	71	9	oc	oc	NOUN
bjos-8641742	71	10	in	in	ADP
bjos-8641742	71	11	patients	patient	NOUN
bjos-8641742	71	12	with	with	ADP
bjos-8641742	71	13	low	low	PROPN
bjos-8641742	71	14	cd4	cd4	PROPN
bjos-8641742	71	15	t	t	PROPN
bjos-8641742	71	16	lymphocyte	lymphocyte	ADJ
bjos-8641742	71	17	count	count	NOUN
bjos-8641742	71	18	(	(	PUNCT
bjos-8641742	71	19	<	<	X
bjos-8641742	71	20	200	200	NUM
bjos-8641742	71	21	cells	cell	NOUN
bjos-8641742	71	22	/	/	SYM
bjos-8641742	71	23	mm3)3,7,910,14,22	mm3)3,7,910,14,22	NOUN
bjos-8641742	71	24	-	-	SYM
bjos-8641742	71	25	23	23	NUM
bjos-8641742	71	26	.	.	PUNCT
bjos-8641742	72	1	campisi	campisi	VERB
bjos-8641742	72	2	et	et	PROPN
bjos-8641742	72	3	al.24	al.24	PROPN
bjos-8641742	72	4	,	,	PUNCT
bjos-8641742	72	5	ghate	ghate	VERB
bjos-8641742	72	6	et	et	PRON
bjos-8641742	72	7	al.9	al.9	PROPN
bjos-8641742	72	8	and	and	CCONJ
bjos-8641742	72	9	shiboski	shiboski	VERB
bjos-8641742	72	10	et	et	PROPN
bjos-8641742	72	11	al.25	al.25	ADV
bjos-8641742	72	12	did	do	AUX
bjos-8641742	72	13	not	not	PART
bjos-8641742	72	14	find	find	VERB
bjos-8641742	72	15	any	any	DET
bjos-8641742	72	16	relation	relation	NOUN
bjos-8641742	72	17	between	between	ADP
bjos-8641742	72	18	oc	oc	NOUN
bjos-8641742	72	19	and	and	CCONJ
bjos-8641742	72	20	low	low	ADJ
bjos-8641742	72	21	cd4	cd4	PROPN
bjos-8641742	72	22	t	t	PROPN
bjos-8641742	72	23	lymphocyte	lymphocyte	ADJ
bjos-8641742	72	24	count	count	NOUN
bjos-8641742	72	25	in	in	ADP
bjos-8641742	72	26	hiv	hiv	PROPN
bjos-8641742	72	27	-	-	PUNCT
bjos-8641742	72	28	infected	infect	VERB
bjos-8641742	72	29	adults	adult	NOUN
bjos-8641742	72	30	,	,	PUNCT
bjos-8641742	72	31	as	as	SCONJ
bjos-8641742	72	32	is	be	AUX
bjos-8641742	72	33	reflected	reflect	VERB
bjos-8641742	72	34	in	in	ADP
bjos-8641742	72	35	the	the	DET
bjos-8641742	72	36	current	current	ADJ
bjos-8641742	72	37	study	study	NOUN
bjos-8641742	72	38	.	.	PUNCT
bjos-8641742	73	1	in	in	ADP
bjos-8641742	73	2	our	our	PRON
bjos-8641742	73	3	study	study	NOUN
bjos-8641742	73	4	,	,	PUNCT
bjos-8641742	73	5	this	this	PRON
bjos-8641742	73	6	may	may	AUX
bjos-8641742	73	7	be	be	AUX
bjos-8641742	73	8	attributed	attribute	VERB
bjos-8641742	73	9	to	to	ADP
bjos-8641742	73	10	the	the	DET
bjos-8641742	73	11	fact	fact	NOUN
bjos-8641742	73	12	that	that	SCONJ
bjos-8641742	73	13	haart	haart	PROPN
bjos-8641742	73	14	is	be	AUX
bjos-8641742	73	15	easily	easily	ADV
bjos-8641742	73	16	accessible	accessible	ADJ
bjos-8641742	73	17	in	in	ADP
bjos-8641742	73	18	brazil	brazil	PROPN
bjos-8641742	73	19	,	,	PUNCT
bjos-8641742	73	20	especially	especially	ADV
bjos-8641742	73	21	in	in	ADP
bjos-8641742	73	22	ctr	ctr	PROPN
bjos-8641742	73	23	-	-	PUNCT
bjos-8641742	73	24	dip	dip	NOUN
bjos-8641742	73	25	,	,	PUNCT
bjos-8641742	73	26	which	which	PRON
bjos-8641742	73	27	contributes	contribute	VERB
bjos-8641742	73	28	to	to	ADP
bjos-8641742	73	29	the	the	DET
bjos-8641742	73	30	improvement	improvement	NOUN
bjos-8641742	73	31	of	of	ADP
bjos-8641742	73	32	patient	patient	ADJ
bjos-8641742	73	33	immunity	immunity	NOUN
bjos-8641742	73	34	,	,	PUNCT
bjos-8641742	73	35	favoring	favor	VERB
bjos-8641742	73	36	an	an	DET
bjos-8641742	73	37	increase	increase	NOUN
bjos-8641742	73	38	in	in	ADP
bjos-8641742	73	39	the	the	DET
bjos-8641742	73	40	cd4	cd4	PROPN
bjos-8641742	73	41	t	t	PROPN
bjos-8641742	73	42	lymphocyte	lymphocyte	ADJ
bjos-8641742	73	43	count	count	NOUN
bjos-8641742	73	44	(	(	PUNCT
bjos-8641742	73	45	>	>	SYM
bjos-8641742	73	46	200	200	NUM
bjos-8641742	73	47	cells	cell	NOUN
bjos-8641742	73	48	/	/	SYM
bjos-8641742	73	49	mm3)4	mm3)4	PROPN
bjos-8641742	73	50	.	.	PUNCT
bjos-8641742	74	1	previous	previous	ADJ
bjos-8641742	74	2	studies	study	NOUN
bjos-8641742	74	3	have	have	AUX
bjos-8641742	74	4	reported	report	VERB
bjos-8641742	74	5	a	a	DET
bjos-8641742	74	6	heterogeneous	heterogeneous	ADJ
bjos-8641742	74	7	division	division	NOUN
bjos-8641742	74	8	of	of	ADP
bjos-8641742	74	9	viral	viral	ADJ
bjos-8641742	74	10	load	load	NOUN
bjos-8641742	74	11	,	,	PUNCT
bjos-8641742	74	12	ranging	range	VERB
bjos-8641742	74	13	from	from	ADP
bjos-8641742	74	14	3,000	3,000	NUM
bjos-8641742	74	15	to	to	PART
bjos-8641742	74	16	30,000	30,000	NUM
bjos-8641742	74	17	copies/µl3,14,2223,25	copies/µl3,14,2223,25	PROPN
bjos-8641742	74	18	.	.	PUNCT
bjos-8641742	75	1	the	the	DET
bjos-8641742	75	2	high	high	ADJ
bjos-8641742	75	3	viral	viral	ADJ
bjos-8641742	75	4	load	load	NOUN
bjos-8641742	75	5	presented	present	VERB
bjos-8641742	75	6	a	a	DET
bjos-8641742	75	7	significant	significant	ADJ
bjos-8641742	75	8	association	association	NOUN
bjos-8641742	75	9	with	with	ADP
bjos-8641742	75	10	oc	oc	NOUN
bjos-8641742	75	11	,	,	PUNCT
bjos-8641742	75	12	as	as	SCONJ
bjos-8641742	75	13	reported	report	VERB
bjos-8641742	75	14	in	in	ADP
bjos-8641742	75	15	the	the	DET
bjos-8641742	75	16	findings	finding	NOUN
bjos-8641742	75	17	of	of	ADP
bjos-8641742	75	18	other	other	ADJ
bjos-8641742	75	19	studies3,14,23,25	studies3,14,23,25	NOUN
bjos-8641742	75	20	.	.	PUNCT
bjos-8641742	76	1	variable	variable	ADJ
bjos-8641742	76	2	level	level	NOUN
bjos-8641742	76	3	pp	pp	ADP
bjos-8641742	76	4	patients	patient	NOUN
bjos-8641742	76	5	with	with	ADP
bjos-8641742	76	6	oc	oc	X
bjos-8641742	76	7	(	(	PUNCT
bjos-8641742	76	8	n=35	n=35	NUM
bjos-8641742	76	9	)	)	PUNCT
bjos-8641742	76	10	patients	patient	NOUN
bjos-8641742	76	11	without	without	ADP
bjos-8641742	76	12	oc	oc	X
bjos-8641742	76	13	(	(	PUNCT
bjos-8641742	76	14	n=77	n=77	NOUN
bjos-8641742	76	15	)	)	PUNCT
bjos-8641742	76	16	p	p	PROPN
bjos-8641742	77	1	cd4	cd4	PROPN
bjos-8641742	77	2	t	t	PROPN
bjos-8641742	77	3	lymphocyte	lymphocyte	ADJ
bjos-8641742	77	4	count	count	NOUN
bjos-8641742	77	5	(	(	PUNCT
bjos-8641742	77	6	cells	cell	NOUN
bjos-8641742	77	7	/	/	SYM
bjos-8641742	77	8	mm3	mm3	PROPN
bjos-8641742	77	9	)	)	PUNCT
bjos-8641742	77	10	<	<	X
bjos-8641742	77	11	200	200	NUM
bjos-8641742	77	12	33.3	33.3	NUM
bjos-8641742	77	13	8	8	NUM
bjos-8641742	77	14	16	16	NUM
bjos-8641742	77	15	0.804f	0.804f	NUM
bjos-8641742	77	16	>	>	PUNCT
bjos-8641742	77	17	200	200	NUM
bjos-8641742	77	18	30.7	30.7	NUM
bjos-8641742	77	19	27	27	NUM
bjos-8641742	77	20	61	61	NUM
bjos-8641742	77	21	viral	viral	ADJ
bjos-8641742	77	22	load	load	NOUN
bjos-8641742	77	23	(	(	PUNCT
bjos-8641742	77	24	copies/µl	copies/µl	PROPN
bjos-8641742	77	25	)	)	PUNCT
bjos-8641742	77	26	<	<	X
bjos-8641742	77	27	3,000	3,000	NUM
bjos-8641742	77	28	23.4	23.4	NUM
bjos-8641742	77	29	15	15	NUM
bjos-8641742	77	30	49	49	NUM
bjos-8641742	77	31	0.042	0.042	NUM
bjos-8641742	77	32	*	*	PUNCT
bjos-8641742	77	33	>	>	PUNCT
bjos-8641742	77	34	3,000	3,000	NUM
bjos-8641742	77	35	41.7	41.7	NUM
bjos-8641742	77	36	20	20	NUM
bjos-8641742	77	37	28	28	NUM
bjos-8641742	77	38	platelets	platelet	NOUN
bjos-8641742	77	39	count	count	NOUN
bjos-8641742	77	40	(	(	PUNCT
bjos-8641742	77	41	mm3	mm3	PROPN
bjos-8641742	77	42	)	)	PUNCT
bjos-8641742	77	43	<	<	X
bjos-8641742	77	44	150,000	150,000	NUM
bjos-8641742	77	45	50.0	50.0	NUM
bjos-8641742	77	46	2	2	NUM
bjos-8641742	77	47	2	2	NUM
bjos-8641742	77	48	0.370f	0.370f	NOUN
bjos-8641742	77	49	>	>	ADP
bjos-8641742	77	50	150,000	150,000	NUM
bjos-8641742	77	51	30.6	30.6	NUM
bjos-8641742	77	52	33	33	NUM
bjos-8641742	77	53	75	75	NUM
bjos-8641742	77	54	haart	haart	INTJ
bjos-8641742	78	1	yes	yes	INTJ
bjos-8641742	78	2	28.9	28.9	NUM
bjos-8641742	78	3	28	28	NUM
bjos-8641742	78	4	69	69	NUM
bjos-8641742	78	5	0.140f	0.140f	NOUN
bjos-8641742	78	6	no	no	DET
bjos-8641742	78	7	46.6	46.6	NUM
bjos-8641742	78	8	7	7	NUM
bjos-8641742	78	9	8	8	NUM
bjos-8641742	78	10	gender	gender	NOUN
bjos-8641742	78	11	men	man	NOUN
bjos-8641742	78	12	32.9	32.9	NUM
bjos-8641742	78	13	27	27	NUM
bjos-8641742	78	14	55	55	NUM
bjos-8641742	78	15	0.527	0.527	NUM
bjos-8641742	78	16	*	*	PUNCT
bjos-8641742	78	17	women	woman	NOUN
bjos-8641742	78	18	26.7	26.7	NUM
bjos-8641742	78	19	8	8	NUM
bjos-8641742	78	20	22	22	NUM
bjos-8641742	78	21	reduction	reduction	NOUN
bjos-8641742	78	22	of	of	ADP
bjos-8641742	78	23	salivary	salivary	ADJ
bjos-8641742	78	24	flow	flow	NOUN
bjos-8641742	78	25	yes	yes	ADV
bjos-8641742	78	26	34.1	34.1	NUM
bjos-8641742	78	27	14	14	NUM
bjos-8641742	78	28	27	27	NUM
bjos-8641742	78	29	0.615	0.615	NUM
bjos-8641742	78	30	*	*	PUNCT
bjos-8641742	79	1	no	no	DET
bjos-8641742	79	2	29.6	29.6	NUM
bjos-8641742	79	3	21	21	NUM
bjos-8641742	79	4	50	50	NUM
bjos-8641742	79	5	xerostomia	xerostomia	NOUN
bjos-8641742	80	1	yes	yes	INTJ
bjos-8641742	80	2	33.3	33.3	NUM
bjos-8641742	80	3	12	12	NUM
bjos-8641742	80	4	24	24	NUM
bjos-8641742	80	5	0.743	0.743	NUM
bjos-8641742	80	6	*	*	PUNCT
bjos-8641742	81	1	no	no	DET
bjos-8641742	81	2	30.3	30.3	NUM
bjos-8641742	81	3	23	23	NUM
bjos-8641742	81	4	53	53	NUM
bjos-8641742	81	5	oral	oral	ADJ
bjos-8641742	81	6	hairy	hairy	ADJ
bjos-8641742	81	7	leukoplakia	leukoplakia	NOUN
bjos-8641742	81	8	yes	yes	INTJ
bjos-8641742	81	9	66.7	66.7	NUM
bjos-8641742	81	10	22	22	NUM
bjos-8641742	81	11	11	11	NUM
bjos-8641742	81	12	<	<	NOUN
bjos-8641742	81	13	.001	.001	NUM
bjos-8641742	81	14	no	no	DET
bjos-8641742	81	15	16.5	16.5	NUM
bjos-8641742	81	16	13	13	NUM
bjos-8641742	81	17	66	66	NUM
bjos-8641742	81	18	previous	previous	ADJ
bjos-8641742	81	19	use	use	NOUN
bjos-8641742	81	20	of	of	ADP
bjos-8641742	81	21	fluconazole	fluconazole	NOUN
bjos-8641742	81	22	yes	yes	INTJ
bjos-8641742	81	23	84.0	84.0	NUM
bjos-8641742	81	24	21	21	NUM
bjos-8641742	81	25	4	4	NUM
bjos-8641742	81	26	<	<	NOUN
bjos-8641742	81	27	.001	.001	NUM
bjos-8641742	81	28	no	no	DET
bjos-8641742	81	29	16.1	16.1	NUM
bjos-8641742	81	30	14	14	NUM
bjos-8641742	81	31	73	73	NUM
bjos-8641742	81	32	previous	previous	ADJ
bjos-8641742	81	33	use	use	NOUN
bjos-8641742	81	34	of	of	ADP
bjos-8641742	81	35	systemic	systemic	ADJ
bjos-8641742	81	36	acyclovir	acyclovir	PROPN
bjos-8641742	82	1	yes	yes	INTJ
bjos-8641742	82	2	50.0	50.0	NUM
bjos-8641742	82	3	5	5	NUM
bjos-8641742	82	4	5	5	NUM
bjos-8641742	82	5	0.160f	0.160f	NOUN
bjos-8641742	82	6	no	no	DET
bjos-8641742	82	7	29.4	29.4	NUM
bjos-8641742	82	8	30	30	NUM
bjos-8641742	82	9	72	72	NUM
bjos-8641742	82	10	use	use	NOUN
bjos-8641742	82	11	of	of	ADP
bjos-8641742	82	12	azt	azt	PROPN
bjos-8641742	83	1	yes	yes	ADV
bjos-8641742	83	2	28.7	28.7	NUM
bjos-8641742	83	3	21	21	NUM
bjos-8641742	83	4	52	52	NUM
bjos-8641742	83	5	0.438	0.438	NUM
bjos-8641742	83	6	*	*	PUNCT
bjos-8641742	83	7	no	no	DET
bjos-8641742	83	8	35.9	35.9	NUM
bjos-8641742	83	9	14	14	NUM
bjos-8641742	83	10	25	25	NUM
bjos-8641742	83	11	intravenous	intravenous	ADJ
bjos-8641742	83	12	drug	drug	NOUN
bjos-8641742	83	13	use	use	NOUN
bjos-8641742	83	14	yes	yes	INTJ
bjos-8641742	83	15	22.2	22.2	NUM
bjos-8641742	83	16	2	2	NUM
bjos-8641742	83	17	7	7	NUM
bjos-8641742	83	18	0.424f	0.424f	NOUN
bjos-8641742	83	19	no	no	DET
bjos-8641742	83	20	32.0	32.0	NUM
bjos-8641742	83	21	33	33	NUM
bjos-8641742	83	22	70	70	NUM
bjos-8641742	83	23	smoking	smoking	NOUN
bjos-8641742	83	24	yes	yes	INTJ
bjos-8641742	83	25	32.0	32.0	NUM
bjos-8641742	83	26	16	16	NUM
bjos-8641742	83	27	34	34	NUM
bjos-8641742	83	28	0.878	0.878	NUM
bjos-8641742	83	29	*	*	PUNCT
bjos-8641742	83	30	no	no	DET
bjos-8641742	83	31	30.6	30.6	NUM
bjos-8641742	83	32	19	19	NUM
bjos-8641742	83	33	43	43	NUM
bjos-8641742	83	34	alcohol	alcohol	NOUN
bjos-8641742	83	35	consumption	consumption	NOUN
bjos-8641742	84	1	yes	yes	INTJ
bjos-8641742	84	2	30.0	30.0	NUM
bjos-8641742	84	3	3	3	NUM
bjos-8641742	84	4	7	7	NUM
bjos-8641742	84	5	0.619f	0.619f	ADJ
bjos-8641742	84	6	no	no	DET
bjos-8641742	84	7	31.4	31.4	NUM
bjos-8641742	84	8	32	32	NUM
bjos-8641742	84	9	70	70	NUM
bjos-8641742	84	10	table	table	NOUN
bjos-8641742	84	11	1	1	NUM
bjos-8641742	84	12	.	.	PUNCT
bjos-8641742	84	13	proportional	proportional	ADJ
bjos-8641742	84	14	prevalence	prevalence	NOUN
bjos-8641742	84	15	and	and	CCONJ
bjos-8641742	84	16	univariate	univariate	ADJ
bjos-8641742	84	17	analyze	analyze	NOUN
bjos-8641742	84	18	for	for	ADP
bjos-8641742	84	19	oral	oral	ADJ
bjos-8641742	84	20	candidiasis	candidiasis	NOUN
bjos-8641742	84	21	among	among	ADP
bjos-8641742	84	22	112	112	NUM
bjos-8641742	84	23	hiv	hiv	PROPN
bjos-8641742	84	24	/	/	SYM
bjos-8641742	84	25	aids	aid	NOUN
bjos-8641742	84	26	patients	patient	NOUN
bjos-8641742	84	27	attended	attend	VERB
bjos-8641742	84	28	to	to	ADP
bjos-8641742	84	29	at	at	ADP
bjos-8641742	84	30	the	the	DET
bjos-8641742	84	31	ctr	ctr	PROPN
bjos-8641742	84	32	-	-	PUNCT
bjos-8641742	84	33	dip	dip	PROPN
bjos-8641742	84	34	,	,	PUNCT
bjos-8641742	84	35	belo	belo	PROPN
bjos-8641742	84	36	horizonte	horizonte	PROPN
bjos-8641742	84	37	,	,	PUNCT
bjos-8641742	84	38	mg	mg	PROPN
bjos-8641742	84	39	,	,	PUNCT
bjos-8641742	84	40	brazil	brazil	PROPN
bjos-8641742	84	41	,	,	PUNCT
bjos-8641742	84	42	during	during	ADP
bjos-8641742	84	43	2002	2002	NUM
bjos-8641742	84	44	to	to	ADP
bjos-8641742	84	45	2004	2004	NUM
bjos-8641742	84	46	*	*	PUNCT
bjos-8641742	84	47	chi	chi	ADJ
bjos-8641742	84	48	-	-	PUNCT
bjos-8641742	84	49	square	square	ADJ
bjos-8641742	84	50	test	test	NOUN
bjos-8641742	84	51	;	;	PUNCT
bjos-8641742	84	52	ffisher	ffisher	PROPN
bjos-8641742	84	53	’s	’s	PART
bjos-8641742	84	54	exact	exact	ADJ
bjos-8641742	84	55	test	test	NOUN
bjos-8641742	84	56	;	;	PUNCT
bjos-8641742	84	57	pp	pp	CCONJ
bjos-8641742	84	58	:	:	PUNCT
bjos-8641742	84	59	proportional	proportional	ADJ
bjos-8641742	84	60	prevalence	prevalence	NOUN
bjos-8641742	84	61	;	;	PUNCT
bjos-8641742	84	62	oc	oc	ADP
bjos-8641742	84	63	:	:	PUNCT
bjos-8641742	84	64	oral	oral	ADJ
bjos-8641742	84	65	candidiasis	candidiasis	NOUN
bjos-8641742	84	66	;	;	PUNCT
bjos-8641742	84	67	haart	haart	PROPN
bjos-8641742	84	68	:	:	PUNCT
bjos-8641742	84	69	highly	highly	ADV
bjos-8641742	84	70	active	active	ADJ
bjos-8641742	84	71	anti	anti	ADJ
bjos-8641742	84	72	-	-	ADJ
bjos-8641742	84	73	retroviral	retroviral	ADJ
bjos-8641742	84	74	therapy	therapy	NOUN
bjos-8641742	84	75	risk	risk	NOUN
bjos-8641742	84	76	factors	factor	NOUN
bjos-8641742	84	77	for	for	ADP
bjos-8641742	84	78	oral	oral	ADJ
bjos-8641742	84	79	candidiasis	candidiasis	NOUN
bjos-8641742	84	80	in	in	ADP
bjos-8641742	84	81	brazilian	brazilian	ADJ
bjos-8641742	84	82	hiv	hiv	PROPN
bjos-8641742	84	83	-	-	PUNCT
bjos-8641742	84	84	infected	infect	VERB
bjos-8641742	84	85	adult	adult	NOUN
bjos-8641742	84	86	patients	patient	NOUN
bjos-8641742	84	87	braz	braz	PROPN
bjos-8641742	84	88	j	j	PROPN
bjos-8641742	84	89	oral	oral	PROPN
bjos-8641742	84	90	sci	sci	PROPN
bjos-8641742	84	91	.	.	PROPN
bjos-8641742	85	1	9(4):470	9(4):470	NUM
bjos-8641742	85	2	-	-	SYM
bjos-8641742	85	3	474	474	NUM
bjos-8641742	85	4	473473473473473	473473473473473	NUM
bjos-8641742	85	5	mercante	mercante	X
bjos-8641742	85	6	et	et	NOUN
bjos-8641742	85	7	al.10	al.10	NOUN
bjos-8641742	85	8	and	and	CCONJ
bjos-8641742	85	9	coogan	coogan	PROPN
bjos-8641742	85	10	et	et	NOUN
bjos-8641742	85	11	al.26	al.26	PROPN
bjos-8641742	85	12	suggested	suggest	VERB
bjos-8641742	85	13	that	that	SCONJ
bjos-8641742	85	14	viral	viral	ADJ
bjos-8641742	85	15	load	load	NOUN
bjos-8641742	85	16	may	may	AUX
bjos-8641742	85	17	be	be	AUX
bjos-8641742	85	18	a	a	DET
bjos-8641742	85	19	more	more	ADV
bjos-8641742	85	20	important	important	ADJ
bjos-8641742	85	21	predictor	predictor	NOUN
bjos-8641742	85	22	for	for	ADP
bjos-8641742	85	23	oropharyngeal	oropharyngeal	ADJ
bjos-8641742	85	24	candidiasis	candidiasis	NOUN
bjos-8641742	85	25	than	than	ADP
bjos-8641742	85	26	cd4	cd4	PROPN
bjos-8641742	85	27	t	t	PROPN
bjos-8641742	85	28	lymphocyte	lymphocyte	PROPN
bjos-8641742	85	29	count	count	NOUN
bjos-8641742	85	30	.	.	PUNCT
bjos-8641742	86	1	oc	oc	PROPN
bjos-8641742	86	2	was	be	AUX
bjos-8641742	86	3	more	more	ADV
bjos-8641742	86	4	frequent	frequent	ADJ
bjos-8641742	86	5	in	in	ADP
bjos-8641742	86	6	patients	patient	NOUN
bjos-8641742	86	7	with	with	ADP
bjos-8641742	86	8	platelet	platelet	NOUN
bjos-8641742	86	9	count	count	NOUN
bjos-8641742	86	10	<	<	NOUN
bjos-8641742	86	11	150,000	150,000	NUM
bjos-8641742	86	12	,	,	PUNCT
bjos-8641742	86	13	though	though	SCONJ
bjos-8641742	86	14	without	without	ADP
bjos-8641742	86	15	a	a	DET
bjos-8641742	86	16	significant	significant	ADJ
bjos-8641742	86	17	association	association	NOUN
bjos-8641742	86	18	.	.	PUNCT
bjos-8641742	87	1	patton	patton	PROPN
bjos-8641742	87	2	et	et	PROPN
bjos-8641742	87	3	al.27	al.27	PROPN
bjos-8641742	87	4	observed	observe	VERB
bjos-8641742	87	5	that	that	SCONJ
bjos-8641742	87	6	platelet	platelet	NOUN
bjos-8641742	87	7	count	count	NOUN
bjos-8641742	87	8	<	<	NOUN
bjos-8641742	87	9	150,000	150,000	NUM
bjos-8641742	87	10	may	may	AUX
bjos-8641742	87	11	predispose	predispose	VERB
bjos-8641742	87	12	hiv	hiv	PROPN
bjos-8641742	87	13	-	-	PUNCT
bjos-8641742	87	14	infected	infect	VERB
bjos-8641742	87	15	patients	patient	NOUN
bjos-8641742	87	16	to	to	ADP
bjos-8641742	87	17	the	the	DET
bjos-8641742	87	18	development	development	NOUN
bjos-8641742	87	19	of	of	ADP
bjos-8641742	87	20	oral	oral	ADJ
bjos-8641742	87	21	manifestations	manifestation	NOUN
bjos-8641742	87	22	,	,	PUNCT
bjos-8641742	87	23	as	as	SCONJ
bjos-8641742	87	24	verified	verify	VERB
bjos-8641742	87	25	in	in	ADP
bjos-8641742	87	26	15.5	15.5	NUM
bjos-8641742	87	27	%	%	NOUN
bjos-8641742	87	28	of	of	ADP
bjos-8641742	87	29	516	516	NUM
bjos-8641742	87	30	patients	patient	NOUN
bjos-8641742	87	31	.	.	PUNCT
bjos-8641742	88	1	one	one	NUM
bjos-8641742	88	2	possible	possible	ADJ
bjos-8641742	88	3	explanation	explanation	NOUN
bjos-8641742	88	4	for	for	ADP
bjos-8641742	88	5	our	our	PRON
bjos-8641742	88	6	results	result	NOUN
bjos-8641742	88	7	is	be	AUX
bjos-8641742	88	8	the	the	DET
bjos-8641742	88	9	fact	fact	NOUN
bjos-8641742	88	10	that	that	SCONJ
bjos-8641742	88	11	the	the	DET
bjos-8641742	88	12	number	number	NOUN
bjos-8641742	88	13	of	of	ADP
bjos-8641742	88	14	individuals	individual	NOUN
bjos-8641742	88	15	with	with	ADP
bjos-8641742	88	16	platelet	platelet	NOUN
bjos-8641742	88	17	count	count	NOUN
bjos-8641742	88	18	<	<	NOUN
bjos-8641742	88	19	150,000	150,000	NUM
bjos-8641742	88	20	was	be	AUX
bjos-8641742	88	21	small	small	ADJ
bjos-8641742	88	22	(	(	PUNCT
bjos-8641742	88	23	1.7	1.7	NUM
bjos-8641742	88	24	%	%	NOUN
bjos-8641742	88	25	)	)	PUNCT
bjos-8641742	88	26	.	.	PUNCT
bjos-8641742	89	1	oc	oc	PROPN
bjos-8641742	89	2	can	can	AUX
bjos-8641742	89	3	be	be	AUX
bjos-8641742	89	4	considered	consider	VERB
bjos-8641742	89	5	a	a	DET
bjos-8641742	89	6	measure	measure	NOUN
bjos-8641742	89	7	of	of	ADP
bjos-8641742	89	8	assessment	assessment	NOUN
bjos-8641742	89	9	of	of	ADP
bjos-8641742	89	10	the	the	DET
bjos-8641742	89	11	need	need	NOUN
bjos-8641742	89	12	to	to	PART
bjos-8641742	89	13	begin	begin	VERB
bjos-8641742	89	14	antiretroviral	antiretroviral	ADJ
bjos-8641742	89	15	medication1	medication1	NOUN
bjos-8641742	89	16	1,7	1,7	NUM
bjos-8641742	89	17	-	-	PUNCT
bjos-8641742	89	18	8,11,14,25,28	8,11,14,25,28	NUM
bjos-8641742	89	19	.	.	PUNCT
bjos-8641742	90	1	in	in	ADP
bjos-8641742	90	2	contrast	contrast	NOUN
bjos-8641742	90	3	,	,	PUNCT
bjos-8641742	90	4	we	we	PRON
bjos-8641742	90	5	did	do	AUX
bjos-8641742	90	6	not	not	PART
bjos-8641742	90	7	find	find	VERB
bjos-8641742	90	8	statistically	statistically	ADV
bjos-8641742	90	9	significant	significant	ADJ
bjos-8641742	90	10	association	association	NOUN
bjos-8641742	90	11	between	between	ADP
bjos-8641742	90	12	haart	haart	PROPN
bjos-8641742	90	13	and	and	CCONJ
bjos-8641742	90	14	oc	oc	PROPN
bjos-8641742	90	15	.	.	PROPN
bjos-8641742	90	16	tappuni	tappuni	PROPN
bjos-8641742	90	17	and	and	CCONJ
bjos-8641742	90	18	fleming28	fleming28	NOUN
bjos-8641742	90	19	found	find	VERB
bjos-8641742	90	20	no	no	DET
bjos-8641742	90	21	association	association	NOUN
bjos-8641742	90	22	between	between	ADP
bjos-8641742	90	23	antiretroviral	antiretroviral	ADJ
bjos-8641742	90	24	medication	medication	NOUN
bjos-8641742	90	25	and	and	CCONJ
bjos-8641742	90	26	the	the	DET
bjos-8641742	90	27	presence	presence	NOUN
bjos-8641742	90	28	of	of	ADP
bjos-8641742	90	29	oc	oc	PROPN
bjos-8641742	90	30	.	.	PUNCT
bjos-8641742	91	1	thompson	thompson	PROPN
bjos-8641742	91	2	et	et	PROPN
bjos-8641742	91	3	al.1	al.1	PROPN
bjos-8641742	91	4	confirmed	confirm	VERB
bjos-8641742	91	5	that	that	SCONJ
bjos-8641742	91	6	oc	oc	NOUN
bjos-8641742	91	7	remains	remain	VERB
bjos-8641742	91	8	a	a	DET
bjos-8641742	91	9	significant	significant	ADJ
bjos-8641742	91	10	infection	infection	NOUN
bjos-8641742	91	11	in	in	ADP
bjos-8641742	91	12	advanced	advanced	ADJ
bjos-8641742	91	13	aids	aid	NOUN
bjos-8641742	91	14	,	,	PUNCT
bjos-8641742	91	15	even	even	ADV
bjos-8641742	91	16	with	with	ADP
bjos-8641742	91	17	haart	haart	PROPN
bjos-8641742	91	18	.	.	PUNCT
bjos-8641742	92	1	gender	gender	NOUN
bjos-8641742	92	2	,	,	PUNCT
bjos-8641742	92	3	salivary	salivary	ADJ
bjos-8641742	92	4	flow	flow	NOUN
bjos-8641742	92	5	,	,	PUNCT
bjos-8641742	92	6	xerostomia	xerostomia	NOUN
bjos-8641742	92	7	,	,	PUNCT
bjos-8641742	92	8	previous	previous	ADJ
bjos-8641742	92	9	use	use	NOUN
bjos-8641742	92	10	of	of	ADP
bjos-8641742	92	11	systemic	systemic	ADJ
bjos-8641742	92	12	acyclovir	acyclovir	NOUN
bjos-8641742	92	13	,	,	PUNCT
bjos-8641742	92	14	use	use	NOUN
bjos-8641742	92	15	of	of	ADP
bjos-8641742	92	16	azt	azt	PROPN
bjos-8641742	92	17	,	,	PUNCT
bjos-8641742	92	18	intravenous	intravenous	ADJ
bjos-8641742	92	19	drug	drug	NOUN
bjos-8641742	92	20	use	use	NOUN
bjos-8641742	92	21	,	,	PUNCT
bjos-8641742	92	22	smoking	smoking	NOUN
bjos-8641742	92	23	,	,	PUNCT
bjos-8641742	92	24	and	and	CCONJ
bjos-8641742	92	25	alcohol	alcohol	NOUN
bjos-8641742	92	26	consumption	consumption	NOUN
bjos-8641742	92	27	do	do	AUX
bjos-8641742	92	28	not	not	PART
bjos-8641742	92	29	represent	represent	VERB
bjos-8641742	92	30	risk	risk	NOUN
bjos-8641742	92	31	indicators	indicator	NOUN
bjos-8641742	92	32	for	for	ADP
bjos-8641742	92	33	oc7,14,24	oc7,14,24	NOUN
bjos-8641742	92	34	-	-	NOUN
bjos-8641742	92	35	26,29	26,29	NUM
bjos-8641742	92	36	.	.	PUNCT
bjos-8641742	93	1	although	although	SCONJ
bjos-8641742	93	2	it	it	PRON
bjos-8641742	93	3	was	be	AUX
bjos-8641742	93	4	not	not	PART
bjos-8641742	93	5	statistically	statistically	ADV
bjos-8641742	93	6	significant	significant	ADJ
bjos-8641742	93	7	,	,	PUNCT
bjos-8641742	93	8	in	in	ADP
bjos-8641742	93	9	the	the	DET
bjos-8641742	93	10	present	present	ADJ
bjos-8641742	93	11	study	study	NOUN
bjos-8641742	93	12	,	,	PUNCT
bjos-8641742	93	13	oc	oc	PROPN
bjos-8641742	93	14	was	be	AUX
bjos-8641742	93	15	proportionally	proportionally	ADV
bjos-8641742	93	16	more	more	ADV
bjos-8641742	93	17	frequent	frequent	ADJ
bjos-8641742	93	18	in	in	ADP
bjos-8641742	93	19	men	man	NOUN
bjos-8641742	93	20	,	,	PUNCT
bjos-8641742	93	21	in	in	ADP
bjos-8641742	93	22	patients	patient	NOUN
bjos-8641742	93	23	with	with	ADP
bjos-8641742	93	24	a	a	DET
bjos-8641742	93	25	reduced	reduce	VERB
bjos-8641742	93	26	salivary	salivary	ADJ
bjos-8641742	93	27	flow	flow	NOUN
bjos-8641742	93	28	,	,	PUNCT
bjos-8641742	93	29	with	with	ADP
bjos-8641742	93	30	previous	previous	ADJ
bjos-8641742	93	31	use	use	NOUN
bjos-8641742	93	32	of	of	ADP
bjos-8641742	93	33	systemic	systemic	ADJ
bjos-8641742	93	34	acyclovir	acyclovir	PROPN
bjos-8641742	93	35	,	,	PUNCT
bjos-8641742	93	36	who	who	PRON
bjos-8641742	93	37	were	be	AUX
bjos-8641742	93	38	not	not	PART
bjos-8641742	93	39	taking	take	VERB
bjos-8641742	93	40	azt	azt	PROPN
bjos-8641742	93	41	and	and	CCONJ
bjos-8641742	93	42	who	who	PRON
bjos-8641742	93	43	did	do	AUX
bjos-8641742	93	44	not	not	PART
bjos-8641742	93	45	use	use	VERB
bjos-8641742	93	46	intravenously	intravenously	ADV
bjos-8641742	93	47	drug	drug	NOUN
bjos-8641742	93	48	.	.	PUNCT
bjos-8641742	94	1	although	although	SCONJ
bjos-8641742	94	2	our	our	PRON
bjos-8641742	94	3	study	study	NOUN
bjos-8641742	94	4	was	be	AUX
bjos-8641742	94	5	directed	direct	VERB
bjos-8641742	94	6	towards	towards	ADP
bjos-8641742	94	7	oc	oc	PROPN
bjos-8641742	94	8	,	,	PUNCT
bjos-8641742	94	9	the	the	DET
bjos-8641742	94	10	presence	presence	NOUN
bjos-8641742	94	11	of	of	ADP
bjos-8641742	94	12	ohl	ohl	PROPN
bjos-8641742	94	13	and	and	CCONJ
bjos-8641742	94	14	oc	oc	NOUN
bjos-8641742	94	15	was	be	AUX
bjos-8641742	94	16	also	also	ADV
bjos-8641742	94	17	verified	verify	VERB
bjos-8641742	94	18	,	,	PUNCT
bjos-8641742	94	19	simultaneously	simultaneously	ADV
bjos-8641742	94	20	,	,	PUNCT
bjos-8641742	94	21	as	as	ADP
bjos-8641742	94	22	being	be	AUX
bjos-8641742	94	23	the	the	DET
bjos-8641742	94	24	two	two	NUM
bjos-8641742	94	25	most	most	ADV
bjos-8641742	94	26	common	common	ADJ
bjos-8641742	94	27	oral	oral	ADJ
bjos-8641742	94	28	lesions	lesion	NOUN
bjos-8641742	94	29	in	in	ADP
bjos-8641742	94	30	hiv	hiv	PROPN
bjos-8641742	94	31	-	-	PUNCT
bjos-8641742	94	32	infected	infect	VERB
bjos-8641742	94	33	adults	adult	NOUN
bjos-8641742	94	34	.	.	PUNCT
bjos-8641742	95	1	the	the	DET
bjos-8641742	95	2	association	association	NOUN
bjos-8641742	95	3	between	between	ADP
bjos-8641742	95	4	the	the	DET
bjos-8641742	95	5	presence	presence	NOUN
bjos-8641742	95	6	of	of	ADP
bjos-8641742	95	7	oc	oc	NOUN
bjos-8641742	95	8	and	and	CCONJ
bjos-8641742	95	9	ohl	ohl	PROPN
bjos-8641742	95	10	verified	verify	VERB
bjos-8641742	95	11	in	in	ADP
bjos-8641742	95	12	this	this	DET
bjos-8641742	95	13	study	study	NOUN
bjos-8641742	95	14	has	have	AUX
bjos-8641742	95	15	also	also	ADV
bjos-8641742	95	16	been	be	AUX
bjos-8641742	95	17	observed	observe	VERB
bjos-8641742	95	18	in	in	ADP
bjos-8641742	95	19	many	many	ADJ
bjos-8641742	95	20	other	other	ADJ
bjos-8641742	95	21	studies	study	NOUN
bjos-8641742	95	22	in	in	ADP
bjos-8641742	95	23	the	the	DET
bjos-8641742	95	24	us	us	PROPN
bjos-8641742	95	25	and	and	CCONJ
bjos-8641742	95	26	europe3,7,11,27,29	europe3,7,11,27,29	NOUN
bjos-8641742	95	27	.	.	PUNCT
bjos-8641742	96	1	the	the	DET
bjos-8641742	96	2	previous	previous	ADJ
bjos-8641742	96	3	use	use	NOUN
bjos-8641742	96	4	of	of	ADP
bjos-8641742	96	5	fluconazole	fluconazole	NOUN
bjos-8641742	96	6	was	be	AUX
bjos-8641742	96	7	a	a	DET
bjos-8641742	96	8	strong	strong	ADJ
bjos-8641742	96	9	indicator	indicator	NOUN
bjos-8641742	96	10	of	of	ADP
bjos-8641742	96	11	risk	risk	NOUN
bjos-8641742	96	12	for	for	ADP
bjos-8641742	96	13	oc	oc	PROPN
bjos-8641742	96	14	.	.	PUNCT
bjos-8641742	97	1	schmidt	schmidt	PROPN
bjos-8641742	97	2	-	-	PUNCT
bjos-8641742	97	3	westhausen	westhausen	NOUN
bjos-8641742	97	4	et	et	NOUN
bjos-8641742	97	5	al.30	al.30	NOUN
bjos-8641742	97	6	found	find	VERB
bjos-8641742	97	7	different	different	ADJ
bjos-8641742	97	8	results	result	NOUN
bjos-8641742	97	9	,	,	PUNCT
bjos-8641742	97	10	and	and	CCONJ
bjos-8641742	97	11	they	they	PRON
bjos-8641742	97	12	concluded	conclude	VERB
bjos-8641742	97	13	that	that	SCONJ
bjos-8641742	97	14	the	the	DET
bjos-8641742	97	15	presence	presence	NOUN
bjos-8641742	97	16	of	of	ADP
bjos-8641742	97	17	oral	oral	ADJ
bjos-8641742	97	18	lesions	lesion	NOUN
bjos-8641742	97	19	associated	associate	VERB
bjos-8641742	97	20	with	with	ADP
bjos-8641742	97	21	hiv	hiv	PROPN
bjos-8641742	97	22	-	-	PUNCT
bjos-8641742	97	23	infection	infection	NOUN
bjos-8641742	97	24	did	do	AUX
bjos-8641742	97	25	not	not	PART
bjos-8641742	97	26	have	have	VERB
bjos-8641742	97	27	a	a	DET
bjos-8641742	97	28	correlation	correlation	NOUN
bjos-8641742	97	29	with	with	ADP
bjos-8641742	97	30	the	the	DET
bjos-8641742	97	31	use	use	NOUN
bjos-8641742	97	32	of	of	ADP
bjos-8641742	97	33	fluconazole	fluconazole	NOUN
bjos-8641742	97	34	.	.	PUNCT
bjos-8641742	98	1	it	it	PRON
bjos-8641742	98	2	is	be	AUX
bjos-8641742	98	3	possible	possible	ADJ
bjos-8641742	98	4	that	that	SCONJ
bjos-8641742	98	5	candida	candida	PROPN
bjos-8641742	98	6	resistance	resistance	NOUN
bjos-8641742	98	7	to	to	ADP
bjos-8641742	98	8	fluconazole	fluconazole	NOUN
bjos-8641742	98	9	is	be	AUX
bjos-8641742	98	10	responsible	responsible	ADJ
bjos-8641742	98	11	for	for	ADP
bjos-8641742	98	12	our	our	PRON
bjos-8641742	98	13	finding	finding	NOUN
bjos-8641742	98	14	.	.	PUNCT
bjos-8641742	99	1	the	the	DET
bjos-8641742	99	2	high	high	ADJ
bjos-8641742	99	3	incidence	incidence	NOUN
bjos-8641742	99	4	of	of	ADP
bjos-8641742	99	5	mucosal	mucosal	NOUN
bjos-8641742	99	6	and	and	CCONJ
bjos-8641742	99	7	deep	deep	ADJ
bjos-8641742	99	8	seated	seated	ADJ
bjos-8641742	99	9	forms	form	NOUN
bjos-8641742	99	10	of	of	ADP
bjos-8641742	99	11	candidiasis	candidiasis	NOUN
bjos-8641742	99	12	in	in	ADP
bjos-8641742	99	13	hiv	hiv	PROPN
bjos-8641742	99	14	-	-	PUNCT
bjos-8641742	99	15	infected	infect	VERB
bjos-8641742	99	16	patients	patient	NOUN
bjos-8641742	99	17	has	have	AUX
bjos-8641742	99	18	resulted	result	VERB
bjos-8641742	99	19	in	in	ADP
bjos-8641742	99	20	the	the	DET
bjos-8641742	99	21	use	use	NOUN
bjos-8641742	99	22	of	of	ADP
bjos-8641742	99	23	fluconazole	fluconazole	NOUN
bjos-8641742	99	24	.	.	PUNCT
bjos-8641742	100	1	their	their	PRON
bjos-8641742	100	2	widespread	widespread	ADJ
bjos-8641742	100	3	use	use	NOUN
bjos-8641742	100	4	has	have	AUX
bjos-8641742	100	5	been	be	AUX
bjos-8641742	100	6	followed	follow	VERB
bjos-8641742	100	7	by	by	ADP
bjos-8641742	100	8	an	an	DET
bjos-8641742	100	9	increase	increase	NOUN
bjos-8641742	100	10	in	in	ADP
bjos-8641742	100	11	antifungal	antifungal	ADJ
bjos-8641742	100	12	resistance	resistance	NOUN
bjos-8641742	100	13	and	and	CCONJ
bjos-8641742	100	14	candida	candida	PROPN
bjos-8641742	100	15	resistance	resistance	NOUN
bjos-8641742	100	16	.	.	PUNCT
bjos-8641742	101	1	various	various	ADJ
bjos-8641742	101	2	factors	factor	NOUN
bjos-8641742	101	3	may	may	AUX
bjos-8641742	101	4	contribute	contribute	VERB
bjos-8641742	101	5	to	to	ADP
bjos-8641742	101	6	fluconazole	fluconazole	NOUN
bjos-8641742	101	7	resistance	resistance	NOUN
bjos-8641742	101	8	,	,	PUNCT
bjos-8641742	101	9	such	such	ADJ
bjos-8641742	101	10	as	as	ADP
bjos-8641742	101	11	the	the	DET
bjos-8641742	101	12	degree	degree	NOUN
bjos-8641742	101	13	of	of	ADP
bjos-8641742	101	14	immunosuppression	immunosuppression	NOUN
bjos-8641742	101	15	of	of	ADP
bjos-8641742	101	16	the	the	DET
bjos-8641742	101	17	patients	patient	NOUN
bjos-8641742	101	18	,	,	PUNCT
bjos-8641742	101	19	the	the	DET
bjos-8641742	101	20	chemotherapeutic	chemotherapeutic	ADJ
bjos-8641742	101	21	use	use	NOUN
bjos-8641742	101	22	of	of	ADP
bjos-8641742	101	23	drugs	drug	NOUN
bjos-8641742	101	24	and	and	CCONJ
bjos-8641742	101	25	the	the	DET
bjos-8641742	101	26	intrinsic	intrinsic	ADJ
bjos-8641742	101	27	resistance	resistance	NOUN
bjos-8641742	101	28	of	of	ADP
bjos-8641742	101	29	candida	candida	PROPN
bjos-8641742	101	30	species2	species2	NOUN
bjos-8641742	101	31	.	.	PUNCT
bjos-8641742	102	1	fluconazole	fluconazole	NOUN
bjos-8641742	102	2	used	use	VERB
bjos-8641742	102	3	for	for	ADP
bjos-8641742	102	4	prolonged	prolonged	ADJ
bjos-8641742	102	5	periods	period	NOUN
bjos-8641742	102	6	can	can	AUX
bjos-8641742	102	7	select	select	VERB
bjos-8641742	102	8	for	for	ADP
bjos-8641742	102	9	less	less	ADV
bjos-8641742	102	10	susceptible	susceptible	ADJ
bjos-8641742	102	11	species	specie	NOUN
bjos-8641742	102	12	candida2	candida2	NOUN
bjos-8641742	102	13	.	.	PUNCT
bjos-8641742	103	1	the	the	DET
bjos-8641742	103	2	resistance	resistance	NOUN
bjos-8641742	103	3	of	of	ADP
bjos-8641742	103	4	candida	candida	PROPN
bjos-8641742	103	5	,	,	PUNCT
bjos-8641742	103	6	isolated	isolate	VERB
bjos-8641742	103	7	to	to	ADP
bjos-8641742	103	8	currently	currently	ADV
bjos-8641742	103	9	available	available	ADJ
bjos-8641742	103	10	antifungal	antifungal	ADJ
bjos-8641742	103	11	drugs	drug	NOUN
bjos-8641742	103	12	,	,	PUNCT
bjos-8641742	103	13	is	be	AUX
bjos-8641742	103	14	a	a	DET
bjos-8641742	103	15	highly	highly	ADV
bjos-8641742	103	16	relevant	relevant	ADJ
bjos-8641742	103	17	factor	factor	NOUN
bjos-8641742	103	18	because	because	SCONJ
bjos-8641742	103	19	it	it	PRON
bjos-8641742	103	20	presents	present	VERB
bjos-8641742	103	21	important	important	ADJ
bjos-8641742	103	22	implications	implication	NOUN
bjos-8641742	103	23	for	for	ADP
bjos-8641742	103	24	morbidity	morbidity	NOUN
bjos-8641742	103	25	and	and	CCONJ
bjos-8641742	103	26	mortality1,6	mortality1,6	PROPN
bjos-8641742	103	27	.	.	PUNCT
bjos-8641742	103	28	systemically	systemically	ADV
bjos-8641742	103	29	applied	apply	VERB
bjos-8641742	103	30	antifungal	antifungal	ADJ
bjos-8641742	103	31	drugs	drug	NOUN
bjos-8641742	103	32	have	have	VERB
bjos-8641742	103	33	the	the	DET
bjos-8641742	103	34	greatest	great	ADJ
bjos-8641742	103	35	efficacy	efficacy	NOUN
bjos-8641742	103	36	for	for	ADP
bjos-8641742	103	37	the	the	DET
bjos-8641742	103	38	treatment	treatment	NOUN
bjos-8641742	103	39	of	of	ADP
bjos-8641742	103	40	oral	oral	ADJ
bjos-8641742	103	41	candidiasis	candidiasis	NOUN
bjos-8641742	103	42	.	.	PUNCT
bjos-8641742	104	1	however	however	ADV
bjos-8641742	104	2	,	,	PUNCT
bjos-8641742	104	3	these	these	DET
bjos-8641742	104	4	therapies	therapy	NOUN
bjos-8641742	104	5	must	must	AUX
bjos-8641742	104	6	be	be	AUX
bjos-8641742	104	7	prescribed	prescribe	VERB
bjos-8641742	104	8	following	follow	VERB
bjos-8641742	104	9	a	a	DET
bjos-8641742	104	10	thorough	thorough	ADJ
bjos-8641742	104	11	assessment	assessment	NOUN
bjos-8641742	104	12	of	of	ADP
bjos-8641742	104	13	the	the	DET
bjos-8641742	104	14	risk	risk	NOUN
bjos-8641742	104	15	for	for	ADP
bjos-8641742	104	16	developing	develop	VERB
bjos-8641742	104	17	drug	drug	NOUN
bjos-8641742	104	18	-	-	PUNCT
bjos-8641742	104	19	induced	induce	VERB
bjos-8641742	104	20	toxicities	toxicity	NOUN
bjos-8641742	104	21	,	,	PUNCT
bjos-8641742	104	22	the	the	DET
bjos-8641742	104	23	likelihood	likelihood	NOUN
bjos-8641742	104	24	of	of	ADP
bjos-8641742	104	25	candida	candida	PROPN
bjos-8641742	104	26	species	specie	NOUN
bjos-8641742	104	27	resistance	resistance	NOUN
bjos-8641742	104	28	,	,	PUNCT
bjos-8641742	104	29	and	and	CCONJ
bjos-8641742	104	30	the	the	DET
bjos-8641742	104	31	cost	cost	NOUN
bjos-8641742	104	32	-	-	PUNCT
bjos-8641742	104	33	effectiveness	effectiveness	NOUN
bjos-8641742	104	34	of	of	ADP
bjos-8641742	104	35	medications	medication	NOUN
bjos-8641742	104	36	.	.	PUNCT
bjos-8641742	105	1	fluconazole	fluconazole	NOUN
bjos-8641742	105	2	prophylaxis	prophylaxis	NOUN
bjos-8641742	105	3	should	should	AUX
bjos-8641742	105	4	be	be	AUX
bjos-8641742	105	5	reserved	reserve	VERB
bjos-8641742	105	6	for	for	ADP
bjos-8641742	105	7	patients	patient	NOUN
bjos-8641742	105	8	at	at	ADP
bjos-8641742	105	9	high	high	ADJ
bjos-8641742	105	10	risk	risk	NOUN
bjos-8641742	105	11	for	for	ADP
bjos-8641742	105	12	recurrence	recurrence	NOUN
bjos-8641742	105	13	of	of	ADP
bjos-8641742	105	14	fungal	fungal	ADJ
bjos-8641742	105	15	infections	infection	NOUN
bjos-8641742	105	16	,	,	PUNCT
bjos-8641742	105	17	and	and	CCONJ
bjos-8641742	105	18	not	not	PART
bjos-8641742	105	19	for	for	ADP
bjos-8641742	105	20	routine	routine	ADJ
bjos-8641742	105	21	prophylaxis6	prophylaxis6	NOUN
bjos-8641742	105	22	.	.	PUNCT
bjos-8641742	106	1	additionally	additionally	ADV
bjos-8641742	106	2	,	,	PUNCT
bjos-8641742	106	3	another	another	DET
bjos-8641742	106	4	explanation	explanation	NOUN
bjos-8641742	106	5	for	for	ADP
bjos-8641742	106	6	the	the	DET
bjos-8641742	106	7	association	association	NOUN
bjos-8641742	106	8	of	of	ADP
bjos-8641742	106	9	oc	oc	NOUN
bjos-8641742	106	10	with	with	ADP
bjos-8641742	106	11	previous	previous	ADJ
bjos-8641742	106	12	use	use	NOUN
bjos-8641742	106	13	of	of	ADP
bjos-8641742	106	14	fluconazole	fluconazole	NOUN
bjos-8641742	106	15	could	could	AUX
bjos-8641742	106	16	be	be	AUX
bjos-8641742	106	17	the	the	DET
bjos-8641742	106	18	fact	fact	NOUN
bjos-8641742	106	19	that	that	SCONJ
bjos-8641742	106	20	patients	patient	NOUN
bjos-8641742	106	21	with	with	ADP
bjos-8641742	106	22	hiv	hiv	PROPN
bjos-8641742	106	23	infection	infection	NOUN
bjos-8641742	106	24	can	can	AUX
bjos-8641742	106	25	have	have	AUX
bjos-8641742	106	26	recurrent	recurrent	ADJ
bjos-8641742	106	27	oc	oc	NOUN
bjos-8641742	106	28	and	and	CCONJ
bjos-8641742	106	29	that	that	PRON
bjos-8641742	106	30	are	be	AUX
bjos-8641742	106	31	treated	treat	VERB
bjos-8641742	106	32	with	with	ADP
bjos-8641742	106	33	fluconazole1	fluconazole1	PROPN
bjos-8641742	106	34	.	.	PUNCT
bjos-8641742	107	1	these	these	DET
bjos-8641742	107	2	results	result	NOUN
bjos-8641742	107	3	are	be	AUX
bjos-8641742	107	4	important	important	ADJ
bjos-8641742	107	5	for	for	ADP
bjos-8641742	107	6	the	the	DET
bjos-8641742	107	7	development	development	NOUN
bjos-8641742	107	8	of	of	ADP
bjos-8641742	107	9	strategies	strategy	NOUN
bjos-8641742	107	10	to	to	PART
bjos-8641742	107	11	eliminate	eliminate	VERB
bjos-8641742	107	12	these	these	DET
bjos-8641742	107	13	indicators	indicator	NOUN
bjos-8641742	107	14	of	of	ADP
bjos-8641742	107	15	risk	risk	NOUN
bjos-8641742	107	16	and	and	CCONJ
bjos-8641742	107	17	significantly	significantly	ADV
bjos-8641742	107	18	reduce	reduce	VERB
bjos-8641742	107	19	oc	oc	NOUN
bjos-8641742	107	20	in	in	ADP
bjos-8641742	107	21	brazilian	brazilian	ADJ
bjos-8641742	107	22	hiv	hiv	PROPN
bjos-8641742	107	23	-	-	PUNCT
bjos-8641742	107	24	infected	infect	VERB
bjos-8641742	107	25	adult	adult	NOUN
bjos-8641742	107	26	patients	patient	NOUN
bjos-8641742	107	27	.	.	PUNCT
bjos-8641742	108	1	acknowledgements	acknowledgement	NOUN
bjos-8641742	108	2	this	this	DET
bjos-8641742	108	3	study	study	NOUN
bjos-8641742	108	4	was	be	AUX
bjos-8641742	108	5	supported	support	VERB
bjos-8641742	108	6	by	by	ADP
bjos-8641742	108	7	grants	grant	NOUN
bjos-8641742	108	8	from	from	ADP
bjos-8641742	108	9	the	the	DET
bjos-8641742	108	10	the	the	DET
bjos-8641742	108	11	national	national	ADJ
bjos-8641742	108	12	council	council	PROPN
bjos-8641742	108	13	for	for	ADP
bjos-8641742	108	14	scientific	scientific	ADJ
bjos-8641742	108	15	and	and	CCONJ
bjos-8641742	108	16	technological	technological	ADJ
bjos-8641742	108	17	development	development	NOUN
bjos-8641742	108	18	(	(	PUNCT
bjos-8641742	108	19	cnpq	cnpq	NOUN
bjos-8641742	108	20	#	#	SYM
bjos-8641742	108	21	301490/2007	301490/2007	NUM
bjos-8641742	108	22	-	-	SYM
bjos-8641742	108	23	4	4	NUM
bjos-8641742	108	24	)	)	PUNCT
bjos-8641742	108	25	.	.	PUNCT
bjos-8641742	109	1	mesquita	mesquita	PROPN
bjos-8641742	109	2	ra	ra	PROPN
bjos-8641742	109	3	is	be	AUX
bjos-8641742	109	4	research	research	NOUN
bjos-8641742	109	5	fellows	fellow	NOUN
bjos-8641742	109	6	of	of	ADP
bjos-8641742	109	7	the	the	DET
bjos-8641742	109	8	cnpq	cnpq	NOUN
bjos-8641742	109	9	.	.	PUNCT
bjos-8641742	110	1	references	reference	NOUN
bjos-8641742	110	2	1	1	NUM
bjos-8641742	110	3	.	.	PUNCT
bjos-8641742	111	1	thompson	thompson	PROPN
bjos-8641742	111	2	gr	gr	PROPN
bjos-8641742	111	3	,	,	PUNCT
bjos-8641742	111	4	patel	patel	PROPN
bjos-8641742	111	5	pk	pk	PROPN
bjos-8641742	111	6	,	,	PUNCT
bjos-8641742	111	7	kirkpatrick	kirkpatrick	PROPN
bjos-8641742	111	8	wr	wr	PROPN
bjos-8641742	111	9	,	,	PUNCT
bjos-8641742	111	10	westbrook	westbrook	PROPN
bjos-8641742	111	11	sd	sd	PROPN
bjos-8641742	111	12	,	,	PUNCT
bjos-8641742	111	13	berg	berg	PROPN
bjos-8641742	111	14	d	d	PROPN
bjos-8641742	111	15	,	,	PUNCT
bjos-8641742	111	16	erlandsen	erlandsen	PROPN
bjos-8641742	111	17	j	j	PROPN
bjos-8641742	111	18	,	,	PUNCT
bjos-8641742	111	19	et	et	PROPN
bjos-8641742	111	20	al	al	PROPN
bjos-8641742	111	21	.	.	PUNCT
bjos-8641742	111	22	oropharyngeal	oropharyngeal	ADJ
bjos-8641742	111	23	candidiasis	candidiasis	NOUN
bjos-8641742	111	24	in	in	ADP
bjos-8641742	111	25	the	the	DET
bjos-8641742	111	26	era	era	NOUN
bjos-8641742	111	27	of	of	ADP
bjos-8641742	111	28	antiretroviral	antiretroviral	ADJ
bjos-8641742	111	29	therapy	therapy	NOUN
bjos-8641742	111	30	.	.	PUNCT
bjos-8641742	112	1	oral	oral	ADJ
bjos-8641742	112	2	surg	surg	NOUN
bjos-8641742	112	3	oral	oral	ADJ
bjos-8641742	112	4	med	med	ADJ
bjos-8641742	112	5	oral	oral	ADJ
bjos-8641742	112	6	pathol	pathol	NOUN
bjos-8641742	112	7	oral	oral	ADJ
bjos-8641742	112	8	radiol	radiol	NOUN
bjos-8641742	112	9	endod	endod	PROPN
bjos-8641742	112	10	.	.	PUNCT
bjos-8641742	113	1	2010	2010	NUM
bjos-8641742	113	2	;	;	PUNCT
bjos-8641742	113	3	109	109	NUM
bjos-8641742	113	4	:	:	PUNCT
bjos-8641742	113	5	488	488	NUM
bjos-8641742	113	6	-	-	SYM
bjos-8641742	113	7	95	95	NUM
bjos-8641742	113	8	.	.	PUNCT
bjos-8641742	114	1	2	2	X
bjos-8641742	114	2	.	.	X
bjos-8641742	114	3	chunchanur	chunchanur	NOUN
bjos-8641742	114	4	sk	sk	NOUN
bjos-8641742	114	5	,	,	PUNCT
bjos-8641742	114	6	nadgir	nadgir	PROPN
bjos-8641742	114	7	sd	sd	NOUN
bjos-8641742	114	8	,	,	PUNCT
bjos-8641742	114	9	halesh	halesh	PROPN
bjos-8641742	114	10	lh	lh	PROPN
bjos-8641742	114	11	,	,	PUNCT
bjos-8641742	114	12	patil	patil	PROPN
bjos-8641742	114	13	bs	bs	PROPN
bjos-8641742	114	14	,	,	PUNCT
bjos-8641742	114	15	kausar	kausar	VERB
bjos-8641742	114	16	y	y	PROPN
bjos-8641742	114	17	,	,	PUNCT
bjos-8641742	114	18	chandrasekhar	chandrasekhar	PROPN
bjos-8641742	114	19	mr	mr	PROPN
bjos-8641742	114	20	.	.	PROPN
bjos-8641742	114	21	detection	detection	PROPN
bjos-8641742	114	22	and	and	CCONJ
bjos-8641742	114	23	antifungal	antifungal	ADJ
bjos-8641742	114	24	susceptibility	susceptibility	NOUN
bjos-8641742	114	25	testing	testing	NOUN
bjos-8641742	114	26	of	of	ADP
bjos-8641742	114	27	oral	oral	ADJ
bjos-8641742	114	28	candida	candida	NOUN
bjos-8641742	114	29	dubliniensis	dubliniensis	NOUN
bjos-8641742	114	30	from	from	ADP
bjos-8641742	114	31	human	human	ADJ
bjos-8641742	114	32	immunodeficiency	immunodeficiency	NOUN
bjos-8641742	114	33	virus	virus	NOUN
bjos-8641742	114	34	-	-	PUNCT
bjos-8641742	114	35	infected	infect	VERB
bjos-8641742	114	36	patients	patient	NOUN
bjos-8641742	114	37	.	.	PUNCT
bjos-8641742	115	1	indian	indian	PROPN
bjos-8641742	115	2	j	j	PROPN
bjos-8641742	115	3	pathol	pathol	VERB
bjos-8641742	115	4	microbiol	microbiol	NOUN
bjos-8641742	115	5	.	.	PUNCT
bjos-8641742	116	1	2009	2009	NUM
bjos-8641742	116	2	;	;	PUNCT
bjos-8641742	116	3	52	52	NUM
bjos-8641742	116	4	:	:	SYM
bjos-8641742	116	5	501	501	NUM
bjos-8641742	116	6	-	-	SYM
bjos-8641742	116	7	4	4	NUM
bjos-8641742	116	8	.	.	NOUN
bjos-8641742	117	1	3	3	X
bjos-8641742	117	2	.	.	X
bjos-8641742	117	3	miziara	miziara	PROPN
bjos-8641742	117	4	i	i	PROPN
bjos-8641742	117	5	d	d	PROPN
bjos-8641742	117	6	,	,	PUNCT
bjos-8641742	117	7	weber	weber	PROPN
bjos-8641742	117	8	r.	r.	PROPN
bjos-8641742	117	9	oral	oral	PROPN
bjos-8641742	117	10	candidosis	candidosis	NOUN
bjos-8641742	117	11	and	and	CCONJ
bjos-8641742	117	12	oral	oral	ADJ
bjos-8641742	117	13	hairy	hairy	ADJ
bjos-8641742	117	14	leukoplakia	leukoplakia	NOUN
bjos-8641742	117	15	as	as	ADP
bjos-8641742	117	16	predictors	predictor	NOUN
bjos-8641742	117	17	of	of	ADP
bjos-8641742	117	18	haart	haart	PROPN
bjos-8641742	117	19	failure	failure	NOUN
bjos-8641742	117	20	in	in	ADP
bjos-8641742	117	21	brazilian	brazilian	ADJ
bjos-8641742	117	22	hiv	hiv	PROPN
bjos-8641742	117	23	-	-	PUNCT
bjos-8641742	117	24	infected	infect	VERB
bjos-8641742	117	25	patients	patient	NOUN
bjos-8641742	117	26	.	.	PUNCT
bjos-8641742	118	1	oral	oral	ADJ
bjos-8641742	118	2	dis	dis	PROPN
bjos-8641742	118	3	.	.	PUNCT
bjos-8641742	119	1	2006	2006	NUM
bjos-8641742	119	2	;	;	PUNCT
bjos-8641742	119	3	12	12	NUM
bjos-8641742	119	4	:	:	PUNCT
bjos-8641742	119	5	402	402	NUM
bjos-8641742	119	6	-	-	SYM
bjos-8641742	119	7	7	7	NUM
bjos-8641742	119	8	.	.	NOUN
bjos-8641742	119	9	4	4	NUM
bjos-8641742	119	10	.	.	X
bjos-8641742	119	11	moura	moura	PROPN
bjos-8641742	119	12	mdg	mdg	PROPN
bjos-8641742	119	13	,	,	PUNCT
bjos-8641742	119	14	grossmann	grossmann	PROPN
bjos-8641742	119	15	smc	smc	PROPN
bjos-8641742	119	16	,	,	PUNCT
bjos-8641742	119	17	fonseca	fonseca	PROPN
bjos-8641742	119	18	lms	lms	PROPN
bjos-8641742	119	19	,	,	PUNCT
bjos-8641742	119	20	senna	senna	PROPN
bjos-8641742	119	21	mib	mib	PROPN
bjos-8641742	119	22	,	,	PUNCT
bjos-8641742	119	23	mesquita	mesquita	PROPN
bjos-8641742	119	24	ra	ra	PROPN
bjos-8641742	119	25	.	.	PUNCT
bjos-8641742	120	1	risk	risk	NOUN
bjos-8641742	120	2	factors	factor	NOUN
bjos-8641742	120	3	for	for	ADP
bjos-8641742	120	4	oral	oral	ADJ
bjos-8641742	120	5	hairy	hairy	ADJ
bjos-8641742	120	6	leukoplakia	leukoplakia	NOUN
bjos-8641742	120	7	in	in	ADP
bjos-8641742	120	8	hiv	hiv	PROPN
bjos-8641742	120	9	-	-	PUNCT
bjos-8641742	120	10	infected	infect	VERB
bjos-8641742	120	11	adults	adult	NOUN
bjos-8641742	120	12	of	of	ADP
bjos-8641742	120	13	brazil	brazil	PROPN
bjos-8641742	120	14	.	.	PUNCT
bjos-8641742	121	1	j	j	PROPN
bjos-8641742	121	2	oral	oral	ADJ
bjos-8641742	121	3	pathol	pathol	NOUN
bjos-8641742	121	4	med	me	VERB
bjos-8641742	121	5	.	.	PUNCT
bjos-8641742	121	6	2006	2006	NUM
bjos-8641742	121	7	;	;	PUNCT
bjos-8641742	121	8	35	35	NUM
bjos-8641742	121	9	:	:	SYM
bjos-8641742	121	10	321	321	NUM
bjos-8641742	121	11	-	-	SYM
bjos-8641742	121	12	6	6	NUM
bjos-8641742	121	13	.	.	NOUN
bjos-8641742	121	14	5	5	NUM
bjos-8641742	121	15	.	.	X
bjos-8641742	121	16	merçon	merçon	PROPN
bjos-8641742	121	17	m	m	PROPN
bjos-8641742	121	18	,	,	PUNCT
bjos-8641742	121	19	tuboi	tuboi	PROPN
bjos-8641742	121	20	sh	sh	PROPN
bjos-8641742	121	21	,	,	PUNCT
bjos-8641742	121	22	batista	batista	PROPN
bjos-8641742	121	23	sm	sm	PROPN
bjos-8641742	121	24	,	,	PUNCT
bjos-8641742	121	25	telles	telles	PROPN
bjos-8641742	121	26	sr	sr	PROPN
bjos-8641742	121	27	,	,	PUNCT
bjos-8641742	121	28	grangeiro	grangeiro	PROPN
bjos-8641742	121	29	jr	jr	PROPN
bjos-8641742	121	30	,	,	PUNCT
bjos-8641742	121	31	zajdenverg	zajdenverg	PROPN
bjos-8641742	121	32	r	r	PROPN
bjos-8641742	121	33	,	,	PUNCT
bjos-8641742	121	34	et	et	PROPN
bjos-8641742	121	35	al	al	PROPN
bjos-8641742	121	36	.	.	PUNCT
bjos-8641742	121	37	risk	risk	NOUN
bjos-8641742	121	38	-	-	PUNCT
bjos-8641742	121	39	based	base	VERB
bjos-8641742	121	40	assessment	assessment	NOUN
bjos-8641742	121	41	does	do	AUX
bjos-8641742	121	42	not	not	PART
bjos-8641742	121	43	distinguish	distinguish	VERB
bjos-8641742	121	44	between	between	ADP
bjos-8641742	121	45	recent	recent	ADJ
bjos-8641742	121	46	and	and	CCONJ
bjos-8641742	121	47	chronic	chronic	ADJ
bjos-8641742	121	48	hiv-1	hiv-1	VERB
bjos-8641742	121	49	infection	infection	NOUN
bjos-8641742	121	50	in	in	ADP
bjos-8641742	121	51	rio	rio	PROPN
bjos-8641742	121	52	de	de	PROPN
bjos-8641742	121	53	janeiro	janeiro	PROPN
bjos-8641742	121	54	,	,	PUNCT
bjos-8641742	121	55	brazil	brazil	PROPN
bjos-8641742	121	56	.	.	PUNCT
bjos-8641742	122	1	braz	braz	PROPN
bjos-8641742	122	2	j	j	PROPN
bjos-8641742	122	3	infect	infect	PROPN
bjos-8641742	122	4	dis	dis	PROPN
bjos-8641742	122	5	.	.	PUNCT
bjos-8641742	123	1	2009	2009	NUM
bjos-8641742	123	2	;	;	PUNCT
bjos-8641742	123	3	13	13	NUM
bjos-8641742	123	4	:	:	SYM
bjos-8641742	123	5	272	272	NUM
bjos-8641742	123	6	-	-	SYM
bjos-8641742	123	7	5	5	NUM
bjos-8641742	123	8	.	.	NOUN
bjos-8641742	123	9	6	6	NUM
bjos-8641742	123	10	.	.	X
bjos-8641742	123	11	ship	ship	PROPN
bjos-8641742	123	12	ja	ja	PROPN
bjos-8641742	123	13	,	,	PUNCT
bjos-8641742	123	14	vissink	vissink	VERB
bjos-8641742	123	15	a	a	DET
bjos-8641742	123	16	,	,	PUNCT
bjos-8641742	123	17	challacombe	challacombe	ADJ
bjos-8641742	123	18	sj	sj	NOUN
bjos-8641742	123	19	.	.	PUNCT
bjos-8641742	123	20	use	use	NOUN
bjos-8641742	123	21	of	of	ADP
bjos-8641742	123	22	prophylactic	prophylactic	ADJ
bjos-8641742	123	23	antifungals	antifungal	NOUN
bjos-8641742	123	24	in	in	ADP
bjos-8641742	123	25	the	the	DET
bjos-8641742	123	26	immunocompromised	immunocompromise	VERB
bjos-8641742	123	27	host	host	NOUN
bjos-8641742	123	28	.	.	PUNCT
bjos-8641742	124	1	oral	oral	ADJ
bjos-8641742	124	2	surg	surg	NOUN
bjos-8641742	124	3	oral	oral	ADJ
bjos-8641742	124	4	med	med	ADJ
bjos-8641742	124	5	oral	oral	ADJ
bjos-8641742	124	6	pathol	pathol	NOUN
bjos-8641742	124	7	oral	oral	ADJ
bjos-8641742	124	8	radiol	radiol	NOUN
bjos-8641742	124	9	endod	endod	PROPN
bjos-8641742	124	10	.	.	PUNCT
bjos-8641742	125	1	2007	2007	NUM
bjos-8641742	125	2	;	;	PUNCT
bjos-8641742	125	3	103(suppl.1	103(suppl.1	NUM
bjos-8641742	125	4	):	):	PUNCT
bjos-8641742	125	5	s6.e1	s6.e1	PROPN
bjos-8641742	125	6	-	-	PUNCT
bjos-8641742	125	7	s6.e14	s6.e14	NOUN
bjos-8641742	125	8	.	.	PUNCT
bjos-8641742	126	1	7	7	X
bjos-8641742	126	2	.	.	X
bjos-8641742	126	3	chattopadhyay	chattopadhyay	PROPN
bjos-8641742	126	4	a	a	PROPN
bjos-8641742	126	5	,	,	PUNCT
bjos-8641742	126	6	caplan	caplan	PROPN
bjos-8641742	126	7	dj	dj	PROPN
bjos-8641742	126	8	,	,	PUNCT
bjos-8641742	126	9	slade	slade	PROPN
bjos-8641742	126	10	gd	gd	PROPN
bjos-8641742	126	11	,	,	PUNCT
bjos-8641742	126	12	shugars	shugar	VERB
bjos-8641742	126	13	dc	dc	PROPN
bjos-8641742	126	14	,	,	PUNCT
bjos-8641742	126	15	tien	tien	PROPN
bjos-8641742	126	16	hc	hc	PROPN
bjos-8641742	126	17	,	,	PUNCT
bjos-8641742	126	18	patton	patton	PROPN
bjos-8641742	126	19	ll	ll	AUX
bjos-8641742	126	20	.	.	PUNCT
bjos-8641742	127	1	risk	risk	NOUN
bjos-8641742	127	2	indicators	indicator	NOUN
bjos-8641742	127	3	for	for	ADP
bjos-8641742	127	4	oral	oral	ADJ
bjos-8641742	127	5	candidiasis	candidiasis	NOUN
bjos-8641742	127	6	and	and	CCONJ
bjos-8641742	127	7	oral	oral	ADJ
bjos-8641742	127	8	hairy	hairy	ADJ
bjos-8641742	127	9	leukoplakia	leukoplakia	NOUN
bjos-8641742	127	10	in	in	ADP
bjos-8641742	127	11	hivinfected	hivinfecte	VERB
bjos-8641742	127	12	adults	adult	NOUN
bjos-8641742	127	13	.	.	PUNCT
bjos-8641742	128	1	community	community	NOUN
bjos-8641742	128	2	dent	dent	NOUN
bjos-8641742	128	3	oral	oral	ADJ
bjos-8641742	128	4	epidemiol	epidemiol	NOUN
bjos-8641742	128	5	.	.	PUNCT
bjos-8641742	129	1	2005	2005	NUM
bjos-8641742	129	2	;	;	PUNCT
bjos-8641742	129	3	33	33	NUM
bjos-8641742	129	4	:	:	SYM
bjos-8641742	129	5	35	35	NUM
bjos-8641742	129	6	-	-	SYM
bjos-8641742	129	7	44	44	NUM
bjos-8641742	129	8	.	.	NOUN
bjos-8641742	130	1	8	8	NUM
bjos-8641742	130	2	.	.	PUNCT
bjos-8641742	131	1	hodgson	hodgson	PROPN
bjos-8641742	131	2	ta	ta	PROPN
bjos-8641742	131	3	,	,	PUNCT
bjos-8641742	131	4	greenspan	greenspan	PROPN
bjos-8641742	131	5	d	d	PROPN
bjos-8641742	131	6	,	,	PUNCT
bjos-8641742	131	7	greenspan	greenspan	PROPN
bjos-8641742	131	8	js	js	PROPN
bjos-8641742	131	9	.	.	PUNCT
bjos-8641742	132	1	oral	oral	ADJ
bjos-8641742	132	2	lesions	lesion	NOUN
bjos-8641742	132	3	of	of	ADP
bjos-8641742	132	4	hiv	hiv	PROPN
bjos-8641742	132	5	disease	disease	NOUN
bjos-8641742	132	6	and	and	CCONJ
bjos-8641742	132	7	haart	haart	PROPN
bjos-8641742	132	8	in	in	ADP
bjos-8641742	132	9	industrialized	industrialized	ADJ
bjos-8641742	132	10	countries	country	NOUN
bjos-8641742	132	11	.	.	PUNCT
bjos-8641742	133	1	adv	adv	PROPN
bjos-8641742	133	2	dent	dent	NOUN
bjos-8641742	133	3	res	re	NOUN
bjos-8641742	133	4	.	.	PUNCT
bjos-8641742	134	1	2006	2006	NUM
bjos-8641742	134	2	;	;	PUNCT
bjos-8641742	134	3	19	19	NUM
bjos-8641742	134	4	:	:	SYM
bjos-8641742	134	5	57	57	NUM
bjos-8641742	134	6	-	-	SYM
bjos-8641742	134	7	62	62	NUM
bjos-8641742	134	8	.	.	PUNCT
bjos-8641742	135	1	9	9	NUM
bjos-8641742	135	2	.	.	X
bjos-8641742	135	3	ghate	ghate	PROPN
bjos-8641742	135	4	m	m	PROPN
bjos-8641742	135	5	,	,	PUNCT
bjos-8641742	135	6	deshpande	deshpande	PROPN
bjos-8641742	135	7	s	s	PROPN
bjos-8641742	135	8	,	,	PUNCT
bjos-8641742	135	9	tripathy	tripathy	PROPN
bjos-8641742	135	10	s	s	PROPN
bjos-8641742	135	11	,	,	PUNCT
bjos-8641742	135	12	nene	nene	PROPN
bjos-8641742	135	13	m	m	PROPN
bjos-8641742	135	14	,	,	PUNCT
bjos-8641742	135	15	gedam	gedam	PROPN
bjos-8641742	135	16	p	p	X
bjos-8641742	135	17	,	,	PUNCT
bjos-8641742	135	18	godbole	godbole	NOUN
bjos-8641742	135	19	s	s	PROPN
bjos-8641742	135	20	,	,	PUNCT
bjos-8641742	135	21	et	et	PROPN
bjos-8641742	135	22	al	al	PROPN
bjos-8641742	135	23	.	.	PROPN
bjos-8641742	135	24	incidence	incidence	NOUN
bjos-8641742	135	25	of	of	ADP
bjos-8641742	135	26	common	common	ADJ
bjos-8641742	135	27	opportunistic	opportunistic	ADJ
bjos-8641742	135	28	infections	infection	NOUN
bjos-8641742	135	29	in	in	ADP
bjos-8641742	135	30	hiv	hiv	PROPN
bjos-8641742	135	31	-	-	PUNCT
bjos-8641742	135	32	infected	infect	VERB
bjos-8641742	135	33	individuals	individual	NOUN
bjos-8641742	135	34	in	in	ADP
bjos-8641742	135	35	pune	pune	NOUN
bjos-8641742	135	36	,	,	PUNCT
bjos-8641742	135	37	india	india	PROPN
bjos-8641742	135	38	:	:	PUNCT
bjos-8641742	135	39	analysis	analysis	NOUN
bjos-8641742	135	40	by	by	ADP
bjos-8641742	135	41	stages	stage	NOUN
bjos-8641742	135	42	of	of	ADP
bjos-8641742	135	43	immunosuppression	immunosuppression	NOUN
bjos-8641742	135	44	represented	represent	VERB
bjos-8641742	135	45	by	by	ADP
bjos-8641742	135	46	cd4	cd4	PROPN
bjos-8641742	135	47	counts	count	NOUN
bjos-8641742	135	48	.	.	PUNCT
bjos-8641742	136	1	int	int	NOUN
bjos-8641742	136	2	j	j	PROPN
bjos-8641742	136	3	infect	infect	VERB
bjos-8641742	136	4	dis	dis	PROPN
bjos-8641742	136	5	.	.	PUNCT
bjos-8641742	137	1	2009	2009	NUM
bjos-8641742	137	2	;	;	PUNCT
bjos-8641742	137	3	13	13	NUM
bjos-8641742	137	4	:	:	PUNCT
bjos-8641742	137	5	e1	e1	NOUN
bjos-8641742	137	6	-	-	PUNCT
bjos-8641742	137	7	8	8	NUM
bjos-8641742	137	8	.	.	PUNCT
bjos-8641742	137	9	10	10	NUM
bjos-8641742	137	10	.	.	PUNCT
bjos-8641742	138	1	mercante	mercante	PROPN
bjos-8641742	138	2	de	de	PROPN
bjos-8641742	138	3	,	,	PUNCT
bjos-8641742	138	4	leigh	leigh	PROPN
bjos-8641742	138	5	je	je	PROPN
bjos-8641742	138	6	,	,	PUNCT
bjos-8641742	138	7	lilly	lilly	PROPN
bjos-8641742	138	8	ea	ea	PROPN
bjos-8641742	138	9	,	,	PUNCT
bjos-8641742	138	10	mcnulty	mcnulty	PROPN
bjos-8641742	138	11	k	k	PROPN
bjos-8641742	138	12	,	,	PUNCT
bjos-8641742	138	13	fidel	fidel	PROPN
bjos-8641742	138	14	pl	pl	PROPN
bjos-8641742	138	15	.	.	PROPN
bjos-8641742	138	16	assessment	assessment	NOUN
bjos-8641742	138	17	of	of	ADP
bjos-8641742	138	18	the	the	DET
bjos-8641742	138	19	association	association	NOUN
bjos-8641742	138	20	between	between	ADP
bjos-8641742	138	21	hiv	hiv	PROPN
bjos-8641742	138	22	viral	viral	ADJ
bjos-8641742	138	23	load	load	NOUN
bjos-8641742	138	24	and	and	CCONJ
bjos-8641742	138	25	cd4	cd4	PROPN
bjos-8641742	138	26	cell	cell	NOUN
bjos-8641742	138	27	count	count	NOUN
bjos-8641742	138	28	on	on	ADP
bjos-8641742	138	29	the	the	DET
bjos-8641742	138	30	occurrence	occurrence	NOUN
bjos-8641742	138	31	of	of	ADP
bjos-8641742	138	32	oropharyngeal	oropharyngeal	ADJ
bjos-8641742	138	33	candidiasis	candidiasis	NOUN
bjos-8641742	138	34	in	in	ADP
bjos-8641742	138	35	hiv	hiv	PROPN
bjos-8641742	138	36	-	-	PUNCT
bjos-8641742	138	37	infected	infect	VERB
bjos-8641742	138	38	patients	patient	NOUN
bjos-8641742	138	39	.	.	PUNCT
bjos-8641742	139	1	j	j	PROPN
bjos-8641742	139	2	acquir	acquir	PROPN
bjos-8641742	139	3	immune	immune	VERB
bjos-8641742	139	4	defic	defic	ADJ
bjos-8641742	139	5	syndr	syndr	NOUN
bjos-8641742	139	6	.	.	PUNCT
bjos-8641742	140	1	2006	2006	NUM
bjos-8641742	140	2	;	;	PUNCT
bjos-8641742	140	3	42	42	NUM
bjos-8641742	140	4	:	:	PUNCT
bjos-8641742	140	5	578	578	NUM
bjos-8641742	140	6	-	-	SYM
bjos-8641742	140	7	83	83	NUM
bjos-8641742	140	8	.	.	PUNCT
bjos-8641742	141	1	11	11	NUM
bjos-8641742	141	2	.	.	PUNCT
bjos-8641742	142	1	pinheiro	pinheiro	PROPN
bjos-8641742	142	2	a	a	PRON
bjos-8641742	142	3	,	,	PUNCT
bjos-8641742	142	4	marcenes	marcenes	PROPN
bjos-8641742	142	5	w	w	PROPN
bjos-8641742	142	6	,	,	PUNCT
bjos-8641742	142	7	zakrzewska	zakrzewska	PROPN
bjos-8641742	142	8	jm	jm	PROPN
bjos-8641742	142	9	,	,	PUNCT
bjos-8641742	142	10	robinson	robinson	PROPN
bjos-8641742	142	11	pg	pg	PROPN
bjos-8641742	142	12	.	.	PUNCT
bjos-8641742	143	1	dental	dental	ADJ
bjos-8641742	143	2	and	and	CCONJ
bjos-8641742	143	3	oral	oral	ADJ
bjos-8641742	143	4	lesions	lesion	NOUN
bjos-8641742	143	5	in	in	ADP
bjos-8641742	143	6	hiv	hiv	PROPN
bjos-8641742	143	7	infected	infected	ADJ
bjos-8641742	143	8	patients	patient	NOUN
bjos-8641742	143	9	:	:	PUNCT
bjos-8641742	143	10	a	a	DET
bjos-8641742	143	11	study	study	NOUN
bjos-8641742	143	12	in	in	ADP
bjos-8641742	143	13	brazil	brazil	PROPN
bjos-8641742	143	14	.	.	PUNCT
bjos-8641742	144	1	int	int	PROPN
bjos-8641742	144	2	dent	dent	PROPN
bjos-8641742	144	3	j.	j.	PROPN
bjos-8641742	144	4	2004	2004	NUM
bjos-8641742	144	5	;	;	PUNCT
bjos-8641742	144	6	54	54	NUM
bjos-8641742	144	7	:	:	SYM
bjos-8641742	144	8	131	131	NUM
bjos-8641742	144	9	-	-	SYM
bjos-8641742	144	10	7	7	NUM
bjos-8641742	144	11	.	.	NOUN
bjos-8641742	144	12	12	12	NUM
bjos-8641742	144	13	.	.	PUNCT
bjos-8641742	145	1	world	world	PROPN
bjos-8641742	145	2	health	health	PROPN
bjos-8641742	145	3	organization	organization	PROPN
bjos-8641742	145	4	.	.	PUNCT
bjos-8641742	146	1	oral	oral	ADJ
bjos-8641742	146	2	health	health	NOUN
bjos-8641742	146	3	survey	survey	NOUN
bjos-8641742	146	4	:	:	PUNCT
bjos-8641742	146	5	basic	basic	ADJ
bjos-8641742	146	6	methods	method	NOUN
bjos-8641742	146	7	.	.	PUNCT
bjos-8641742	147	1	4.ed	4.ed	NUM
bjos-8641742	147	2	.	.	PUNCT
bjos-8641742	148	1	geneva	geneva	PROPN
bjos-8641742	148	2	:	:	PUNCT
bjos-8641742	148	3	who	who	PRON
bjos-8641742	148	4	health	health	NOUN
bjos-8641742	148	5	organization	organization	NOUN
bjos-8641742	148	6	;	;	PUNCT
bjos-8641742	148	7	1997	1997	NUM
bjos-8641742	148	8	.	.	PUNCT
bjos-8641742	149	1	13	13	NUM
bjos-8641742	149	2	.	.	PUNCT
bjos-8641742	150	1	ec	ec	NOUN
bjos-8641742	150	2	-	-	PUNCT
bjos-8641742	150	3	clearinghouse	clearinghouse	NOUN
bjos-8641742	150	4	on	on	ADP
bjos-8641742	150	5	oral	oral	ADJ
bjos-8641742	150	6	problems	problem	NOUN
bjos-8641742	150	7	related	relate	VERB
bjos-8641742	150	8	to	to	ADP
bjos-8641742	150	9	hiv	hiv	PROPN
bjos-8641742	150	10	infection	infection	NOUN
bjos-8641742	150	11	and	and	CCONJ
bjos-8641742	150	12	who	who	PRON
bjos-8641742	150	13	collaborating	collaborate	VERB
bjos-8641742	150	14	centre	centre	NOUN
bjos-8641742	150	15	on	on	ADP
bjos-8641742	150	16	oral	oral	ADJ
bjos-8641742	150	17	manifestations	manifestation	NOUN
bjos-8641742	150	18	of	of	ADP
bjos-8641742	150	19	immunodeficiency	immunodeficiency	NOUN
bjos-8641742	150	20	virus	virus	NOUN
bjos-8641742	150	21	.	.	PUNCT
bjos-8641742	151	1	classification	classification	NOUN
bjos-8641742	151	2	and	and	CCONJ
bjos-8641742	151	3	diagnostic	diagnostic	ADJ
bjos-8641742	151	4	criteria	criterion	NOUN
bjos-8641742	151	5	for	for	ADP
bjos-8641742	151	6	oral	oral	ADJ
bjos-8641742	151	7	lesions	lesion	NOUN
bjos-8641742	151	8	in	in	ADP
bjos-8641742	151	9	hiv	hiv	PROPN
bjos-8641742	151	10	infection	infection	NOUN
bjos-8641742	151	11	.	.	PUNCT
bjos-8641742	152	1	j	j	PROPN
bjos-8641742	152	2	oral	oral	ADJ
bjos-8641742	152	3	pathol	pathol	NOUN
bjos-8641742	152	4	med	me	VERB
bjos-8641742	152	5	.	.	PUNCT
bjos-8641742	152	6	1993	1993	NUM
bjos-8641742	152	7	;	;	PUNCT
bjos-8641742	152	8	22	22	NUM
bjos-8641742	152	9	:	:	SYM
bjos-8641742	152	10	289	289	NUM
bjos-8641742	152	11	-	-	SYM
bjos-8641742	152	12	91	91	NUM
bjos-8641742	152	13	.	.	PUNCT
bjos-8641742	153	1	risk	risk	NOUN
bjos-8641742	153	2	factors	factor	NOUN
bjos-8641742	153	3	for	for	ADP
bjos-8641742	153	4	oral	oral	ADJ
bjos-8641742	153	5	candidiasis	candidiasis	NOUN
bjos-8641742	153	6	in	in	ADP
bjos-8641742	153	7	brazilian	brazilian	ADJ
bjos-8641742	153	8	hiv	hiv	PROPN
bjos-8641742	153	9	-	-	PUNCT
bjos-8641742	153	10	infected	infect	VERB
bjos-8641742	153	11	adult	adult	NOUN
bjos-8641742	153	12	patients	patient	NOUN
bjos-8641742	153	13	braz	braz	PROPN
bjos-8641742	153	14	j	j	PROPN
bjos-8641742	153	15	oral	oral	PROPN
bjos-8641742	153	16	sci	sci	PROPN
bjos-8641742	153	17	.	.	PROPN
bjos-8641742	154	1	9(4):470	9(4):470	NUM
bjos-8641742	154	2	-	-	SYM
bjos-8641742	154	3	474	474	NUM
bjos-8641742	154	4	474474474474474	474474474474474	NUM
bjos-8641742	154	5	14	14	NUM
bjos-8641742	154	6	.	.	PUNCT
bjos-8641742	155	1	chattopadhyay	chattopadhyay	PROPN
bjos-8641742	155	2	a	a	PROPN
bjos-8641742	155	3	,	,	PUNCT
bjos-8641742	155	4	caplan	caplan	PROPN
bjos-8641742	155	5	dj	dj	PROPN
bjos-8641742	155	6	,	,	PUNCT
bjos-8641742	155	7	slade	slade	PROPN
bjos-8641742	155	8	gd	gd	PROPN
bjos-8641742	155	9	,	,	PUNCT
bjos-8641742	155	10	shugars	shugar	VERB
bjos-8641742	155	11	dc	dc	PROPN
bjos-8641742	155	12	,	,	PUNCT
bjos-8641742	155	13	tien	tien	PROPN
bjos-8641742	155	14	hc	hc	PROPN
bjos-8641742	155	15	,	,	PUNCT
bjos-8641742	155	16	patton	patton	PROPN
bjos-8641742	155	17	ll	ll	NOUN
bjos-8641742	155	18	.	.	PUNCT
bjos-8641742	156	1	incidence	incidence	NOUN
bjos-8641742	156	2	of	of	ADP
bjos-8641742	156	3	oral	oral	ADJ
bjos-8641742	156	4	candidiasis	candidiasis	NOUN
bjos-8641742	156	5	and	and	CCONJ
bjos-8641742	156	6	oral	oral	ADJ
bjos-8641742	156	7	hairy	hairy	ADJ
bjos-8641742	156	8	leukoplakia	leukoplakia	NOUN
bjos-8641742	156	9	in	in	ADP
bjos-8641742	156	10	hiv	hiv	PROPN
bjos-8641742	156	11	-	-	PUNCT
bjos-8641742	156	12	infected	infect	VERB
bjos-8641742	156	13	adults	adult	NOUN
bjos-8641742	156	14	in	in	ADP
bjos-8641742	156	15	north	north	PROPN
bjos-8641742	156	16	carolina	carolina	PROPN
bjos-8641742	156	17	.	.	PUNCT
bjos-8641742	157	1	oral	oral	ADJ
bjos-8641742	157	2	surg	surg	NOUN
bjos-8641742	157	3	oral	oral	ADJ
bjos-8641742	157	4	med	med	ADJ
bjos-8641742	157	5	oral	oral	ADJ
bjos-8641742	157	6	pathol	pathol	NOUN
bjos-8641742	157	7	oral	oral	ADJ
bjos-8641742	157	8	radiol	radiol	NOUN
bjos-8641742	157	9	endod	endod	PROPN
bjos-8641742	157	10	.	.	PUNCT
bjos-8641742	158	1	2005	2005	NUM
bjos-8641742	158	2	;	;	PUNCT
bjos-8641742	158	3	99	99	NUM
bjos-8641742	158	4	:	:	SYM
bjos-8641742	158	5	39	39	NUM
bjos-8641742	158	6	-	-	SYM
bjos-8641742	158	7	47	47	NUM
bjos-8641742	158	8	.	.	PUNCT
bjos-8641742	159	1	15	15	NUM
bjos-8641742	159	2	.	.	PUNCT
bjos-8641742	160	1	patton	patton	PROPN
bjos-8641742	160	2	ll	ll	AUX
bjos-8641742	160	3	.	.	PUNCT
bjos-8641742	161	1	hematologic	hematologic	NOUN
bjos-8641742	161	2	abnormalities	abnormality	NOUN
bjos-8641742	161	3	among	among	ADP
bjos-8641742	161	4	hiv	hiv	PROPN
bjos-8641742	161	5	-	-	PUNCT
bjos-8641742	161	6	infected	infect	VERB
bjos-8641742	161	7	patients	patient	NOUN
bjos-8641742	161	8	:	:	PUNCT
bjos-8641742	161	9	associations	association	NOUN
bjos-8641742	161	10	of	of	ADP
bjos-8641742	161	11	significance	significance	NOUN
bjos-8641742	161	12	for	for	ADP
bjos-8641742	161	13	dentistry	dentistry	NOUN
bjos-8641742	161	14	.	.	PUNCT
bjos-8641742	162	1	oral	oral	ADJ
bjos-8641742	162	2	surg	surg	NOUN
bjos-8641742	162	3	oral	oral	ADJ
bjos-8641742	162	4	med	med	ADJ
bjos-8641742	162	5	oral	oral	ADJ
bjos-8641742	162	6	pathol	pathol	NOUN
bjos-8641742	162	7	oral	oral	ADJ
bjos-8641742	162	8	radiol	radiol	NOUN
bjos-8641742	162	9	endod	endod	PROPN
bjos-8641742	162	10	.	.	PUNCT
bjos-8641742	163	1	1999	1999	NUM
bjos-8641742	163	2	;	;	PUNCT
bjos-8641742	163	3	88	88	NUM
bjos-8641742	163	4	:	:	PUNCT
bjos-8641742	163	5	561	561	NUM
bjos-8641742	163	6	-	-	SYM
bjos-8641742	163	7	7	7	NUM
bjos-8641742	163	8	.	.	NOUN
bjos-8641742	163	9	16	16	NUM
bjos-8641742	163	10	.	.	PUNCT
bjos-8641742	164	1	tomar	tomar	PROPN
bjos-8641742	164	2	sl	sl	PROPN
bjos-8641742	164	3	,	,	PUNCT
bjos-8641742	164	4	asma	asma	PROPN
bjos-8641742	164	5	s.	s.	PROPN
bjos-8641742	164	6	smoking	smoking	PROPN
bjos-8641742	164	7	-	-	PUNCT
bjos-8641742	164	8	attributable	attributable	ADJ
bjos-8641742	164	9	periodontitis	periodontitis	NOUN
bjos-8641742	164	10	in	in	ADP
bjos-8641742	164	11	the	the	DET
bjos-8641742	164	12	united	united	PROPN
bjos-8641742	164	13	states	states	PROPN
bjos-8641742	164	14	:	:	PUNCT
bjos-8641742	164	15	findings	finding	NOUN
bjos-8641742	164	16	from	from	ADP
bjos-8641742	164	17	nhanes	nhanes	PROPN
bjos-8641742	164	18	iii	iii	PROPN
bjos-8641742	164	19	.	.	PUNCT
bjos-8641742	165	1	national	national	PROPN
bjos-8641742	165	2	health	health	PROPN
bjos-8641742	165	3	and	and	CCONJ
bjos-8641742	165	4	nutrition	nutrition	NOUN
bjos-8641742	165	5	examination	examination	NOUN
bjos-8641742	165	6	survey	survey	NOUN
bjos-8641742	165	7	.	.	PUNCT
bjos-8641742	166	1	j	j	PROPN
bjos-8641742	166	2	periodontol	periodontol	NOUN
bjos-8641742	166	3	.	.	PUNCT
bjos-8641742	167	1	2000	2000	NUM
bjos-8641742	167	2	;	;	PUNCT
bjos-8641742	167	3	71	71	NUM
bjos-8641742	167	4	:	:	PUNCT
bjos-8641742	167	5	743	743	NUM
bjos-8641742	167	6	-	-	SYM
bjos-8641742	167	7	751	751	NUM
bjos-8641742	167	8	.	.	PUNCT
bjos-8641742	168	1	17	17	NUM
bjos-8641742	168	2	.	.	PUNCT
bjos-8641742	169	1	tarzia	tarzia	PROPN
bjos-8641742	169	2	o.	o.	PROPN
bjos-8641742	169	3	importância	importância	PROPN
bjos-8641742	169	4	do	do	AUX
bjos-8641742	169	5	fluxo	fluxo	PROPN
bjos-8641742	169	6	salivar	salivar	PROPN
bjos-8641742	169	7	com	com	NOUN
bjos-8641742	169	8	relação	relação	PROPN
bjos-8641742	169	9	à	à	PROPN
bjos-8641742	169	10	saúde	saúde	PROPN
bjos-8641742	169	11	bucal	bucal	NOUN
bjos-8641742	169	12	.	.	PUNCT
bjos-8641742	170	1	cecade	cecade	PROPN
bjos-8641742	170	2	news	news	PROPN
bjos-8641742	170	3	.	.	PUNCT
bjos-8641742	171	1	1993	1993	NUM
bjos-8641742	171	2	;	;	PUNCT
bjos-8641742	171	3	1	1	NUM
bjos-8641742	171	4	:	:	SYM
bjos-8641742	171	5	13	13	NUM
bjos-8641742	171	6	-	-	SYM
bjos-8641742	171	7	7	7	NUM
bjos-8641742	171	8	.	.	NOUN
bjos-8641742	171	9	18	18	NUM
bjos-8641742	171	10	.	.	PUNCT
bjos-8641742	172	1	fraga	fraga	NOUN
bjos-8641742	172	2	-	-	PUNCT
bjos-8641742	172	3	fernandes	fernandes	PROPN
bjos-8641742	172	4	j	j	PROPN
bjos-8641742	172	5	,	,	PUNCT
bjos-8641742	172	6	vicandi	vicandi	NOUN
bjos-8641742	172	7	-	-	PUNCT
bjos-8641742	172	8	plaza	plaza	PROPN
bjos-8641742	172	9	b.	b.	PROPN
bjos-8641742	172	10	diagnosis	diagnosis	NOUN
bjos-8641742	172	11	of	of	ADP
bjos-8641742	172	12	hairy	hairy	ADJ
bjos-8641742	172	13	leukoplakia	leukoplakia	NOUN
bjos-8641742	172	14	by	by	ADP
bjos-8641742	172	15	cytologic	cytologic	ADJ
bjos-8641742	172	16	methods	method	NOUN
bjos-8641742	172	17	.	.	PUNCT
bjos-8641742	173	1	am	be	AUX
bjos-8641742	173	2	j	j	PROPN
bjos-8641742	173	3	clinic	clinic	NOUN
bjos-8641742	173	4	pathol	pathol	NOUN
bjos-8641742	173	5	.	.	PUNCT
bjos-8641742	174	1	1992	1992	NUM
bjos-8641742	174	2	;	;	PUNCT
bjos-8641742	174	3	97	97	NUM
bjos-8641742	174	4	:	:	SYM
bjos-8641742	174	5	262	262	NUM
bjos-8641742	174	6	-	-	SYM
bjos-8641742	174	7	6	6	NUM
bjos-8641742	174	8	.	.	NOUN
bjos-8641742	174	9	19	19	NUM
bjos-8641742	174	10	.	.	PUNCT
bjos-8641742	174	11	epstein	epstein	PROPN
bjos-8641742	174	12	jb	jb	PROPN
bjos-8641742	174	13	,	,	PUNCT
bjos-8641742	174	14	fatahzadeh	fatahzadeh	PROPN
bjos-8641742	174	15	m	m	PROPN
bjos-8641742	174	16	,	,	PUNCT
bjos-8641742	174	17	matisic	matisic	PROPN
bjos-8641742	174	18	j	j	PROPN
bjos-8641742	174	19	,	,	PUNCT
bjos-8641742	174	20	anderson	anderson	PROPN
bjos-8641742	174	21	g.	g.	PROPN
bjos-8641742	174	22	exfoliative	exfoliative	PROPN
bjos-8641742	174	23	cytology	cytology	PROPN
bjos-8641742	174	24	and	and	CCONJ
bjos-8641742	174	25	electron	electron	NOUN
bjos-8641742	174	26	microscopy	microscopy	NOUN
bjos-8641742	174	27	in	in	ADP
bjos-8641742	174	28	the	the	DET
bjos-8641742	174	29	diagnosis	diagnosis	NOUN
bjos-8641742	174	30	of	of	ADP
bjos-8641742	174	31	hairy	hairy	ADJ
bjos-8641742	174	32	leukoplakia	leukoplakia	NOUN
bjos-8641742	174	33	.	.	PUNCT
bjos-8641742	175	1	oral	oral	ADJ
bjos-8641742	175	2	surg	surg	NOUN
bjos-8641742	175	3	oral	oral	ADJ
bjos-8641742	175	4	med	med	ADJ
bjos-8641742	175	5	oral	oral	ADJ
bjos-8641742	175	6	pathol	pathol	NOUN
bjos-8641742	175	7	oral	oral	ADJ
bjos-8641742	175	8	radiol	radiol	NOUN
bjos-8641742	175	9	endod	endod	PROPN
bjos-8641742	175	10	.	.	PUNCT
bjos-8641742	175	11	1995	1995	NUM
bjos-8641742	175	12	;	;	PUNCT
bjos-8641742	175	13	79	79	NUM
bjos-8641742	175	14	:	:	PUNCT
bjos-8641742	175	15	564	564	NUM
bjos-8641742	175	16	-	-	SYM
bjos-8641742	175	17	9	9	NUM
bjos-8641742	175	18	.	.	NOUN
bjos-8641742	175	19	20	20	NUM
bjos-8641742	175	20	.	.	PUNCT
bjos-8641742	176	1	moura	moura	PROPN
bjos-8641742	176	2	mdg	mdg	PROPN
bjos-8641742	176	3	,	,	PUNCT
bjos-8641742	176	4	guimaraes	guimaraes	PROPN
bjos-8641742	176	5	trm	trm	PROPN
bjos-8641742	176	6	,	,	PUNCT
bjos-8641742	176	7	fonseca	fonseca	PROPN
bjos-8641742	176	8	lms	lms	PROPN
bjos-8641742	176	9	,	,	PUNCT
bjos-8641742	176	10	pordeus	pordeus	PROPN
bjos-8641742	176	11	ia	ia	PROPN
bjos-8641742	176	12	,	,	PUNCT
bjos-8641742	176	13	mesquita	mesquita	PROPN
bjos-8641742	176	14	ra	ra	PROPN
bjos-8641742	176	15	.	.	PUNCT
bjos-8641742	177	1	a	a	DET
bjos-8641742	177	2	random	random	ADJ
bjos-8641742	177	3	clinical	clinical	ADJ
bjos-8641742	177	4	trial	trial	NOUN
bjos-8641742	177	5	study	study	NOUN
bjos-8641742	177	6	to	to	PART
bjos-8641742	177	7	assess	assess	VERB
bjos-8641742	177	8	the	the	DET
bjos-8641742	177	9	efficiency	efficiency	NOUN
bjos-8641742	177	10	of	of	ADP
bjos-8641742	177	11	topical	topical	ADJ
bjos-8641742	177	12	applications	application	NOUN
bjos-8641742	177	13	of	of	ADP
bjos-8641742	177	14	podophyllin	podophyllin	ADJ
bjos-8641742	177	15	resin	resin	NOUN
bjos-8641742	177	16	(	(	PUNCT
bjos-8641742	177	17	25	25	NUM
bjos-8641742	177	18	%	%	NOUN
bjos-8641742	177	19	)	)	PUNCT
bjos-8641742	177	20	versus	versus	ADP
bjos-8641742	177	21	podophyllin	podophyllin	ADJ
bjos-8641742	177	22	resin	resin	NOUN
bjos-8641742	177	23	(	(	PUNCT
bjos-8641742	177	24	25	25	NUM
bjos-8641742	177	25	%	%	NOUN
bjos-8641742	177	26	)	)	PUNCT
bjos-8641742	177	27	together	together	ADV
bjos-8641742	177	28	with	with	ADP
bjos-8641742	177	29	acyclovir	acyclovir	PROPN
bjos-8641742	177	30	cream	cream	PROPN
bjos-8641742	177	31	(	(	PUNCT
bjos-8641742	177	32	5	5	NUM
bjos-8641742	177	33	%	%	NOUN
bjos-8641742	177	34	)	)	PUNCT
bjos-8641742	177	35	(	(	PUNCT
bjos-8641742	177	36	pa	pa	PROPN
bjos-8641742	177	37	)	)	PUNCT
bjos-8641742	177	38	in	in	ADP
bjos-8641742	177	39	the	the	DET
bjos-8641742	177	40	treatment	treatment	NOUN
bjos-8641742	177	41	of	of	ADP
bjos-8641742	177	42	oral	oral	ADJ
bjos-8641742	177	43	hairy	hairy	ADJ
bjos-8641742	177	44	leukoplakia	leukoplakia	NOUN
bjos-8641742	177	45	.	.	PUNCT
bjos-8641742	178	1	oral	oral	ADJ
bjos-8641742	178	2	surg	surg	NOUN
bjos-8641742	178	3	oral	oral	ADJ
bjos-8641742	178	4	med	med	ADJ
bjos-8641742	178	5	oral	oral	ADJ
bjos-8641742	178	6	pathol	pathol	NOUN
bjos-8641742	178	7	oral	oral	ADJ
bjos-8641742	178	8	radiol	radiol	NOUN
bjos-8641742	178	9	endod	endod	PROPN
bjos-8641742	178	10	.	.	PUNCT
bjos-8641742	179	1	2007	2007	NUM
bjos-8641742	179	2	;	;	PUNCT
bjos-8641742	179	3	103	103	NUM
bjos-8641742	179	4	:	:	SYM
bjos-8641742	179	5	64	64	NUM
bjos-8641742	179	6	-	-	SYM
bjos-8641742	179	7	71	71	NUM
bjos-8641742	179	8	.	.	PUNCT
bjos-8641742	180	1	21	21	NUM
bjos-8641742	180	2	.	.	PUNCT
bjos-8641742	181	1	lourenço	lourenço	PROPN
bjos-8641742	181	2	ag	ag	PROPN
bjos-8641742	181	3	,	,	PUNCT
bjos-8641742	181	4	figueiredo	figueiredo	PROPN
bjos-8641742	181	5	lt	lt	PROPN
bjos-8641742	181	6	.	.	PROPN
bjos-8641742	181	7	oral	oral	ADJ
bjos-8641742	181	8	lesions	lesion	NOUN
bjos-8641742	181	9	in	in	ADP
bjos-8641742	181	10	hiv	hiv	PROPN
bjos-8641742	181	11	infected	infect	VERB
bjos-8641742	181	12	individuals	individual	NOUN
bjos-8641742	181	13	from	from	ADP
bjos-8641742	181	14	ribeirão	ribeirão	PROPN
bjos-8641742	181	15	preto	preto	PROPN
bjos-8641742	181	16	,	,	PUNCT
bjos-8641742	181	17	brazil	brazil	PROPN
bjos-8641742	181	18	.	.	PUNCT
bjos-8641742	182	1	med	med	ADJ
bjos-8641742	182	2	oral	oral	ADJ
bjos-8641742	182	3	patol	patol	NOUN
bjos-8641742	182	4	oral	oral	ADJ
bjos-8641742	182	5	cir	cir	NOUN
bjos-8641742	182	6	bucal	bucal	NOUN
bjos-8641742	182	7	.	.	PUNCT
bjos-8641742	183	1	2008	2008	NUM
bjos-8641742	183	2	;	;	PUNCT
bjos-8641742	183	3	13	13	NUM
bjos-8641742	183	4	:	:	PUNCT
bjos-8641742	184	1	e281	e281	PROPN
bjos-8641742	184	2	-	-	SYM
bjos-8641742	184	3	6	6	NUM
bjos-8641742	184	4	.	.	NOUN
bjos-8641742	184	5	22	22	NUM
bjos-8641742	184	6	.	.	PUNCT
bjos-8641742	185	1	fidel	fidel	PROPN
bjos-8641742	185	2	pl	pl	PROPN
bjos-8641742	185	3	.	.	PUNCT
bjos-8641742	185	4	candida	candida	PROPN
bjos-8641742	185	5	-	-	PUNCT
bjos-8641742	185	6	host	host	NOUN
bjos-8641742	185	7	interactions	interaction	NOUN
bjos-8641742	185	8	in	in	ADP
bjos-8641742	185	9	hiv	hiv	PROPN
bjos-8641742	185	10	disease	disease	NOUN
bjos-8641742	185	11	:	:	PUNCT
bjos-8641742	185	12	relationships	relationship	NOUN
bjos-8641742	185	13	in	in	ADP
bjos-8641742	185	14	oropharyngeal	oropharyngeal	ADJ
bjos-8641742	185	15	candidiasis	candidiasis	NOUN
bjos-8641742	185	16	.	.	PUNCT
bjos-8641742	186	1	adv	adv	PROPN
bjos-8641742	186	2	dent	dent	NOUN
bjos-8641742	186	3	res	re	NOUN
bjos-8641742	186	4	.	.	PUNCT
bjos-8641742	187	1	2006	2006	NUM
bjos-8641742	187	2	;	;	PUNCT
bjos-8641742	187	3	19	19	NUM
bjos-8641742	187	4	:	:	SYM
bjos-8641742	187	5	80	80	NUM
bjos-8641742	187	6	-	-	SYM
bjos-8641742	187	7	4	4	NUM
bjos-8641742	187	8	.	.	NOUN
bjos-8641742	187	9	23	23	NUM
bjos-8641742	187	10	.	.	PUNCT
bjos-8641742	188	1	gautam	gautam	PROPN
bjos-8641742	188	2	h	h	PROPN
bjos-8641742	188	3	,	,	PUNCT
bjos-8641742	188	4	bhalla	bhalla	PROPN
bjos-8641742	188	5	p	p	PROPN
bjos-8641742	188	6	,	,	PUNCT
bjos-8641742	188	7	saini	saini	PROPN
bjos-8641742	188	8	s	s	PROPN
bjos-8641742	188	9	,	,	PUNCT
bjos-8641742	188	10	uppal	uppal	PROPN
bjos-8641742	188	11	b	b	PROPN
bjos-8641742	188	12	,	,	PUNCT
bjos-8641742	188	13	kaur	kaur	PROPN
bjos-8641742	188	14	r	r	PROPN
bjos-8641742	188	15	,	,	PUNCT
bjos-8641742	188	16	baveja	baveja	PROPN
bjos-8641742	188	17	cp	cp	PROPN
bjos-8641742	188	18	,	,	PUNCT
bjos-8641742	188	19	et	et	PROPN
bjos-8641742	188	20	al	al	PROPN
bjos-8641742	188	21	.	.	PUNCT
bjos-8641742	189	1	epidemiology	epidemiology	NOUN
bjos-8641742	189	2	of	of	ADP
bjos-8641742	189	3	opportunistic	opportunistic	ADJ
bjos-8641742	189	4	infections	infection	NOUN
bjos-8641742	189	5	and	and	CCONJ
bjos-8641742	189	6	its	its	PRON
bjos-8641742	189	7	correlation	correlation	NOUN
bjos-8641742	189	8	with	with	ADP
bjos-8641742	189	9	cd4	cd4	PROPN
bjos-8641742	189	10	tlymphocyte	tlymphocyte	NOUN
bjos-8641742	189	11	counts	count	VERB
bjos-8641742	189	12	and	and	CCONJ
bjos-8641742	189	13	plasma	plasma	VERB
bjos-8641742	189	14	viral	viral	ADJ
bjos-8641742	189	15	load	load	NOUN
bjos-8641742	189	16	among	among	ADP
bjos-8641742	189	17	hiv	hiv	PROPN
bjos-8641742	189	18	-	-	PUNCT
bjos-8641742	189	19	positive	positive	ADJ
bjos-8641742	189	20	patients	patient	NOUN
bjos-8641742	189	21	at	at	ADP
bjos-8641742	189	22	a	a	DET
bjos-8641742	189	23	tertiary	tertiary	ADJ
bjos-8641742	189	24	care	care	NOUN
bjos-8641742	189	25	hospital	hospital	NOUN
bjos-8641742	189	26	in	in	ADP
bjos-8641742	189	27	india	india	PROPN
bjos-8641742	189	28	.	.	PUNCT
bjos-8641742	190	1	j	j	PROPN
bjos-8641742	190	2	int	int	PROPN
bjos-8641742	190	3	assoc	assoc	PROPN
bjos-8641742	190	4	physicians	physicians	PROPN
bjos-8641742	190	5	aids	aids	PROPN
bjos-8641742	190	6	care	care	PROPN
bjos-8641742	190	7	.	.	PUNCT
bjos-8641742	191	1	2009	2009	NUM
bjos-8641742	191	2	;	;	PUNCT
bjos-8641742	191	3	8	8	NUM
bjos-8641742	191	4	:	:	SYM
bjos-8641742	191	5	333	333	NUM
bjos-8641742	191	6	-	-	SYM
bjos-8641742	191	7	7	7	NUM
bjos-8641742	191	8	.	.	NUM
bjos-8641742	191	9	24	24	NUM
bjos-8641742	191	10	.	.	PUNCT
bjos-8641742	192	1	campisi	campisi	PROPN
bjos-8641742	192	2	g	g	PROPN
bjos-8641742	192	3	,	,	PUNCT
bjos-8641742	192	4	pizzo	pizzo	PROPN
bjos-8641742	192	5	c	c	PROPN
bjos-8641742	192	6	,	,	PUNCT
bjos-8641742	192	7	mancuso	mancuso	PROPN
bjos-8641742	192	8	s	s	PROPN
bjos-8641742	192	9	,	,	PUNCT
bjos-8641742	192	10	margiotta	margiotta	PROPN
bjos-8641742	192	11	v.	v.	ADP
bjos-8641742	192	12	gender	gender	NOUN
bjos-8641742	192	13	differences	difference	NOUN
bjos-8641742	192	14	in	in	ADP
bjos-8641742	192	15	human	human	ADJ
bjos-8641742	192	16	immunodeficiency	immunodeficiency	NOUN
bjos-8641742	192	17	virus	virus	NOUN
bjos-8641742	192	18	-	-	PUNCT
bjos-8641742	192	19	related	relate	VERB
bjos-8641742	192	20	oral	oral	ADJ
bjos-8641742	192	21	lesions	lesion	NOUN
bjos-8641742	192	22	:	:	PUNCT
bjos-8641742	192	23	an	an	DET
bjos-8641742	192	24	italian	italian	ADJ
bjos-8641742	192	25	study	study	NOUN
bjos-8641742	192	26	.	.	PUNCT
bjos-8641742	193	1	oral	oral	ADJ
bjos-8641742	193	2	surg	surg	NOUN
bjos-8641742	193	3	oral	oral	ADJ
bjos-8641742	193	4	med	med	ADJ
bjos-8641742	193	5	oral	oral	ADJ
bjos-8641742	193	6	pathol	pathol	NOUN
bjos-8641742	193	7	oral	oral	ADJ
bjos-8641742	193	8	radiol	radiol	NOUN
bjos-8641742	193	9	endod	endod	PROPN
bjos-8641742	193	10	.	.	PUNCT
bjos-8641742	194	1	2001	2001	NUM
bjos-8641742	194	2	;	;	PUNCT
bjos-8641742	194	3	91	91	NUM
bjos-8641742	194	4	:	:	SYM
bjos-8641742	194	5	546	546	NUM
bjos-8641742	194	6	-	-	SYM
bjos-8641742	194	7	51	51	NUM
bjos-8641742	194	8	.	.	PUNCT
bjos-8641742	194	9	25	25	NUM
bjos-8641742	194	10	.	.	PUNCT
bjos-8641742	195	1	shiboski	shiboski	PROPN
bjos-8641742	195	2	ch	ch	PROPN
bjos-8641742	195	3	,	,	PUNCT
bjos-8641742	195	4	wilson	wilson	PROPN
bjos-8641742	195	5	cm	cm	PROPN
bjos-8641742	195	6	,	,	PUNCT
bjos-8641742	195	7	greenspan	greenspan	PROPN
bjos-8641742	195	8	d	d	PROPN
bjos-8641742	195	9	,	,	PUNCT
bjos-8641742	195	10	hilton	hilton	PROPN
bjos-8641742	195	11	j	j	PROPN
bjos-8641742	195	12	,	,	PUNCT
bjos-8641742	195	13	greenspan	greenspan	PROPN
bjos-8641742	195	14	js	js	PROPN
bjos-8641742	195	15	,	,	PUNCT
bjos-8641742	195	16	moscicki	moscicki	PROPN
bjos-8641742	195	17	ab	ab	PROPN
bjos-8641742	195	18	.	.	PROPN
bjos-8641742	195	19	hiv	hiv	PROPN
bjos-8641742	195	20	-	-	PUNCT
bjos-8641742	195	21	related	relate	VERB
bjos-8641742	195	22	oral	oral	ADJ
bjos-8641742	195	23	manifestations	manifestation	NOUN
bjos-8641742	195	24	among	among	ADP
bjos-8641742	195	25	adolescents	adolescent	NOUN
bjos-8641742	195	26	in	in	ADP
bjos-8641742	195	27	a	a	DET
bjos-8641742	195	28	multicenter	multicenter	ADJ
bjos-8641742	195	29	cohort	cohort	NOUN
bjos-8641742	195	30	study	study	NOUN
bjos-8641742	195	31	.	.	PUNCT
bjos-8641742	196	1	j	j	PROPN
bjos-8641742	196	2	adolesc	adolesc	PROPN
bjos-8641742	196	3	health	health	PROPN
bjos-8641742	196	4	.	.	PUNCT
bjos-8641742	197	1	2001	2001	NUM
bjos-8641742	197	2	;	;	PUNCT
bjos-8641742	197	3	29(suppl.3	29(suppl.3	NUM
bjos-8641742	197	4	):	):	PUNCT
bjos-8641742	197	5	109	109	NUM
bjos-8641742	197	6	-	-	SYM
bjos-8641742	197	7	14	14	NUM
bjos-8641742	197	8	.	.	PUNCT
bjos-8641742	198	1	26	26	NUM
bjos-8641742	198	2	.	.	PUNCT
bjos-8641742	199	1	coogan	coogan	PROPN
bjos-8641742	199	2	mm	mm	PROPN
bjos-8641742	199	3	,	,	PUNCT
bjos-8641742	199	4	fidel	fidel	PROPN
bjos-8641742	199	5	pl	pl	PROPN
bjos-8641742	199	6	,	,	PUNCT
bjos-8641742	199	7	komesu	komesu	PROPN
bjos-8641742	199	8	mc	mc	PROPN
bjos-8641742	199	9	,	,	PUNCT
bjos-8641742	199	10	maeda	maeda	PROPN
bjos-8641742	199	11	n	n	CCONJ
bjos-8641742	199	12	,	,	PUNCT
bjos-8641742	199	13	samaranayake	samaranayake	NOUN
bjos-8641742	199	14	lp	lp	NOUN
bjos-8641742	199	15	.	.	PUNCT
bjos-8641742	200	1	candida	candida	PROPN
bjos-8641742	200	2	and	and	CCONJ
bjos-8641742	200	3	mycotic	mycotic	ADJ
bjos-8641742	200	4	infections	infection	NOUN
bjos-8641742	200	5	.	.	PUNCT
bjos-8641742	201	1	adv	adv	PROPN
bjos-8641742	201	2	dent	dent	NOUN
bjos-8641742	201	3	res	re	NOUN
bjos-8641742	201	4	.	.	PUNCT
bjos-8641742	202	1	2006	2006	NUM
bjos-8641742	202	2	;	;	PUNCT
bjos-8641742	202	3	19	19	NUM
bjos-8641742	202	4	:	:	SYM
bjos-8641742	202	5	130	130	NUM
bjos-8641742	202	6	-	-	SYM
bjos-8641742	202	7	8	8	NUM
bjos-8641742	202	8	.	.	NOUN
bjos-8641742	202	9	27	27	NUM
bjos-8641742	202	10	.	.	PUNCT
bjos-8641742	203	1	patton	patton	PROPN
bjos-8641742	203	2	ll	ll	PROPN
bjos-8641742	203	3	,	,	PUNCT
bjos-8641742	203	4	mckaig	mckaig	PROPN
bjos-8641742	203	5	rg	rg	PROPN
bjos-8641742	203	6	,	,	PUNCT
bjos-8641742	203	7	strauss	strauss	PROPN
bjos-8641742	203	8	rp	rp	PROPN
bjos-8641742	203	9	,	,	PUNCT
bjos-8641742	203	10	eron	eron	PROPN
bjos-8641742	203	11	jjjr	jjjr	PROPN
bjos-8641742	203	12	.	.	PUNCT
bjos-8641742	204	1	oral	oral	ADJ
bjos-8641742	204	2	manifestations	manifestation	NOUN
bjos-8641742	204	3	of	of	ADP
bjos-8641742	204	4	hiv	hiv	PROPN
bjos-8641742	204	5	in	in	ADP
bjos-8641742	204	6	a	a	DET
bjos-8641742	204	7	southeast	southeast	PROPN
bjos-8641742	204	8	usa	usa	PROPN
bjos-8641742	204	9	population	population	NOUN
bjos-8641742	204	10	.	.	PUNCT
bjos-8641742	205	1	oral	oral	ADJ
bjos-8641742	205	2	dis	dis	PROPN
bjos-8641742	205	3	.	.	PUNCT
bjos-8641742	206	1	1998	1998	NUM
bjos-8641742	206	2	;	;	PUNCT
bjos-8641742	206	3	4	4	NUM
bjos-8641742	206	4	:	:	SYM
bjos-8641742	206	5	164	164	NUM
bjos-8641742	206	6	-	-	SYM
bjos-8641742	206	7	9	9	NUM
bjos-8641742	206	8	.	.	NOUN
bjos-8641742	206	9	28	28	NUM
bjos-8641742	206	10	.	.	PUNCT
bjos-8641742	206	11	tappuni	tappuni	PROPN
bjos-8641742	206	12	ar	ar	PROPN
bjos-8641742	206	13	,	,	PUNCT
bjos-8641742	206	14	fleming	fleme	VERB
bjos-8641742	206	15	gjp	gjp	NOUN
bjos-8641742	206	16	.	.	PUNCT
bjos-8641742	207	1	the	the	DET
bjos-8641742	207	2	effect	effect	NOUN
bjos-8641742	207	3	of	of	ADP
bjos-8641742	207	4	antiretroviral	antiretroviral	ADJ
bjos-8641742	207	5	therapy	therapy	NOUN
bjos-8641742	207	6	on	on	ADP
bjos-8641742	207	7	the	the	DET
bjos-8641742	207	8	prevalence	prevalence	NOUN
bjos-8641742	207	9	of	of	ADP
bjos-8641742	207	10	oral	oral	ADJ
bjos-8641742	207	11	manifestations	manifestation	NOUN
bjos-8641742	207	12	in	in	ADP
bjos-8641742	207	13	hiv	hiv	PROPN
bjos-8641742	207	14	-	-	PUNCT
bjos-8641742	207	15	infected	infect	VERB
bjos-8641742	207	16	patients	patient	NOUN
bjos-8641742	207	17	:	:	PUNCT
bjos-8641742	207	18	a	a	DET
bjos-8641742	207	19	uk	uk	PROPN
bjos-8641742	207	20	study	study	NOUN
bjos-8641742	207	21	.	.	PUNCT
bjos-8641742	208	1	oral	oral	ADJ
bjos-8641742	208	2	surg	surg	NOUN
bjos-8641742	208	3	oral	oral	ADJ
bjos-8641742	208	4	med	med	ADJ
bjos-8641742	208	5	oral	oral	ADJ
bjos-8641742	208	6	pathol	pathol	NOUN
bjos-8641742	208	7	oral	oral	ADJ
bjos-8641742	208	8	radiol	radiol	NOUN
bjos-8641742	208	9	endod	endod	PROPN
bjos-8641742	208	10	.	.	PUNCT
bjos-8641742	209	1	2001	2001	NUM
bjos-8641742	209	2	;	;	PUNCT
bjos-8641742	209	3	92	92	NUM
bjos-8641742	209	4	:	:	SYM
bjos-8641742	209	5	623	623	NUM
bjos-8641742	209	6	-	-	SYM
bjos-8641742	209	7	8	8	NUM
bjos-8641742	209	8	.	.	NOUN
bjos-8641742	209	9	29	29	NUM
bjos-8641742	209	10	.	.	PUNCT
bjos-8641742	210	1	nittayananta	nittayananta	PROPN
bjos-8641742	210	2	w	w	PROPN
bjos-8641742	210	3	,	,	PUNCT
bjos-8641742	210	4	chanowanna	chanowanna	NOUN
bjos-8641742	210	5	n	n	CCONJ
bjos-8641742	210	6	,	,	PUNCT
bjos-8641742	210	7	sripatanakul	sripatanakul	VERB
bjos-8641742	210	8	s	s	PROPN
bjos-8641742	210	9	,	,	PUNCT
bjos-8641742	210	10	winn	winn	PROPN
bjos-8641742	210	11	t.	t.	NOUN
bjos-8641742	210	12	risk	risk	NOUN
bjos-8641742	210	13	factors	factor	NOUN
bjos-8641742	210	14	associated	associate	VERB
bjos-8641742	210	15	with	with	ADP
bjos-8641742	210	16	oral	oral	ADJ
bjos-8641742	210	17	lesions	lesion	NOUN
bjos-8641742	210	18	in	in	ADP
bjos-8641742	210	19	hiv	hiv	PROPN
bjos-8641742	210	20	-	-	PUNCT
bjos-8641742	210	21	infected	infect	VERB
bjos-8641742	210	22	heterosexual	heterosexual	ADJ
bjos-8641742	210	23	people	people	NOUN
bjos-8641742	210	24	and	and	CCONJ
bjos-8641742	210	25	intravenous	intravenous	ADJ
bjos-8641742	210	26	drug	drug	NOUN
bjos-8641742	210	27	users	user	NOUN
bjos-8641742	210	28	in	in	ADP
bjos-8641742	210	29	thailand	thailand	PROPN
bjos-8641742	210	30	.	.	PUNCT
bjos-8641742	211	1	j	j	PROPN
bjos-8641742	211	2	oral	oral	ADJ
bjos-8641742	211	3	pathol	pathol	NOUN
bjos-8641742	211	4	med	me	VERB
bjos-8641742	211	5	.	.	PUNCT
bjos-8641742	211	6	2001	2001	NUM
bjos-8641742	211	7	;	;	PUNCT
bjos-8641742	211	8	30	30	NUM
bjos-8641742	211	9	:	:	PUNCT
bjos-8641742	211	10	224	224	NUM
bjos-8641742	211	11	-	-	SYM
bjos-8641742	211	12	30	30	NUM
bjos-8641742	211	13	.	.	PUNCT
bjos-8641742	212	1	30	30	NUM
bjos-8641742	212	2	.	.	PUNCT
bjos-8641742	213	1	schmidt	schmidt	NOUN
bjos-8641742	213	2	-	-	PUNCT
bjos-8641742	213	3	westhausen	westhausen	PROPN
bjos-8641742	213	4	am	am	NOUN
bjos-8641742	213	5	,	,	PUNCT
bjos-8641742	213	6	priepke	priepke	PROPN
bjos-8641742	213	7	f	f	PROPN
bjos-8641742	213	8	,	,	PUNCT
bjos-8641742	213	9	bergmann	bergmann	PROPN
bjos-8641742	213	10	fj	fj	PROPN
bjos-8641742	213	11	,	,	PUNCT
bjos-8641742	213	12	reichart	reichart	PROPN
bjos-8641742	213	13	pa	pa	PROPN
bjos-8641742	213	14	.	.	PROPN
bjos-8641742	213	15	decline	decline	PROPN
bjos-8641742	213	16	in	in	ADP
bjos-8641742	213	17	the	the	DET
bjos-8641742	213	18	rate	rate	NOUN
bjos-8641742	213	19	of	of	ADP
bjos-8641742	213	20	oral	oral	ADJ
bjos-8641742	213	21	opportunistic	opportunistic	ADJ
bjos-8641742	213	22	infections	infection	NOUN
bjos-8641742	213	23	following	follow	VERB
bjos-8641742	213	24	introduction	introduction	NOUN
bjos-8641742	213	25	of	of	ADP
bjos-8641742	213	26	highly	highly	ADV
bjos-8641742	213	27	active	active	ADJ
bjos-8641742	213	28	antiretroviral	antiretroviral	ADJ
bjos-8641742	213	29	therapy	therapy	NOUN
bjos-8641742	213	30	.	.	PUNCT
bjos-8641742	214	1	j	j	PROPN
bjos-8641742	214	2	oral	oral	ADJ
bjos-8641742	214	3	pathol	pathol	NOUN
bjos-8641742	214	4	med	me	VERB
bjos-8641742	214	5	.	.	PROPN
bjos-8641742	214	6	2000	2000	NUM
bjos-8641742	214	7	;	;	PUNCT
bjos-8641742	214	8	29	29	NUM
bjos-8641742	214	9	:	:	SYM
bjos-8641742	214	10	336	336	NUM
bjos-8641742	214	11	-	-	SYM
bjos-8641742	214	12	41	41	NUM
bjos-8641742	214	13	.	.	PUNCT
bjos-8641742	215	1	risk	risk	NOUN
bjos-8641742	215	2	factors	factor	NOUN
bjos-8641742	215	3	for	for	ADP
bjos-8641742	215	4	oral	oral	ADJ
bjos-8641742	215	5	candidiasis	candidiasis	NOUN
bjos-8641742	215	6	in	in	ADP
bjos-8641742	215	7	brazilian	brazilian	ADJ
bjos-8641742	215	8	hiv	hiv	PROPN
bjos-8641742	215	9	-	-	PUNCT
bjos-8641742	215	10	infected	infect	VERB
bjos-8641742	215	11	adult	adult	NOUN
bjos-8641742	215	12	patients	patient	NOUN
bjos-8641742	215	13	braz	braz	PROPN
bjos-8641742	215	14	j	j	PROPN
bjos-8641742	215	15	oral	oral	PROPN
bjos-8641742	215	16	sci	sci	PROPN
bjos-8641742	215	17	.	.	PROPN
bjos-8641742	216	1	9(4):470	9(4):470	NUM
bjos-8641742	216	2	-	-	PUNCT
bjos-8641742	216	3	474	474	NUM